US9657313B2 - Isoprene oligomer, polyisoprene, processes for producing these materials, rubber composition, and pneumatic tire - Google Patents
Isoprene oligomer, polyisoprene, processes for producing these materials, rubber composition, and pneumatic tire Download PDFInfo
- Publication number
- US9657313B2 US9657313B2 US15/133,084 US201615133084A US9657313B2 US 9657313 B2 US9657313 B2 US 9657313B2 US 201615133084 A US201615133084 A US 201615133084A US 9657313 B2 US9657313 B2 US 9657313B2
- Authority
- US
- United States
- Prior art keywords
- group
- atom
- formula
- isoprene
- diphosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 title claims abstract description 383
- 238000000034 method Methods 0.000 title claims description 72
- 230000008569 process Effects 0.000 title claims description 19
- 229920001195 polyisoprene Polymers 0.000 title abstract description 101
- 229920001971 elastomer Polymers 0.000 title abstract description 99
- 239000005060 rubber Substances 0.000 title abstract description 99
- 239000000203 mixture Substances 0.000 title abstract description 60
- 239000000463 material Substances 0.000 title description 7
- NUHSROFQTUXZQQ-UHFFFAOYSA-N isopentenyl diphosphate Chemical compound CC(=C)CCO[P@](O)(=O)OP(O)(O)=O NUHSROFQTUXZQQ-UHFFFAOYSA-N 0.000 claims abstract description 77
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 64
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract description 14
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 14
- 125000004185 ester group Chemical group 0.000 claims abstract description 12
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims abstract description 11
- 102000004190 Enzymes Human genes 0.000 claims description 198
- 108090000790 Enzymes Proteins 0.000 claims description 198
- 125000004429 atom Chemical group 0.000 claims description 85
- 230000000694 effects Effects 0.000 claims description 81
- 230000015572 biosynthetic process Effects 0.000 claims description 59
- 150000001413 amino acids Chemical class 0.000 claims description 54
- 238000006243 chemical reaction Methods 0.000 claims description 52
- 108010006731 Dimethylallyltranstransferase Proteins 0.000 claims description 47
- 102000005454 Dimethylallyltranstransferase Human genes 0.000 claims description 47
- 108090000623 proteins and genes Proteins 0.000 claims description 45
- 239000001177 diphosphate Substances 0.000 claims description 36
- 235000011180 diphosphates Nutrition 0.000 claims description 36
- 102000004169 proteins and genes Human genes 0.000 claims description 36
- 125000000746 allylic group Chemical group 0.000 claims description 30
- 229910052799 carbon Inorganic materials 0.000 claims description 13
- 238000007792 addition Methods 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 238000006467 substitution reaction Methods 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims description 5
- 238000012217 deletion Methods 0.000 claims description 5
- 230000037430 deletion Effects 0.000 claims description 5
- 238000003780 insertion Methods 0.000 claims description 5
- 230000037431 insertion Effects 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 4
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 claims description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 4
- 229910052710 silicon Inorganic materials 0.000 claims description 4
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims 3
- 125000004434 sulfur atom Chemical group 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 description 234
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 123
- 239000000758 substrate Substances 0.000 description 89
- 230000000977 initiatory effect Effects 0.000 description 85
- 210000004027 cell Anatomy 0.000 description 76
- 238000002360 preparation method Methods 0.000 description 55
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 51
- 238000003786 synthesis reaction Methods 0.000 description 49
- 108020004414 DNA Proteins 0.000 description 48
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 46
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 44
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 42
- -1 chlorosulfenyl group Chemical group 0.000 description 40
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 38
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 36
- 238000004519 manufacturing process Methods 0.000 description 36
- 239000000243 solution Substances 0.000 description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 102220550275 Usher syndrome type-1C protein-binding protein 1_N77Q_mutation Human genes 0.000 description 33
- 235000018102 proteins Nutrition 0.000 description 33
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 31
- XPPKVPWEQAFLFU-UHFFFAOYSA-K diphosphate(3-) Chemical compound OP([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-K 0.000 description 28
- 125000003158 alcohol group Chemical group 0.000 description 25
- VWFJDQUYCIWHTN-YFVJMOTDSA-N 2-trans,6-trans-farnesyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-YFVJMOTDSA-N 0.000 description 24
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 24
- VWFJDQUYCIWHTN-FBXUGWQNSA-N Farnesyl diphosphate Natural products CC(C)=CCC\C(C)=C/CC\C(C)=C/COP(O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-FBXUGWQNSA-N 0.000 description 23
- 239000000945 filler Substances 0.000 description 22
- 239000000377 silicon dioxide Substances 0.000 description 22
- 239000002904 solvent Substances 0.000 description 22
- 239000000126 substance Substances 0.000 description 22
- 238000004809 thin layer chromatography Methods 0.000 description 22
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 21
- 230000000692 anti-sense effect Effects 0.000 description 21
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 21
- 239000002609 medium Substances 0.000 description 21
- 150000001299 aldehydes Chemical group 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 239000005792 Geraniol Substances 0.000 description 19
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 19
- 241000191938 Micrococcus luteus Species 0.000 description 19
- 102220475439 Vacuolar protein sorting-associated protein 33A_N31A_mutation Human genes 0.000 description 19
- 229940113087 geraniol Drugs 0.000 description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 238000005299 abrasion Methods 0.000 description 18
- 229920003049 isoprene rubber Polymers 0.000 description 18
- 244000043261 Hevea brasiliensis Species 0.000 description 17
- GVVPGTZRZFNKDS-JXMROGBWSA-N geranyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O GVVPGTZRZFNKDS-JXMROGBWSA-N 0.000 description 17
- 238000007254 oxidation reaction Methods 0.000 description 17
- 108010028731 undecaprenyl pyrophosphate synthetase Proteins 0.000 description 17
- 102220565668 Carboxylesterase 4A_F95A_mutation Human genes 0.000 description 16
- 241000588724 Escherichia coli Species 0.000 description 16
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 16
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 16
- 108020004511 Recombinant DNA Proteins 0.000 description 15
- 150000002148 esters Chemical group 0.000 description 15
- 239000012467 final product Substances 0.000 description 15
- 239000007858 starting material Substances 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 15
- 239000013604 expression vector Substances 0.000 description 14
- 230000003647 oxidation Effects 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 13
- 229940024606 amino acid Drugs 0.000 description 13
- 230000000845 anti-microbial effect Effects 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 13
- 102100039291 Geranylgeranyl pyrophosphate synthase Human genes 0.000 description 12
- 229920003052 natural elastomer Polymers 0.000 description 12
- 229920001194 natural rubber Polymers 0.000 description 12
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 description 11
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 11
- 229940043259 farnesol Drugs 0.000 description 11
- 229930002886 farnesol Natural products 0.000 description 11
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 11
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 11
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 10
- 239000004593 Epoxy Substances 0.000 description 10
- 241000238631 Hexapoda Species 0.000 description 10
- BMTUFQKYWWLCLC-UHFFFAOYSA-K [hydroxy(oxido)phosphoryl] phosphate;tetrabutylazanium Chemical compound OP([O-])(=O)OP([O-])([O-])=O.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC BMTUFQKYWWLCLC-UHFFFAOYSA-K 0.000 description 10
- 239000000460 chlorine Substances 0.000 description 10
- 229910052801 chlorine Inorganic materials 0.000 description 10
- 229920006173 natural rubber latex Polymers 0.000 description 10
- 235000002639 sodium chloride Nutrition 0.000 description 10
- 238000004073 vulcanization Methods 0.000 description 10
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 9
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 9
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 8
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical group CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 8
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 8
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 8
- 229960000723 ampicillin Drugs 0.000 description 8
- 235000009582 asparagine Nutrition 0.000 description 8
- 229960001230 asparagine Drugs 0.000 description 8
- 229910001629 magnesium chloride Inorganic materials 0.000 description 8
- 244000005700 microbiome Species 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 7
- GVVPGTZRZFNKDS-YFHOEESVSA-N Geranyl diphosphate Natural products CC(C)=CCC\C(C)=C/COP(O)(=O)OP(O)(O)=O GVVPGTZRZFNKDS-YFHOEESVSA-N 0.000 description 7
- 241000205098 Sulfolobus acidocaldarius Species 0.000 description 7
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 210000001672 ovary Anatomy 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000011593 sulfur Substances 0.000 description 7
- 239000012138 yeast extract Substances 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 6
- 108010007508 Farnesyltranstransferase Proteins 0.000 description 6
- 108010026318 Geranyltranstransferase Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 235000004279 alanine Nutrition 0.000 description 6
- 210000004102 animal cell Anatomy 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 229940041514 candida albicans extract Drugs 0.000 description 6
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- UWNADWZGEHDQAB-UHFFFAOYSA-N i-Pr2C2H4i-Pr2 Natural products CC(C)CCC(C)C UWNADWZGEHDQAB-UHFFFAOYSA-N 0.000 description 6
- 229920000126 latex Polymers 0.000 description 6
- 239000004816 latex Substances 0.000 description 6
- 229910052744 lithium Inorganic materials 0.000 description 6
- 238000002703 mutagenesis Methods 0.000 description 6
- 231100000350 mutagenesis Toxicity 0.000 description 6
- 150000002825 nitriles Chemical group 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 6
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 6
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 5
- 239000007818 Grignard reagent Substances 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- 239000005062 Polybutadiene Substances 0.000 description 5
- 235000021355 Stearic acid Nutrition 0.000 description 5
- 239000013504 Triton X-100 Substances 0.000 description 5
- 229920004890 Triton X-100 Polymers 0.000 description 5
- 235000003704 aspartic acid Nutrition 0.000 description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 5
- 239000006229 carbon black Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 150000002009 diols Chemical group 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 238000006911 enzymatic reaction Methods 0.000 description 5
- 150000004795 grignard reagents Chemical class 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000001771 impaired effect Effects 0.000 description 5
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 5
- TWLXDPFBEPBAQB-UHFFFAOYSA-N orthoperiodic acid Chemical compound OI(O)(O)(O)(O)=O TWLXDPFBEPBAQB-UHFFFAOYSA-N 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 229920002857 polybutadiene Polymers 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000008117 stearic acid Substances 0.000 description 5
- 241000701447 unidentified baculovirus Species 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 239000011787 zinc oxide Substances 0.000 description 5
- DVKDNGRTVQWALI-DOMIDYPGSA-N 3-methyl(114C)but-1-enyl phosphono hydrogen phosphate Chemical compound CC(C)C=[14CH]OP(=O)(O)OP(=O)(O)O DVKDNGRTVQWALI-DOMIDYPGSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 244000063299 Bacillus subtilis Species 0.000 description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 description 4
- RPRRZMFQEMBIBS-UHFFFAOYSA-N COP(=O)(O)OP(C)(=O)O Chemical compound COP(=O)(O)OP(C)(=O)O RPRRZMFQEMBIBS-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 230000032050 esterification Effects 0.000 description 4
- 238000005886 esterification reaction Methods 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000005567 liquid scintillation counting Methods 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- ASUAYTHWZCLXAN-UHFFFAOYSA-N prenol Chemical compound CC(C)=CCO ASUAYTHWZCLXAN-UHFFFAOYSA-N 0.000 description 4
- CBIDRCWHNCKSTO-UHFFFAOYSA-N prenyl diphosphate Chemical compound CC(C)=CCO[P@](O)(=O)OP(O)(O)=O CBIDRCWHNCKSTO-UHFFFAOYSA-N 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 241000255789 Bombyx mori Species 0.000 description 3
- AZVSAVHUQJONRL-FLTRNQRFSA-N C/C=C(\C)C(CC)C/C=C(\C)CCC=C(C)C.C/C=C(\C)CC/C=C(\C)CCC(CC)OC(C)=O.C/C=C(\C)CC/C=C(\C)CCC(O)CC.C/C=C(\C)CC/C=C(\C)COCC1=CC=CC=C1.C/C=C(\C)CC/C=C(\C)CO[Si](C)(C)C(C)(C)C.C/C=C(\C)CCCN=[N+]=[N-] Chemical compound C/C=C(\C)C(CC)C/C=C(\C)CCC=C(C)C.C/C=C(\C)CC/C=C(\C)CCC(CC)OC(C)=O.C/C=C(\C)CC/C=C(\C)CCC(O)CC.C/C=C(\C)CC/C=C(\C)COCC1=CC=CC=C1.C/C=C(\C)CC/C=C(\C)CO[Si](C)(C)C(C)(C)C.C/C=C(\C)CCCN=[N+]=[N-] AZVSAVHUQJONRL-FLTRNQRFSA-N 0.000 description 3
- VVBSGZDPGVYUBO-DRFBXLRXSA-N C/C=C(\C)CC/C=C(\C)C(CCCC)OC.C/C=C(\C)CC/C=C(\C)C(CCCC)OC(C)=O.C/C=C(\C)CC/C=C(\C)C(O)CCCC.C/C=C(\C)CC/C=C(\C)CCCN(C)C(C)=O.C/C=C(\C)CC/C=C(\C)CC[C@@H](O)CC.C/C=C(\C)CC/C=C(\C)CC[C@H](O)CC.C/C=C(\C)CC/C=C(\C)CO.C/C=C(\C)CC/C=C(\C)COC(C)=O.C/C=C(\C)CC/C=C(\C)COCC(C)C.C/C=C(\C)CC/C=C(\C)COCOC.C/C=C(\C)CC/C=C(\C)CSCCC.C/C=C(\C)CCCC(OC)OC.C/C=C(\C)CCCN(CCCC)C(C)=O Chemical compound C/C=C(\C)CC/C=C(\C)C(CCCC)OC.C/C=C(\C)CC/C=C(\C)C(CCCC)OC(C)=O.C/C=C(\C)CC/C=C(\C)C(O)CCCC.C/C=C(\C)CC/C=C(\C)CCCN(C)C(C)=O.C/C=C(\C)CC/C=C(\C)CC[C@@H](O)CC.C/C=C(\C)CC/C=C(\C)CC[C@H](O)CC.C/C=C(\C)CC/C=C(\C)CO.C/C=C(\C)CC/C=C(\C)COC(C)=O.C/C=C(\C)CC/C=C(\C)COCC(C)C.C/C=C(\C)CC/C=C(\C)COCOC.C/C=C(\C)CC/C=C(\C)CSCCC.C/C=C(\C)CCCC(OC)OC.C/C=C(\C)CCCN(CCCC)C(C)=O VVBSGZDPGVYUBO-DRFBXLRXSA-N 0.000 description 3
- DHXYGCQAXXTHEK-LTCREPBCSA-N CC(C)=CCC/C(C)=C/CC/C(C)=C\C[Y] Chemical compound CC(C)=CCC/C(C)=C/CC/C(C)=C\C[Y] DHXYGCQAXXTHEK-LTCREPBCSA-N 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 3
- 241000186226 Corynebacterium glutamicum Species 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 241000588698 Erwinia Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 201000008225 Klebsiella pneumonia Diseases 0.000 description 3
- 241000588747 Klebsiella pneumoniae Species 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- 229920000459 Nitrile rubber Polymers 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- 206010035717 Pneumonia klebsiella Diseases 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000003570 biosynthesizing effect Effects 0.000 description 3
- GRKYVDXKQHWFBO-UHFFFAOYSA-N butylazanium [hydroxy(oxido)phosphoryl] phosphate Chemical compound CCCC[NH3+].CCCC[NH3+].CCCC[NH3+].OP([O-])(=O)OP([O-])([O-])=O GRKYVDXKQHWFBO-UHFFFAOYSA-N 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- 125000004437 phosphorous atom Chemical group 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011403 purification operation Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 229910052711 selenium Inorganic materials 0.000 description 3
- 239000011669 selenium Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 3
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 3
- 239000004636 vulcanized rubber Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- IZXLJAKFMBYUMK-GXGUWVMISA-N *.B.CC(C)=CCC/C(C)=C/CC/C(C)=C\C[Y] Chemical compound *.B.CC(C)=CCC/C(C)=C/CC/C(C)=C\C[Y] IZXLJAKFMBYUMK-GXGUWVMISA-N 0.000 description 2
- NSPPRYXGGYQMPY-UHFFFAOYSA-N 3-Methylbuten-2-ol-1 Natural products CC(C)C(O)=C NSPPRYXGGYQMPY-UHFFFAOYSA-N 0.000 description 2
- ZZMVLMVFYMGSMY-UHFFFAOYSA-N 4-n-(4-methylpentan-2-yl)-1-n-phenylbenzene-1,4-diamine Chemical compound C1=CC(NC(C)CC(C)C)=CC=C1NC1=CC=CC=C1 ZZMVLMVFYMGSMY-UHFFFAOYSA-N 0.000 description 2
- 241000589158 Agrobacterium Species 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 241000186063 Arthrobacter Species 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000186146 Brevibacterium Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000701489 Cauliflower mosaic virus Species 0.000 description 2
- 241000282552 Chlorocebus aethiops Species 0.000 description 2
- 241000190831 Chromatium Species 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 2
- 241000588722 Escherichia Species 0.000 description 2
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- OINNEUNVOZHBOX-XBQSVVNOSA-N Geranylgeranyl diphosphate Natural products [P@](=O)(OP(=O)(O)O)(OC/C=C(\CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)/C)O OINNEUNVOZHBOX-XBQSVVNOSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 241000588696 Pantoea ananatis Species 0.000 description 2
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 2
- 241000187561 Rhodococcus erythropolis Species 0.000 description 2
- 229920005683 SIBR Polymers 0.000 description 2
- 239000006087 Silane Coupling Agent Substances 0.000 description 2
- 241000256251 Spodoptera frugiperda Species 0.000 description 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical group C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
- 241000255993 Trichoplusia ni Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001336 alkenes Chemical group 0.000 description 2
- NTXGVHCCXVHYCL-RDQGWRCRSA-N all-trans-undecaprenyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\COP(O)(=O)OP(O)(O)=O NTXGVHCCXVHYCL-RDQGWRCRSA-N 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical group OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- OINNEUNVOZHBOX-KGODAQDXSA-N geranylgeranyl diphosphate Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C\CC\C(C)=C\CO[P@@](O)(=O)OP(O)(O)=O OINNEUNVOZHBOX-KGODAQDXSA-N 0.000 description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000004898 kneading Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- IUJLOAKJZQBENM-UHFFFAOYSA-N n-(1,3-benzothiazol-2-ylsulfanyl)-2-methylpropan-2-amine Chemical compound C1=CC=C2SC(SNC(C)(C)C)=NC2=C1 IUJLOAKJZQBENM-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 229920001084 poly(chloroprene) Polymers 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 150000003138 primary alcohols Chemical group 0.000 description 2
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000005987 sulfurization reaction Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000009864 tensile test Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- OJISWRZIEWCUBN-QIRCYJPOSA-N (E,E,E)-geranylgeraniol Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CO OJISWRZIEWCUBN-QIRCYJPOSA-N 0.000 description 1
- MFHNAXHSHOCFEC-UHFFFAOYSA-N 1,1-diphenylguanidine Chemical compound C=1C=CC=CC=1N(C(=N)N)C1=CC=CC=C1 MFHNAXHSHOCFEC-UHFFFAOYSA-N 0.000 description 1
- OWRCNXZUPFZXOS-UHFFFAOYSA-N 1,3-diphenylguanidine Chemical compound C=1C=CC=CC=1NC(=N)NC1=CC=CC=C1 OWRCNXZUPFZXOS-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WCASXYBKJHWFMY-NSCUHMNNSA-N 2-Buten-1-ol Chemical compound C\C=C\CO WCASXYBKJHWFMY-NSCUHMNNSA-N 0.000 description 1
- SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101710197633 Actin-1 Proteins 0.000 description 1
- 241000190969 Afifella marina Species 0.000 description 1
- 241000589156 Agrobacterium rhizogenes Species 0.000 description 1
- 241001135511 Agrobacterium rubi Species 0.000 description 1
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 1
- 241001147780 Alicyclobacillus Species 0.000 description 1
- 241000190857 Allochromatium vinosum Species 0.000 description 1
- 241000880915 Allochromatium warmingii Species 0.000 description 1
- 239000001729 Ammonium fumarate Substances 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 241000192542 Anabaena Species 0.000 description 1
- 241000192537 Anabaena cylindrica Species 0.000 description 1
- 241000219195 Arabidopsis thaliana Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000185996 Arthrobacter citreus Species 0.000 description 1
- 241000186074 Arthrobacter globiformis Species 0.000 description 1
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 1
- 241000589151 Azotobacter Species 0.000 description 1
- 241000194107 Bacillus megaterium Species 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- LMXSAVWYKFDHLK-DIBJZOHASA-N C.CC(C)=CCC/C(C)=C/CC/C(C)=C\C[Y].[2HH] Chemical compound C.CC(C)=CCC/C(C)=C/CC/C(C)=C\C[Y].[2HH] LMXSAVWYKFDHLK-DIBJZOHASA-N 0.000 description 1
- NSUPMJNSYMGKFR-PVQRRINASA-N C/C(=C\CC/C(C)=C/COC1CCCCO1)CCl.C/C(=C\CC/C(C)=C/COC1CCCCO1)CO.CC(C)=CCC/C(C)=C/CO.CC(C)=CCC/C(C)=C/COC1CCCCO1.CCCSC/C(C)=C/CC/C(C)=C/CCl.CCCSC/C(C)=C/CC/C(C)=C/CO.CCCSC/C(C)=C/CC/C(C)=C/COC1CCCCO1.CCCSC/C(C)=C/CC/C(C)=C/COPP Chemical compound C/C(=C\CC/C(C)=C/COC1CCCCO1)CCl.C/C(=C\CC/C(C)=C/COC1CCCCO1)CO.CC(C)=CCC/C(C)=C/CO.CC(C)=CCC/C(C)=C/COC1CCCCO1.CCCSC/C(C)=C/CC/C(C)=C/CCl.CCCSC/C(C)=C/CC/C(C)=C/CO.CCCSC/C(C)=C/CC/C(C)=C/COC1CCCCO1.CCCSC/C(C)=C/CC/C(C)=C/COPP NSUPMJNSYMGKFR-PVQRRINASA-N 0.000 description 1
- JBQPELLQEWGQNU-CAJNGGPCSA-N C/C(=C\CC/C(C)=C/COC1CCCCO1)CO.C/C(=C\CCl)CC/C=C(\C)COCC1=CC=CC=C1.C/C(=C\CO)CC/C=C(\C)COCC1=CC=CC=C1.C/C(=C\COC1CCCCO1)CC/C=C(\C)COCC1=CC=CC=C1.C/C(=C\COPP)CC/C=C(\C)COCC1=CC=CC=C1.CC(C)=CCC/C(C)=C/CO.CC(C)=CCC/C(C)=C/COC1CCCCO1 Chemical compound C/C(=C\CC/C(C)=C/COC1CCCCO1)CO.C/C(=C\CCl)CC/C=C(\C)COCC1=CC=CC=C1.C/C(=C\CO)CC/C=C(\C)COCC1=CC=CC=C1.C/C(=C\COC1CCCCO1)CC/C=C(\C)COCC1=CC=CC=C1.C/C(=C\COPP)CC/C=C(\C)COCC1=CC=CC=C1.CC(C)=CCC/C(C)=C/CO.CC(C)=CCC/C(C)=C/COC1CCCCO1 JBQPELLQEWGQNU-CAJNGGPCSA-N 0.000 description 1
- VPWAMMIPKGKHQI-FZCITUQKSA-N C/C(=C\CC/C(C)=C/COPP)CO.C/C(=C\COPP)CC/C=C(\C)COCC(C)C.CC(=O)N(C)CCC/C(C)=C/CC/C(C)=C/COPP.CC(=O)OC/C(C)=C/CC/C(C)=C/COPP.CCCCC(O)/C(C)=C/CC/C(C)=C/COPP.CCCCC(OC(C)=O)/C(C)=C/CC/C(C)=C/COPP.CCCCC(OC)/C(C)=C/CC/C(C)=C/COPP.CCCCN(CCC/C(C)=C/COPP)C(C)=O.CC[C@@H](O)CC/C(C)=C/CC/C(C)=C/COPP.CC[C@H](O)CC/C(C)=C/CC/C(C)=C/COPP.COC(CCC/C(C)=C/COPP)OC.COCOC/C(C)=C/CC/C(C)=C/COPP Chemical compound C/C(=C\CC/C(C)=C/COPP)CO.C/C(=C\COPP)CC/C=C(\C)COCC(C)C.CC(=O)N(C)CCC/C(C)=C/CC/C(C)=C/COPP.CC(=O)OC/C(C)=C/CC/C(C)=C/COPP.CCCCC(O)/C(C)=C/CC/C(C)=C/COPP.CCCCC(OC(C)=O)/C(C)=C/CC/C(C)=C/COPP.CCCCC(OC)/C(C)=C/CC/C(C)=C/COPP.CCCCN(CCC/C(C)=C/COPP)C(C)=O.CC[C@@H](O)CC/C(C)=C/CC/C(C)=C/COPP.CC[C@H](O)CC/C(C)=C/CC/C(C)=C/COPP.COC(CCC/C(C)=C/COPP)OC.COCOC/C(C)=C/CC/C(C)=C/COPP VPWAMMIPKGKHQI-FZCITUQKSA-N 0.000 description 1
- LMMYAYAUZFJIPY-CKNMXMKASA-N C/C(=C\CCl)CC/C=C(\C)CO[Si](C)(C)C(C)(C)C.C/C(=C\CO)CC/C=C(\C)CO[Si](C)(C)C(C)(C)C.C/C(=C\COPP)CC/C=C(\C)CO[Si](C)(C)C(C)(C)C.CC(=O)OC/C=C(\C)CC/C=C(\C)CO[Si](C)(C)C(C)(C)C.CC(=O)OC/C=C(\C)CC/C=C(\C)O.CC(=O)OC/C=C(\C)CCC=C(C)C.CC(C)=CCC/C(C)=C/CO Chemical compound C/C(=C\CCl)CC/C=C(\C)CO[Si](C)(C)C(C)(C)C.C/C(=C\CO)CC/C=C(\C)CO[Si](C)(C)C(C)(C)C.C/C(=C\COPP)CC/C=C(\C)CO[Si](C)(C)C(C)(C)C.CC(=O)OC/C=C(\C)CC/C=C(\C)CO[Si](C)(C)C(C)(C)C.CC(=O)OC/C=C(\C)CC/C=C(\C)O.CC(=O)OC/C=C(\C)CCC=C(C)C.CC(C)=CCC/C(C)=C/CO LMMYAYAUZFJIPY-CKNMXMKASA-N 0.000 description 1
- UXRQUHUZINVYBU-BPSJRNCMSA-N C/C(=C\COPP)CC/C=C(\C)COCC1=CC=CC=C1.C/C(=C\COPP)CC/C=C(\C)CO[Si](C)(C)C(C)(C)C.C/C(=C\COPP)CCCN=[N+]=[N-].CCC(C/C=C(\C)CCC=C(C)C)/C(C)=C/COPP.CCC(CC/C(C)=C/CC/C(C)=C/COPP)OC(C)=O.CCC(O)CC/C(C)=C/CC/C(C)=C/COPP.CCCSC/C(C)=C/CC/C(C)=C/COPP.O=P(O)(O)OP(=O)(O)O.O=P[P] Chemical compound C/C(=C\COPP)CC/C=C(\C)COCC1=CC=CC=C1.C/C(=C\COPP)CC/C=C(\C)CO[Si](C)(C)C(C)(C)C.C/C(=C\COPP)CCCN=[N+]=[N-].CCC(C/C=C(\C)CCC=C(C)C)/C(C)=C/COPP.CCC(CC/C(C)=C/CC/C(C)=C/COPP)OC(C)=O.CCC(O)CC/C(C)=C/CC/C(C)=C/COPP.CCCSC/C(C)=C/CC/C(C)=C/COPP.O=P(O)(O)OP(=O)(O)O.O=P[P] UXRQUHUZINVYBU-BPSJRNCMSA-N 0.000 description 1
- LRBPNQGJUOSZMU-PVYQHYRWSA-N C/C(=C\CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)CC/C=C(\C)CCC1OC1(C)C.CC(C)(C)[SiH](C1=CC=CC=C1)C1=CC=CC=C1.CC(C)(C)[Si](C)(C1=CC=CC=C1)C1=CC=CC=C1.CC(C)=CCC/C(C)=C/CC/C(C)=C/CO.CC(C)=CCC/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C.CC(C)=O.CC=CC.CCC(CC/C(C)=C/CC/C(C)=C/CCl)OC(C)=O.CCC(CC/C(C)=C/CC/C(C)=C/CO)OC(C)=O.CCC(CC/C(C)=C/CC/C(C)=C/COPP)OC(C)=O.CCC(CC/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)OC(C)=O.CCC(O)CC/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C.COCC/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C.O=P(O)(O)OP(=O)(O)O Chemical compound C/C(=C\CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)CC/C=C(\C)CCC1OC1(C)C.CC(C)(C)[SiH](C1=CC=CC=C1)C1=CC=CC=C1.CC(C)(C)[Si](C)(C1=CC=CC=C1)C1=CC=CC=C1.CC(C)=CCC/C(C)=C/CC/C(C)=C/CO.CC(C)=CCC/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C.CC(C)=O.CC=CC.CCC(CC/C(C)=C/CC/C(C)=C/CCl)OC(C)=O.CCC(CC/C(C)=C/CC/C(C)=C/CO)OC(C)=O.CCC(CC/C(C)=C/CC/C(C)=C/COPP)OC(C)=O.CCC(CC/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)OC(C)=O.CCC(O)CC/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C.COCC/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C.O=P(O)(O)OP(=O)(O)O LRBPNQGJUOSZMU-PVYQHYRWSA-N 0.000 description 1
- JOSRCMFQJMJOKI-MKXBOAPDSA-N C/C(=C\CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)CC/C=C(\C)CCC1OC1(C)C.CC(C)=CCC/C(C)=C/CC/C(C)=C/CO.CC(C)=CCC/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C.CCC(C)CC/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C.CC[C@@H](O)CC/C(C)=C/CC/C(C)=C/CCl.CC[C@@H](O)CC/C(C)=C/CC/C(C)=C/CO.CC[C@@H](O)CC/C(C)=C/CC/C(C)=C/COPP.CC[C@@H](O)CC/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C.COCC/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C Chemical compound C/C(=C\CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)CC/C=C(\C)CCC1OC1(C)C.CC(C)=CCC/C(C)=C/CC/C(C)=C/CO.CC(C)=CCC/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C.CCC(C)CC/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C.CC[C@@H](O)CC/C(C)=C/CC/C(C)=C/CCl.CC[C@@H](O)CC/C(C)=C/CC/C(C)=C/CO.CC[C@@H](O)CC/C(C)=C/CC/C(C)=C/COPP.CC[C@@H](O)CC/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C.COCC/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C JOSRCMFQJMJOKI-MKXBOAPDSA-N 0.000 description 1
- JOSRCMFQJMJOKI-JIQUUVAJSA-N C/C(=C\CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)CC/C=C(\C)CCC1OC1(C)C.CC(C)=CCC/C(C)=C/CC/C(C)=C/CO.CC(C)=CCC/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C.CCC(C)CC/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C.CC[C@H](O)CC/C(C)=C/CC/C(C)=C/CCl.CC[C@H](O)CC/C(C)=C/CC/C(C)=C/CO.CC[C@H](O)CC/C(C)=C/CC/C(C)=C/COPP.CC[C@H](O)CC/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C.COCC/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C Chemical compound C/C(=C\CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)CC/C=C(\C)CCC1OC1(C)C.CC(C)=CCC/C(C)=C/CC/C(C)=C/CO.CC(C)=CCC/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C.CCC(C)CC/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C.CC[C@H](O)CC/C(C)=C/CC/C(C)=C/CCl.CC[C@H](O)CC/C(C)=C/CC/C(C)=C/CO.CC[C@H](O)CC/C(C)=C/CC/C(C)=C/COPP.CC[C@H](O)CC/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C.COCC/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C JOSRCMFQJMJOKI-JIQUUVAJSA-N 0.000 description 1
- GWYSWPMIQCVJOG-RHXBEEQSSA-N C/C(=C\CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)CC/C=C(\C)CCC1OC1(C)C.CC(C)=CCC/C(C)=C/CC/C(C)=C/CO.CC(C)=CCC/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C.CCC(O)CC/C(C)=C/CC/C(C)=C/CCl.CCC(O)CC/C(C)=C/CC/C(C)=C/CO.CCC(O)CC/C(C)=C/CC/C(C)=C/COPP.CCC(O)CC/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C.COCC/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C Chemical compound C/C(=C\CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C)CC/C=C(\C)CCC1OC1(C)C.CC(C)=CCC/C(C)=C/CC/C(C)=C/CO.CC(C)=CCC/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C.CCC(O)CC/C(C)=C/CC/C(C)=C/CCl.CCC(O)CC/C(C)=C/CC/C(C)=C/CO.CCC(O)CC/C(C)=C/CC/C(C)=C/COPP.CCC(O)CC/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C.COCC/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C GWYSWPMIQCVJOG-RHXBEEQSSA-N 0.000 description 1
- KTUDKJRPYPDAAL-JFSRBFGKSA-N C/C(C=O)=C\CC/C(C)=C/CO.C/C(C=O)=C\CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C.CC(=O)OC/C=C(\C)CCC=C(C)C.CC(C)=CCC/C(C)=C/CO.CCCCC(O)/C(C)=C/CC/C(C)=C/CO.CCCCC(O)/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C.CCCCC(OC)/C(C)=C/CC/C(C)=C/CCl.CCCCC(OC)/C(C)=C/CC/C(C)=C/COPP.CCCCC(OC)/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C.CO/C(C)=C/CC/C(C)=C/COC(C)=O Chemical compound C/C(C=O)=C\CC/C(C)=C/CO.C/C(C=O)=C\CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C.CC(=O)OC/C=C(\C)CCC=C(C)C.CC(C)=CCC/C(C)=C/CO.CCCCC(O)/C(C)=C/CC/C(C)=C/CO.CCCCC(O)/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C.CCCCC(OC)/C(C)=C/CC/C(C)=C/CCl.CCCCC(OC)/C(C)=C/CC/C(C)=C/COPP.CCCCC(OC)/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C.CO/C(C)=C/CC/C(C)=C/COC(C)=O KTUDKJRPYPDAAL-JFSRBFGKSA-N 0.000 description 1
- GUOZQAJRWFXDGE-ZNDVYTPLSA-N C/C(C=O)=C\CC/C(C)=C/CO.CC(=O)OC/C=C(\C)CCC=C(C)C.CC(C)=CCC/C(C)=C/CO.CCCCC(O)/C(C)=C/CC/C(C)=C/CCl.CCCCC(O)/C(C)=C/CC/C(C)=C/CO.CCCCC(O)/C(C)=C/CC/C(C)=C/COPP.CCCCC(O)/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C.CO/C(C)=C/CC/C(C)=C/COC(C)=O Chemical compound C/C(C=O)=C\CC/C(C)=C/CO.CC(=O)OC/C=C(\C)CCC=C(C)C.CC(C)=CCC/C(C)=C/CO.CCCCC(O)/C(C)=C/CC/C(C)=C/CCl.CCCCC(O)/C(C)=C/CC/C(C)=C/CO.CCCCC(O)/C(C)=C/CC/C(C)=C/COPP.CCCCC(O)/C(C)=C/CC/C(C)=C/CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C.CO/C(C)=C/CC/C(C)=C/COC(C)=O GUOZQAJRWFXDGE-ZNDVYTPLSA-N 0.000 description 1
- FKHQPMJTQQJXOD-FDRFSGEISA-N C/C=C/CCl.C/C=C/CO.C/C=C/COPP Chemical compound C/C=C/CCl.C/C=C/CO.C/C=C/COPP FKHQPMJTQQJXOD-FDRFSGEISA-N 0.000 description 1
- VRAGNDTXJPKCES-HPYBRQCNSA-N C/C=C/COPP.CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C/COPP.CC(C)=CCC/C(C)=C/CC/C(C)=C/COPP.CC(C)=CCC/C(C)=C/CC/C=C/COPP.CC(C)=CCC/C=C/COPP.FPP Chemical compound C/C=C/COPP.CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C/COPP.CC(C)=CCC/C(C)=C/CC/C(C)=C/COPP.CC(C)=CCC/C(C)=C/CC/C=C/COPP.CC(C)=CCC/C=C/COPP.FPP VRAGNDTXJPKCES-HPYBRQCNSA-N 0.000 description 1
- PORVPGAWNBQFCF-IHWYPQMZSA-N C/C=C\COPP.I Chemical compound C/C=C\COPP.I PORVPGAWNBQFCF-IHWYPQMZSA-N 0.000 description 1
- KDQROXLMMWIHSI-PVTQJAALSA-N C=C(C)CCOPP.C=C(C)CCOPP.CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\COPP.CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\COPP.CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\COPP.CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\COPP.O=P(O)(O)OP(=O)(O)O.O=P[P] Chemical compound C=C(C)CCOPP.C=C(C)CCOPP.CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\COPP.CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\COPP.CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\COPP.CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\CC/C(C)=C\COPP.O=P(O)(O)OP(=O)(O)O.O=P[P] KDQROXLMMWIHSI-PVTQJAALSA-N 0.000 description 1
- LGNVQMUETRQWSH-SIOQNCKXSA-N C=C(C)CCOPP.C=C(C)CCOPP.CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC/C(C)=C\CC/C(C)=C\COPP.CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC/C(C)=C\COPP.CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC/C(C)=C\COPP.CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/COPP.O=P(O)(O)OP(=O)(O)O.O=P[P] Chemical compound C=C(C)CCOPP.C=C(C)CCOPP.CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC/C(C)=C\CC/C(C)=C\COPP.CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC/C(C)=C\COPP.CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC/C(C)=C\COPP.CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/COPP.O=P(O)(O)OP(=O)(O)O.O=P[P] LGNVQMUETRQWSH-SIOQNCKXSA-N 0.000 description 1
- CIAWTTXWRDBPNV-ADKUXPEKSA-N CC(=O)OC/C=C(\C)CC/C=C(\C)CO.CC(=O)OC/C=C(\C)CCC=C(C)C.CC(C)=CCC/C(C)=C/CO.COCOC/C(C)=C/CC/C(C)=C/CCl.COCOC/C(C)=C/CC/C(C)=C/CO.COCOC/C(C)=C/CC/C(C)=C/COC(C)=O.COCOC/C(C)=C/CC/C(C)=C/COPP Chemical compound CC(=O)OC/C=C(\C)CC/C=C(\C)CO.CC(=O)OC/C=C(\C)CCC=C(C)C.CC(C)=CCC/C(C)=C/CO.COCOC/C(C)=C/CC/C(C)=C/CCl.COCOC/C(C)=C/CC/C(C)=C/CO.COCOC/C(C)=C/CC/C(C)=C/COC(C)=O.COCOC/C(C)=C/CC/C(C)=C/COPP CIAWTTXWRDBPNV-ADKUXPEKSA-N 0.000 description 1
- VYAHPZYKBIHVRJ-MGCNEFETSA-N CC(=O)OC/C=C(\C)CCC1OC1(C)C.CC(=O)OC/C=C(\C)CCC=C(C)C.CC(C)=CCC/C(C)=C/CO.CCCCCCCC/C(C)=C/COC(C)=O.CCCCN(CCC/C(C)=C/CCl)C(C)=O.CCCCN(CCC/C(C)=C/CO)C(C)=O.CCCCN(CCC/C(C)=C/COC(C)=O)C(C)=O.CCCCN(CCC/C(C)=C/COPP)C(C)=O.COCC/C(C)=C/COC(C)=O Chemical compound CC(=O)OC/C=C(\C)CCC1OC1(C)C.CC(=O)OC/C=C(\C)CCC=C(C)C.CC(C)=CCC/C(C)=C/CO.CCCCCCCC/C(C)=C/COC(C)=O.CCCCN(CCC/C(C)=C/CCl)C(C)=O.CCCCN(CCC/C(C)=C/CO)C(C)=O.CCCCN(CCC/C(C)=C/COC(C)=O)C(C)=O.CCCCN(CCC/C(C)=C/COPP)C(C)=O.COCC/C(C)=C/COC(C)=O VYAHPZYKBIHVRJ-MGCNEFETSA-N 0.000 description 1
- MXPRNPCTOZXCPH-OCMAEFCKSA-N CC(C)=CCC(C#N)C(=O)O.CC(C)=CCC/C=C/CCl.CC(C)=CCC/C=C/CO.CC(C)=CCC/C=C/COPP.CC(C)=CCCC#N.CC(C)=CCCC=O.CC(C)=CCCl.CC(C)=CCO.CCOC(=O)/C=C/CCC=C(C)C.CCOC(=O)C(C#N)CC=C(C)C Chemical compound CC(C)=CCC(C#N)C(=O)O.CC(C)=CCC/C=C/CCl.CC(C)=CCC/C=C/CO.CC(C)=CCC/C=C/COPP.CC(C)=CCCC#N.CC(C)=CCCC=O.CC(C)=CCCl.CC(C)=CCO.CCOC(=O)/C=C/CCC=C(C)C.CCOC(=O)C(C#N)CC=C(C)C MXPRNPCTOZXCPH-OCMAEFCKSA-N 0.000 description 1
- MWNJJDYOEUTZFB-FVAULRQLSA-N CC(C)=CCC/C(C)=C/CC(C#N)C(=O)O.CC(C)=CCC/C(C)=C/CC/C=C/CCl.CC(C)=CCC/C(C)=C/CC/C=C/CO.CC(C)=CCC/C(C)=C/CC/C=C/COPP.CC(C)=CCC/C(C)=C/CCC#N.CC(C)=CCC/C(C)=C/CCC=O.CC(C)=CCC/C(C)=C/CCl.CC(C)=CCC/C(C)=C/CO.CCOC(=O)/C=C/CC/C=C(\C)CCC=C(C)C.CCOC(=O)C(C#N)C/C=C(\C)CCC=C(C)C Chemical compound CC(C)=CCC/C(C)=C/CC(C#N)C(=O)O.CC(C)=CCC/C(C)=C/CC/C=C/CCl.CC(C)=CCC/C(C)=C/CC/C=C/CO.CC(C)=CCC/C(C)=C/CC/C=C/COPP.CC(C)=CCC/C(C)=C/CCC#N.CC(C)=CCC/C(C)=C/CCC=O.CC(C)=CCC/C(C)=C/CCl.CC(C)=CCC/C(C)=C/CO.CCOC(=O)/C=C/CC/C=C(\C)CCC=C(C)C.CCOC(=O)C(C#N)C/C=C(\C)CCC=C(C)C MWNJJDYOEUTZFB-FVAULRQLSA-N 0.000 description 1
- KRZJMDIPBYGJOQ-LTIZULQESA-N CC(C)=CCC/C(C)=C/CC/C(C)=C/CC(C#N)C(=O)O.CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C/CCl.CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C/CO.CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C/COPP.CC(C)=CCC/C(C)=C/CC/C(C)=C/CCC#N.CC(C)=CCC/C(C)=C/CC/C(C)=C/CCC=O.CC(C)=CCC/C(C)=C/CC/C(C)=C/CCl.CC(C)=CCC/C(C)=C/CC/C(C)=C/CO.CCOC(=O)/C=C/CC/C=C(\C)CC/C=C(\C)CCC=C(C)C.CCOC(=O)C(C#N)C/C=C(\C)CC/C=C(\C)CCC=C(C)C Chemical compound CC(C)=CCC/C(C)=C/CC/C(C)=C/CC(C#N)C(=O)O.CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C/CCl.CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C/CO.CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C=C/COPP.CC(C)=CCC/C(C)=C/CC/C(C)=C/CCC#N.CC(C)=CCC/C(C)=C/CC/C(C)=C/CCC=O.CC(C)=CCC/C(C)=C/CC/C(C)=C/CCl.CC(C)=CCC/C(C)=C/CC/C(C)=C/CO.CCOC(=O)/C=C/CC/C=C(\C)CC/C=C(\C)CCC=C(C)C.CCOC(=O)C(C#N)C/C=C(\C)CC/C=C(\C)CCC=C(C)C KRZJMDIPBYGJOQ-LTIZULQESA-N 0.000 description 1
- YYJJSQOAWYAEKC-FBSFSYHJSA-N CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C\C[Y].II.I[IH]I Chemical compound CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C\C[Y].II.I[IH]I YYJJSQOAWYAEKC-FBSFSYHJSA-N 0.000 description 1
- LHYHCZINPWTWRR-ODZIPUNVSA-K CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C\C[Y].I[V]I.[V]I Chemical compound CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C\C[Y].I[V]I.[V]I LHYHCZINPWTWRR-ODZIPUNVSA-K 0.000 description 1
- IMUGDCQOTKREER-VLCVYXDNSA-M CC(C)=CCC/C(C)=C/CC/C(C)=C/COP(=O)(O)OP(=O)(O)O.[V].[V]I Chemical compound CC(C)=CCC/C(C)=C/CC/C(C)=C/COP(=O)(O)OP(=O)(O)O.[V].[V]I IMUGDCQOTKREER-VLCVYXDNSA-M 0.000 description 1
- HZXTXSFNGWEVNN-JXMROGBWSA-N CC(C)=CCC/C(C)=C/COPP Chemical compound CC(C)=CCC/C(C)=C/COPP HZXTXSFNGWEVNN-JXMROGBWSA-N 0.000 description 1
- FJKPGDOXXAHDGN-HTVUWQLHSA-N CC/C=C(/C)CC/C=C(\C)CC/C=C(\C)CCC=C(C)C.II.II Chemical compound CC/C=C(/C)CC/C=C(\C)CC/C=C(\C)CCC=C(C)C.II.II FJKPGDOXXAHDGN-HTVUWQLHSA-N 0.000 description 1
- XWOYXGHSRDQVQB-HTVUWQLHSA-N CC/C=C(/C)CC/C=C(\C)CC/C=C(\C)CCC=C(C)C.II.I[IH]I Chemical compound CC/C=C(/C)CC/C=C(\C)CC/C=C(\C)CCC=C(C)C.II.I[IH]I XWOYXGHSRDQVQB-HTVUWQLHSA-N 0.000 description 1
- DYLIXDPINFQWQC-ZDKCQUBVSA-K CC/C=C(/C)CC/C=C(\C)CC/C=C(\C)CCC=C(C)C.I[V]I.[V]I Chemical compound CC/C=C(/C)CC/C=C(\C)CC/C=C(\C)CCC=C(C)C.I[V]I.[V]I DYLIXDPINFQWQC-ZDKCQUBVSA-K 0.000 description 1
- RHBKITGXFQFIEM-FYCHQBGDSA-N CCC(CC/C(\C)=C/CC/C(\C)=C/COP(O)(OP(O)(O)=O)=O)C(C)=O Chemical compound CCC(CC/C(\C)=C/CC/C(\C)=C/COP(O)(OP(O)(O)=O)=O)C(C)=O RHBKITGXFQFIEM-FYCHQBGDSA-N 0.000 description 1
- UBEFJJDBXBATPZ-SWZPTJTJSA-N CCCSC\C(C)=C\CC\C(C)=C\COP(O)(=O)OP(O)(O)=O Chemical compound CCCSC\C(C)=C\CC\C(C)=C\COP(O)(=O)OP(O)(O)=O UBEFJJDBXBATPZ-SWZPTJTJSA-N 0.000 description 1
- UBWHNROJGRHAKJ-IAVOFVOCSA-N COCOC\C(C)=C\CC\C(C)=C\COP(O)(=O)OP(O)(O)=O Chemical compound COCOC\C(C)=C\CC\C(C)=C\COP(O)(=O)OP(O)(O)=O UBWHNROJGRHAKJ-IAVOFVOCSA-N 0.000 description 1
- PRFDQHCVOVMMJC-UHFFFAOYSA-N COP(=O)(O)OP(=O)(O)O Chemical compound COP(=O)(O)OP(=O)(O)O PRFDQHCVOVMMJC-UHFFFAOYSA-N 0.000 description 1
- ZRYBTSSYJRTFQM-UHFFFAOYSA-K COP(=O)(O)OP(=O)(O)O.COP(=O)([O-])OP(=O)([O-])[O-] Chemical compound COP(=O)(O)OP(=O)(O)O.COP(=O)([O-])OP(=O)([O-])[O-] ZRYBTSSYJRTFQM-UHFFFAOYSA-K 0.000 description 1
- AIDMKAWEWQKQAF-QYFSLLALSA-N C\C(CC\C=C(/C)CO[Si](C)(C)C(C)(C)C)=C/COP(O)(=O)OP(O)(O)=O Chemical compound C\C(CC\C=C(/C)CO[Si](C)(C)C(C)(C)C)=C/COP(O)(=O)OP(O)(O)=O AIDMKAWEWQKQAF-QYFSLLALSA-N 0.000 description 1
- 101100327917 Caenorhabditis elegans chup-1 gene Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 241001517047 Corynebacterium acetoacidophilum Species 0.000 description 1
- 241000186145 Corynebacterium ammoniagenes Species 0.000 description 1
- 241001485655 Corynebacterium glutamicum ATCC 13032 Species 0.000 description 1
- 241000807905 Corynebacterium glutamicum ATCC 14067 Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241000235646 Cyberlindnera jadinii Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 241000192534 Dolichospermum flos-aquae Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 241001452028 Escherichia coli DH1 Species 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 1
- 240000003537 Ficus benghalensis Species 0.000 description 1
- 240000008168 Ficus benjamina Species 0.000 description 1
- 244000286663 Ficus elastica Species 0.000 description 1
- 241000983593 Ficus lyrata Species 0.000 description 1
- 244000292839 Ficus religiosa Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010001498 Galectin 1 Proteins 0.000 description 1
- 102100021736 Galectin-1 Human genes 0.000 description 1
- 102100024637 Galectin-10 Human genes 0.000 description 1
- 101001011019 Gallus gallus Gallinacin-10 Proteins 0.000 description 1
- 101001011021 Gallus gallus Gallinacin-12 Proteins 0.000 description 1
- 241001401556 Glutamicibacter mysorens Species 0.000 description 1
- 241001524188 Glutamicibacter nicotianae Species 0.000 description 1
- 241001524175 Glutamicibacter protophormiae Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 101150102264 IE gene Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001531414 Isochromatium buderi Species 0.000 description 1
- 241000186984 Kitasatospora aureofaciens Species 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000162718 Lactarius chrysorrheus Species 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241000589323 Methylobacterium Species 0.000 description 1
- 241000589308 Methylobacterium extorquens Species 0.000 description 1
- 241001148217 Methylobacterium rhodesianum Species 0.000 description 1
- 241001467578 Microbacterium Species 0.000 description 1
- 241000144155 Microbacterium ammoniaphilum Species 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 241000256259 Noctuidae Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 101150012394 PHO5 gene Proteins 0.000 description 1
- 241000157908 Paenarthrobacter aurescens Species 0.000 description 1
- 241001524178 Paenarthrobacter ureafaciens Species 0.000 description 1
- 241000157907 Paeniglutamicibacter sulfureus Species 0.000 description 1
- 241000588912 Pantoea agglomerans Species 0.000 description 1
- 241000588701 Pectobacterium carotovorum Species 0.000 description 1
- 241001406327 Periploca sepium Species 0.000 description 1
- 241000192608 Phormidium Species 0.000 description 1
- 241000192605 Phormidium sp. Species 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589774 Pseudomonas sp. Species 0.000 description 1
- 241000191025 Rhodobacter Species 0.000 description 1
- 241000190953 Rhodobacter blasticus Species 0.000 description 1
- 241000191023 Rhodobacter capsulatus Species 0.000 description 1
- 241000191043 Rhodobacter sphaeroides Species 0.000 description 1
- 241000190932 Rhodopseudomonas Species 0.000 description 1
- 241000190950 Rhodopseudomonas palustris Species 0.000 description 1
- 241000190967 Rhodospirillum Species 0.000 description 1
- 241000190984 Rhodospirillum rubrum Species 0.000 description 1
- 241000190982 Rhodothalassium salexigens Species 0.000 description 1
- 241000190980 Rhodovibrio salinarum Species 0.000 description 1
- 229910003797 SPO1 Inorganic materials 0.000 description 1
- 229910003798 SPO2 Inorganic materials 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 101100150136 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SPO1 gene Proteins 0.000 description 1
- 241000195663 Scenedesmus Species 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 101100478210 Schizosaccharomyces pombe (strain 972 / ATCC 24843) spo2 gene Proteins 0.000 description 1
- 241000311088 Schwanniomyces Species 0.000 description 1
- 241000235005 Schwanniomyces occidentalis var. occidentalis Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000881765 Serratia ficaria Species 0.000 description 1
- 241000218654 Serratia fonticola Species 0.000 description 1
- 241000607717 Serratia liquefaciens Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000187758 Streptomyces ambofaciens Species 0.000 description 1
- 241001454747 Streptomyces aureus Species 0.000 description 1
- 241000971005 Streptomyces fungicidicus Species 0.000 description 1
- 241000970979 Streptomyces griseochromogenes Species 0.000 description 1
- 241000187392 Streptomyces griseus Species 0.000 description 1
- 241000187398 Streptomyces lividans Species 0.000 description 1
- 241000813830 Streptomyces olivogriseus Species 0.000 description 1
- 241000970898 Streptomyces rameus Species 0.000 description 1
- 241000946755 Streptomyces tanashiensis Species 0.000 description 1
- 241000187123 Streptomyces vinaceus Species 0.000 description 1
- 241000192707 Synechococcus Species 0.000 description 1
- 241001634922 Tausonia pullulans Species 0.000 description 1
- 241000190988 Thermochromatium tepidum Species 0.000 description 1
- 241000723873 Tobacco mosaic virus Species 0.000 description 1
- 241000078018 Trichormus doliolum Species 0.000 description 1
- 241000223230 Trichosporon Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 238000006959 Williamson synthesis reaction Methods 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 241000588901 Zymomonas Species 0.000 description 1
- 241000588902 Zymomonas mobilis Species 0.000 description 1
- MEDQXQPLZCFIBE-GAECQFIQSA-N [(1E)-6-[acetyl(pentyl)amino]-3-methylhexa-1,3-dienyl] phosphono hydrogen phosphate Chemical compound CCCCCN(CCC=C(C)/C=C/OP(=O)(O)OP(=O)(O)O)C(=O)C MEDQXQPLZCFIBE-GAECQFIQSA-N 0.000 description 1
- SIKVHJCBGPGULN-WAAHFECUSA-N [(2E,6E)-10-hydroxy-3,7-dimethyldodeca-2,6-dienyl] phosphono hydrogen phosphate Chemical compound CCC(O)CC\C(C)=C\CC\C(C)=C\COP(O)(=O)OP(O)(O)=O SIKVHJCBGPGULN-WAAHFECUSA-N 0.000 description 1
- HFDRABRAYASVKA-ZYHSJPTQSA-N [(2E,6E)-3,7-dimethyl-8-phenylmethoxyocta-2,6-dienyl] phosphono hydrogen phosphate Chemical compound C/C(=C\COP(=O)(O)OP(=O)(O)O)/CC/C=C(\C)/COCC1=CC=CC=C1 HFDRABRAYASVKA-ZYHSJPTQSA-N 0.000 description 1
- WDGSFSHXHFSVAG-PJCPOQCISA-N [(2E,6E)-8-hydroxy-3,7-dimethyldodeca-2,6-dienyl] phosphono hydrogen phosphate Chemical compound CCCCC(O)C(\C)=C\CC\C(C)=C\COP(O)(=O)OP(O)(O)=O WDGSFSHXHFSVAG-PJCPOQCISA-N 0.000 description 1
- XTIDUWJDMNIOEA-AOAVBJDHSA-N [(2E,6E)-8-methoxy-3,7-dimethyldodeca-2,6-dienyl] phosphono hydrogen phosphate Chemical compound CCCCC(/C(=C/CC/C(=C/COP(=O)(O)OP(=O)(O)O)/C)/C)OC XTIDUWJDMNIOEA-AOAVBJDHSA-N 0.000 description 1
- 239000006061 abrasive grain Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 238000012644 addition polymerization Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019297 ammonium fumarate Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- CKKXWJDFFQPBQL-SEPHDYHBSA-N azane;(e)-but-2-enedioic acid Chemical compound N.N.OC(=O)\C=C\C(O)=O CKKXWJDFFQPBQL-SEPHDYHBSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
- VFEVXBKBGMAKME-UHFFFAOYSA-N butane;hydrobromide Chemical compound Br.CCCC VFEVXBKBGMAKME-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- FCYRSDMGOLYDHL-UHFFFAOYSA-N chloromethoxyethane Chemical compound CCOCCl FCYRSDMGOLYDHL-UHFFFAOYSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 229920003244 diene elastomer Polymers 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- WCASXYBKJHWFMY-UHFFFAOYSA-N gamma-methylallyl alcohol Natural products CC=CCO WCASXYBKJHWFMY-UHFFFAOYSA-N 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- XWRJRXQNOHXIOX-UHFFFAOYSA-N geranylgeraniol Natural products CC(C)=CCCC(C)=CCOCC=C(C)CCC=C(C)C XWRJRXQNOHXIOX-UHFFFAOYSA-N 0.000 description 1
- OJISWRZIEWCUBN-UHFFFAOYSA-N geranylnerol Natural products CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCO OJISWRZIEWCUBN-UHFFFAOYSA-N 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- NSPJNIDYTSSIIY-UHFFFAOYSA-N methoxy(methoxymethoxy)methane Chemical group COCOCOC NSPJNIDYTSSIIY-UHFFFAOYSA-N 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000002897 organic nitrogen compounds Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 101150019841 penP gene Proteins 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- SUVIGLJNEAMWEG-UHFFFAOYSA-N propane-1-thiol Chemical compound CCCS SUVIGLJNEAMWEG-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003333 secondary alcohols Chemical group 0.000 description 1
- 150000003334 secondary amides Chemical class 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 125000005372 silanol group Chemical group 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 239000005061 synthetic rubber Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- HEUIAKTUJMENAO-UHFFFAOYSA-N tert-butyl-chloro-phenylsilane Chemical compound CC(C)(C)[SiH](Cl)C1=CC=CC=C1 HEUIAKTUJMENAO-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 229910021654 trace metal Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- FBBATURSCRIBHN-UHFFFAOYSA-N triethoxy-[3-(3-triethoxysilylpropyldisulfanyl)propyl]silane Chemical compound CCO[Si](OCC)(OCC)CCCSSCCC[Si](OCC)(OCC)OCC FBBATURSCRIBHN-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P5/00—Preparation of hydrocarbons or halogenated hydrocarbons
- C12P5/007—Preparation of hydrocarbons or halogenated hydrocarbons containing one or more isoprene units, i.e. terpenes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G61/00—Macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chain of the macromolecule
- C08G61/02—Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes
- C08G61/04—Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes only aliphatic carbon atoms
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60C—VEHICLE TYRES; TYRE INFLATION; TYRE CHANGING; CONNECTING VALVES TO INFLATABLE ELASTIC BODIES IN GENERAL; DEVICES OR ARRANGEMENTS RELATED TO TYRES
- B60C1/00—Tyres characterised by the chemical composition or the physical arrangement or mixture of the composition
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60C—VEHICLE TYRES; TYRE INFLATION; TYRE CHANGING; CONNECTING VALVES TO INFLATABLE ELASTIC BODIES IN GENERAL; DEVICES OR ARRANGEMENTS RELATED TO TYRES
- B60C1/00—Tyres characterised by the chemical composition or the physical arrangement or mixture of the composition
- B60C1/0016—Compositions of the tread
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60C—VEHICLE TYRES; TYRE INFLATION; TYRE CHANGING; CONNECTING VALVES TO INFLATABLE ELASTIC BODIES IN GENERAL; DEVICES OR ARRANGEMENTS RELATED TO TYRES
- B60C1/00—Tyres characterised by the chemical composition or the physical arrangement or mixture of the composition
- B60C1/0025—Compositions of the sidewalls
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60C—VEHICLE TYRES; TYRE INFLATION; TYRE CHANGING; CONNECTING VALVES TO INFLATABLE ELASTIC BODIES IN GENERAL; DEVICES OR ARRANGEMENTS RELATED TO TYRES
- B60C13/00—Tyre sidewalls; Protecting, decorating, marking, or the like, thereof
- B60C13/001—Decorating, marking or the like
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C21/00—Acyclic unsaturated compounds containing halogen atoms
- C07C21/02—Acyclic unsaturated compounds containing halogen atoms containing carbon-to-carbon double bonds
- C07C21/04—Chloro-alkenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/06—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms of an acyclic and unsaturated carbon skeleton
- C07C255/07—Mononitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/23—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same unsaturated acyclic carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
- C07C33/02—Acyclic alcohols with carbon-to-carbon double bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
- C07C47/21—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/03—Monocarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/098—Esters of polyphosphoric acids or anhydrides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/141—Esters of phosphorous acids
- C07F9/143—Esters of phosphorous acids with unsaturated acyclic alcohols
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F36/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, at least one having two or more carbon-to-carbon double bonds
- C08F36/02—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, at least one having two or more carbon-to-carbon double bonds the radical having only two carbon-to-carbon double bonds
- C08F36/04—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, at least one having two or more carbon-to-carbon double bonds the radical having only two carbon-to-carbon double bonds conjugated
- C08F36/08—Isoprene
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L9/00—Compositions of homopolymers or copolymers of conjugated diene hydrocarbons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/002—Nitriles (-CN)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/02—Amides, e.g. chloramphenicol or polyamides; Imides or polyimides; Urethanes, i.e. compounds comprising N-C=O structural element or polyurethanes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
- C12P7/04—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/24—Preparation of oxygen-containing organic compounds containing a carbonyl group
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/62—Carboxylic acid esters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P9/00—Preparation of organic compounds containing a metal or atom other than H, N, C, O, S or halogen
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts
Definitions
- the present invention relates to an isoprene oligomer and a polyisoprene; processes for producing these materials; a rubber composition including the isoprene oligomer and/or the polyisoprene; and a pneumatic tire formed from the rubber composition.
- filler e.g., silica, carbon black
- organic rubber fraction e.g., silica, carbon black
- a modified rubber modified diene polymer
- a functional group having affinity for the filler is introduced in rubber molecules in the rubber fraction as a result of, for example, a treatment involving reacting rubber molecules with, for example, a compound containing both a nitrogen atom-containing group and a chlorosulfenyl group (see, for example, Patent Literatures 1 and 2).
- a predetermined functional group is difficult to introduce to a predetermined position in the rubber molecule and is consequently introduced to, particularly, a random position in the main chain constituting the rubber molecule.
- Use of such rubber molecules containing a predetermined functional group introduced in the main chain is less likely to produce the desired effects due to the random bonds between the rubber molecules and filler.
- the functional group-introduced sites have deteriorated rubber properties, which disadvantageously results in deterioration in the properties of the whole rubber.
- An object of the present invention is to solve the problems described above and to provide an isoprene oligomer and a polyisoprene which have been modified substantially only at a terminal site of the molecule.
- Another object of the present invention is to provide a rubber composition including the isoprene oligomer and/or the polyisoprene, and pneumatic tires including various tire components (e.g., treads and sidewalls) formed from the rubber composition.
- the present invention relates to an isoprene oligomer including a trans structural moiety and a cis structural moiety, which is represented by the following formula (1), wherein at least 1 atom or group in the trans structural moiety is replaced by another atom or group:
- n represents an integer from 1 to 10
- m represents an integer from 1 to 30
- Y represents a hydroxy group, a formyl group, a carboxy group, an ester group, a carbonyl group, or a group represented by the following formula (2):
- trans structural moiety should be represented by any of the following formulas (a) to (s):
- the isoprene oligomer should be biosynthesized using an allylic diphosphate and isopentenyl diphosphate;
- the allylic diphosphate is represented by the following formula (3), wherein at least 1 atom or group in the isoprene units in formula (3) is replaced by another atom or group:
- p represents an integer from 1 to 10.
- biosynthesis should be carried out using an enzyme that shows prenyltransferase activity.
- the enzyme that shows prenyltransferase activity should be any of the following proteins:
- p represents an integer from 1 to 10.
- the present invention also relates to a process for producing the isoprene oligomer, which involves the biosynthesis of isoprene oligomer by using an allylic diphosphate and isopentenyl diphosphate, wherein the allylic diphosphate can be represented by the following formula (3), wherein at least 1 atom or group in the isoprene units in formula (3) is replaced by another atom or group:
- p represents an integer from 1 to 10.
- biosynthesis should be carried out using an enzyme showing prenyltransferase activity.
- the present invention further relates to a polyisoprene including a trans structural moiety and a cis structural moiety, which is represented by the following formula (4), wherein at least 1 atom or group in the trans structural moiety is replaced by another atom or group:
- the polyisoprene should be biosynthesized using the isoprene oligomer and isopentenyl diphosphate.
- the present invention further relates to a process for producing the polyisoprene, which involves the biosynthesis of the polyisoprene by using the isoprene oligomer and isopentenyl diphosphate.
- the present invention further relates to a rubber composition including at least 1 of the isoprene oligomers and the polyisoprene.
- the present invention further relates to a pneumatic tire formed from the rubber composition.
- the isoprene oligomer of the present invention is an isoprene oligomer containing a trans structural moiety and a cis structural moiety represented by the formula (1), wherein at least one atom or group contained in the trans structural moiety is replaced by another atom or group.
- the polyisoprene of the present invention is a polyisoprene containing a trans structural moiety and a cis structural moiety represented by the formula (4), wherein at least one atom or group contained in the trans structural moiety is replaced by another atom or group.
- the isoprene oligomer of the present invention and the polyisoprene of the present invention have been modified substantially only at a terminal site of the molecule (rubber molecule) and therefore are excellent in affinity for filler such as silica while the original properties of the molecules (rubber molecules) are not impaired. Accordingly, a rubber composition containing the isoprene oligomer of the present invention and/or the polyisoprene of the present invention is obtained as a rubber composition in which rubber molecules are combined with filler in a level higher than ever.
- the present invention can provide a rubber composition excellent in, for example, low-heat-build-up properties, and wet grip performance.
- Use of the rubber composition in various tire components e.g., treads and sidewalls
- an enzyme such as prenyltransferase is allowed to act on a mixture of an initiating substrate such as farnesyl diphosphate (FPP) and monomer such as isopentenyl diphosphate to produce an isoprene oligomer having approximately 8 isoprene units addition-polymerized to the initiating substrate.
- FPP farnesyl diphosphate
- monomer such as isopentenyl diphosphate
- isoprene oligomer is then further mixed with a latex component containing an enzyme for addition-polymerizing isopentenyl diphosphate to produce a polyisoprene having a large number of isopentenyl diphosphate units linked to the oligomer.
- the addition polymerization mediated by natural enzymes is indispensable to various steps for sequentially linking the monomers starting from the initiating substrate to form a rubber molecule.
- the biosynthesis of a rubber molecule requires using an initiating substrate and monomer whose reaction can be catalyzed by the enzyme used, which results in limitations to the structures of the initiating substrate and monomer used as raw materials for the rubber molecule (polyisoprene).
- the initiating substrate is limited to naturally occurring dimethylallyl diphosphate, geranyl diphosphate, farnesyl diphosphate, geranylgeranyl diphosphate, and the like due to restrictions attributed to the enzyme for producing the oligomer.
- the artificially biosynthesized rubber molecule (polyisoprene) is also limited in the degree of freedom of its structure.
- free molecular design for imparting functionality that is absent in natural rubber is made difficult.
- a functional group having affinity for filler is introduced into a rubber molecule, for example, by a treatment including reacting a rubber molecule (polyisoprene) biosynthesized in advance with, for example, a compound containing both a nitrogen atom-containing group and a chlorosulfenyl group, similarly as in the case of using synthetic rubber as a raw material.
- the present invention is based on the findings that an isoprene oligomer or polyisoprene having a terminal site to which functionality has been imparted can be produced by using partially structurally modified farnesyl diphosphate or the like as an initiating substrate for the isoprene oligomer or polyisoprene production.
- the present invention is based on the findings that by maintaining the structure of moiety I in the following formula (I) in the naturally occurring initiating substrate farnesyl diphosphate or the like, even when a desired structure is introduced in a moiety other than moiety I, it is possible to produce isoprene oligomers in the presence of the naturally occurring oligomer-producing enzyme prenyltransferase or any enzyme obtained by partial mutation thereof. This is probably, albeit not absolutely clear, because prenyltransferase is adsorbed on the structure of moiety I in the formula (I) of the initiating substrate and is relatively insensitive to the structures of other moieties.
- an isoprene oligomer or polyisoprene having a terminal site having desired properties can be provided.
- isoprene oligomers or polyisoprenes having various functions can be provided without impairing the properties of isoprene oligomer or polyisoprene itself.
- the isoprene oligomer of the present invention is an isoprene oligomer containing a trans structural moiety and a cis structural moiety represented by the formula (1) shown below, wherein at least one atom or group contained in the trans structural moiety is replaced by another atom or group.
- the trans structural moiety means a moiety of repeated isoprene units with a trans structure (moiety A in the formula (1) shown below).
- the cis structural moiety means a moiety of repeated isoprene units with a cis structure (moiety ( ) m (moiety B) in the formula (1) shown below).
- the group represented by the formula (2) shown below has three hydroxy groups bonded to a phosphorus atom, and some (or one) or all of these hydroxy groups are dissociated in an aqueous solution (for example, a group represented by the formula (5) shown below is then formed).
- the group represented by the formula (2) also conceptually encompasses such groups in which some (or one) or all of the hydroxy groups have been dissociated.
- the modification of a terminal site of the molecule refers to the introduction of a desired functional group into a predetermined site in the trans structural moiety present at an end of the molecule (rubber molecule), or the introduction of a different structure into a predetermined site in the trans structural moiety present at an end of the molecule (rubber molecule).
- n represents an integer of 1 to 10
- m represents an integer of 1 to 30
- Y represents a hydroxy group, a formyl group, a carboxy group, an ester group, a carbonyl group, or a group represented by the following formula (2).
- the isoprene oligomer of the present invention is structurally similar to natural rubber and is highly compatible with rubber molecules. Moreover, the isoprene oligomer of the present invention has been modified substantially only at a terminal site of the molecule. Specifically, the isoprene oligomer of the present invention contains a hydroxy group, a formyl group, a carboxy group, an ester group, a carbonyl group, or a group represented by the formula (2), positioned at the end of the cis structural moiety, and at least one atom or group contained in the trans structural moiety is replaced by another atom or group.
- the isoprene oligomer of the present invention strongly interacts with filler such as silica while the original properties of isoprene oligomer are not impaired. Since the isoprene oligomer of the present invention is highly compatible with rubber and strongly interacts with filler such as silica, as described above, a rubber composition containing this isoprene oligomer is obtained as a rubber composition in which rubber molecules are combined with filler in a level higher than ever. The resulting rubber composition can have, for example, improved low-heat-build-up properties, wet grip performance, and abrasion resistance.
- the isoprene oligomer of the present invention contains a polar group or the like only at the terminal site of the cis structural moiety and a site close to the end of the trans structural moiety.
- the isoprene oligomer therefore offers high dispersibility of filler such as silica and has a large effect of improving, for example, low-heat-build-up properties, wet grip performance, and abrasion resistance while the original properties of isoprene oligomer are not impaired, compared with isoprene oligomers containing a polar group or the like in the main chain moiety or only at the terminal site of the cis structural moiety.
- the isoprene oligomer of the present invention has excellent antimicrobial activity. This is presumably because the isoprene oligomer of the present invention, in which at least one atom or group contained in the trans structural moiety is replaced by another atom or group, structurally differs from usual isoprene oligomers present in the natural world and thus has effects such as the inhibition of enzymes or coenzymes, the inhibition of nucleic acid synthesis, the inhibition of cell membrane synthesis, the inhibition of cytoplasmic membrane synthesis, cell membrane disruption, and cytoplasmic membrane disruption in microbes.
- n represents an integer of 1 to 10 (preferably 1 to 4, more preferably 1 to 3).
- m represents an integer of 1 to 30 (preferably 1 to 10, more preferably 1 to 8).
- Y represents a hydroxy group (—OH), a formyl group (—CHO), a carboxy group (—COOH), an ester group (—COOR), a carbonyl group (—COR), or a group represented by the formula (2).
- R represents an alkyl group having 1 to 30 (preferably 1 to 17) carbon atoms.
- alkyl group having 1 to 30 carbon atoms include methyl, ethyl, propyl, butyl, and pentyl groups.
- Y is preferably a hydroxy group or a carboxy group, because the resulting isoprene oligomer has excellent antimicrobial properties and strongly interacts with filler such as silica.
- At least one atom or group contained in the trans structural moiety in the formula (1) has been replaced by another atom or group.
- Examples of the atom or group (atom or group before replacement) contained in the trans structural moiety include a hydrogen atom, a methyl group, a methylene group, a carbon atom, and a methine group.
- Examples of the another atom include nitrogen, oxygen, sulfur, silicon, and carbon atoms.
- a nitrogen atom has a strong intermolecular force and causes strong interaction with enzymes or cell membranes. For this reason, a nitrogen atom is preferred in terms of antimicrobial properties.
- Examples of the another group include an acetoxy group, alkoxy groups (preferably, alkoxy groups having 1 to 3 carbon atoms, more preferably a methoxy group), a hydroxy group, aryl groups (preferably, a phenyl group), alkyl groups (preferably, alkyl groups having 1 to 5 carbon atoms, more preferably an ethyl group and a tert-butyl group), an acetyl group, N-alkyl-acetamino groups (whose alkyl preferably has 1 to 5 carbon atoms), and an azide group.
- alkoxy groups preferably, alkoxy groups having 1 to 3 carbon atoms, more preferably a methoxy group
- aryl groups preferably, a phenyl group
- alkyl groups preferably, alkyl groups having 1 to 5 carbon atoms, more preferably an ethyl group and a tert-butyl group
- an acetyl group N-alkyl-ace
- N-alkyl-acetamino groups (more preferably, N-methyl-acetamino and N-butyl-acetamino groups) and azide group are preferred in terms of antimicrobial properties.
- At least one atom or group contained in the trans structural moiety has been replaced by another atom or group.
- n, m, and Y are as defined for n, m, and Y in the formula (1).
- trans structural moiety in the formula (1) include structures represented by the formulas (a) to (s) shown below.
- structures represented by the formulas (c), (d), (e), (f), (k), (l), and (r) are preferred, because the resulting isoprene oligomer has a large effect of improving low-heat-build-up properties, wet grip performance, and abrasion resistance.
- structures represented by the formulas (g) to (q) are preferred, with structures represented by the formulas (k), (l), and (q) being more preferred, because the resulting isoprene oligomer is excellent in antimicrobial properties.
- Examples of the process for producing the isoprene oligomer of the present invention include a process including performing biosynthesis from an allylic diphosphate and isopentenyl diphosphate, the allylic diphosphate (hereinafter, also referred to as an allylic diphosphate derivative) being represented by the formula (3) shown below, wherein at least one atom or group contained in isoprene units in the formula (3) is replaced by another atom or group.
- the allylic diphosphate derivative has three hydroxy groups bonded to a phosphorus atom, and some (or one) or all of these hydroxy groups are dissociated in an aqueous solution (for example, a group represented by the formula (5) is then formed).
- the allylic diphosphate derivative also conceptually encompasses such groups in which some (or one) or all of the hydroxy groups have been dissociated.
- p represents an integer of 1 to 10.
- p represents an integer of 1 to 10 (preferably 1 to 4, more preferably 1 to 3).
- examples of the atom or group (atom or group before replacement) contained in isoprene units in the formula (3) include the same as those exemplified as the atom or group (atom or group before replacement) contained in the trans structural moiety in the formula (1).
- examples of the another atom or group for replacing the atom or group contained in isoprene units in the formula (3) include the same as those exemplified as the another atom or the another group described for the formula (1).
- moiety I in the formula (I) should be maintained after the replacement, as described above.
- at least one atom or group contained in moiety IV in the formula (3-1) shown below should be replaced while no atom or group contained in moiety V in the formula (3-1) should be replaced. This allows favorable production of isoprene oligomers using the naturally occurring oligomer-producing enzyme prenyltransferase or any enzyme obtained by partial mutation thereof.
- allylic diphosphate derivative examples include compounds represented by the following formulas (A) to (S).
- OPP has three hydroxy groups bonded to a phosphorus atom, and some (or one) or all of these hydroxy groups are dissociated in an aqueous solution (for example, a group represented by the formula (5) is then formed).
- OPP also conceptually encompasses such groups in which some (or one) or all of the hydroxy groups have been dissociated.
- Allylic diphosphate derivatives represented by the formulas (A) to (S) and the like can be produced by those skilled in the art with reference to the processes described in Examples, using, for example, dimethylallyl diphosphate, geranyl diphosphate, farnesyl diphosphate, geranylgeranyl diphosphate, geraniol, farnesol, or geranylgeraniol.
- Examples of the process for biosynthesizing the isoprene oligomer of the present invention from the allylic diphosphate derivative and isopentenyl diphosphate include a process using an enzyme having prenyltransferase activity.
- the allylic diphosphate derivative and isopentenyl diphosphate may be allowed to react with each other in the presence of an enzyme having prenyltransferase activity.
- the enzyme having prenyltransferase activity means an enzyme having activity of catalyzing the condensation reaction between an allylic substrate (allylic diphosphate) and isopentenyl diphosphate to synthesize a new allylic diphosphate in which one isoprene unit is added, and catalyzing a reaction through which isopentenyl diphosphate is sequentially linked in a Z form (newly added isoprene unit has a cis structure) starting from the allylic substrate (allylic diphosphate).
- Examples thereof include enzymes for catalyzing the following reaction:
- organisms containing the enzyme having prenyltransferase activity include Micrococcus luteus B-P 26, Escherichia coli, Saccharomyces cerevisiae, Arabidopsis thaliana, Hevea brasiliensis, Periploca sepium, Bacillus Stearothermophilus , and Sulfolobus acidocaldarius (ATCC49426).
- the isoprene oligomer of the present invention can be obtained by reacting the allylic diphosphate derivative with isopentenyl diphosphate in the presence of the enzyme having prenyltransferase activity.
- the phrase “in the presence of the enzyme having prenyltransferase activity” means the presence of a culture of the organism, biological cells separated from the culture, a treated product of the biological cells, the enzyme purified from the culture or the biological cells, a culture of biological cells (transformant) transformed by a genetic engineering approach so as to express the enzyme having prenyltransferase activity (this enzyme also encompasses variant enzymes described later), biological cells separated from the culture, a treated product of the biological cells, the enzyme purified from the culture or the biological cells, or the like.
- the biological cells transformed so as to express the enzyme having prenyltransferase activity refer to a transformant prepared by a genetic engineering approach conventionally known in the art. The preparation method will be described later.
- the organism can be cultured in an appropriate medium.
- the medium for this purpose is not particularly limited as long as the organism can proliferate therein.
- a usual medium containing usual carbon source, nitrogen source and inorganic ions, and optionally organic nutrient sources can be used.
- any carbon sources that can be utilized by the organism can be used.
- usable carbon sources include: sugars such as glucose, fructose, maltose, and amylose; alcohols such as sorbitol, ethanol, and glycerol; organic acids such as fumaric acid, citric acid, acetic acid, and propionic acid, and salts thereof; carbohydrates such as paraffin; and mixtures thereof.
- Examples of usable nitrogen sources include: inorganic ammonium salts such as ammonium sulfate and ammonium chloride; ammonium salts of organic acids such as ammonium fumarate and ammonium citrate; nitrates such as sodium nitrate and potassium nitrate; organic nitrogen compounds such as peptone, yeast extracts, meat extracts, and corn steep liquor; and mixtures thereof.
- inorganic ammonium salts such as ammonium sulfate and ammonium chloride
- ammonium salts of organic acids such as ammonium fumarate and ammonium citrate
- nitrates such as sodium nitrate and potassium nitrate
- organic nitrogen compounds such as peptone, yeast extracts, meat extracts, and corn steep liquor; and mixtures thereof.
- nutrient sources used in usual media such as inorganic salts, trace metal salts, vitamins, and hormones, can be mixed appropriately for use.
- the culture conditions are not particularly limited and culture can be performed at pH and temperature appropriately controlled in the ranges of pH 5 to 8 and temperature 20 to 60° C., for approximately 12 to 480 hours under aerobic conditions.
- Examples of the culture of the organism include a culture solution obtained by culturing the organism under the culture conditions described above, and a culture filtrate (culture supernatant) obtained by separating the organism (biological cells) from the culture solution by filtration or the like. Also, examples of the biological cells separated from the culture include biological cells (organism) separated from the culture solution by filtration, centrifugation, or the like.
- Examples of the treated product of the biological cells include disrupted biological cells obtained by homogenizing the biological cells separated from the culture, and disrupted biological cells obtained by sonicating the biological cells separated from the culture.
- the enzyme purified from the culture or the biological cells may be obtained, for example, by a known purification operation, such as salting out, ion-exchange chromatography, affinity chromatography, or gel-filtration chromatography, for the enzyme present in the culture or the biological cells.
- the purified enzyme is not particularly limited in its purity.
- the isoprene oligomer of the present invention can be obtained by reacting the allylic diphosphate derivative with isopentenyl diphosphate in the presence of the enzyme having prenyltransferase activity.
- the culture of the biological cells, the purified enzyme or the like can be added into a solution containing the allylic diphosphate derivative and isopentenyl diphosphate to perform the reaction.
- the reaction temperature can be set to, for example, 20 to 60° C.
- the reaction time can be set to, for example, 1 to 16 hours
- the pH can be set to, for example, 5 to 8.
- magnesium chloride, a surfactant, 2-mercaptoethanol, and the like may further be added thereto.
- the isoprene oligomer of the present invention obtained by the reaction is usually represented by the formula (1) wherein Y is a group represented by the formula (2) or a hydroxy group. This hydroxy group is formed through the hydrolysis of the group represented by the formula (2).
- the isoprene oligomer represented by the formula (1) wherein Y is a formyl group can be obtained, for example, by the oxidation of the isoprene oligomer of the formula (1) wherein Y is a group represented by the formula (2).
- the isoprene oligomer represented by the formula (1) wherein Y is a carboxy group can be obtained, for example, by the oxidation of the isoprene oligomer of the formula (1) wherein Y is a group represented by the formula (2).
- the isoprene oligomer represented by the formula (1) wherein Y is an ester group can be obtained, for example, by the oxidation and esterification of the isoprene oligomer of the formula (1) wherein Y is a group represented by the formula (2).
- the isoprene oligomer represented by the formula (1) wherein Y is a carbonyl group can be obtained, for example, by the oxidation and esterification of the isoprene oligomer of the formula (1) wherein Y is a group represented by the formula (2).
- the isoprene oligomer of the present invention is obtained by biosynthesis except for the organic synthesis of the allylic diphosphate derivative as an initiating substrate, and can thus take into account the exhaustion of petroleum resources and environmental issues.
- the base sequence and the amino acid sequence of Micrococcus luteus B-P 26 are shown in SEQ ID NOs: 1 and 2, respectively, in the Sequence Listing.
- the base sequence and the amino acid sequence of Micrococcus luteus B-P 26-derived undecaprenyl diphosphate synthase are known in the art and included in the database DDBJ (DNA Data Bank of Japan) (Accession No. AB004319 (base sequence) and Accession No. BAA31993.1 (amino acid sequence)).
- the original substrate (initiating substrate) for the enzyme (enzyme having prenyltransferase activity) derived from this organism is an allylic diphosphate.
- the allylic diphosphate derivative used as an initiating substrate in the present invention originally functions as an inhibitor of the enzyme produced by the organism.
- the enzyme produced by the organism often has low enzymatic activity on the allylic diphosphate derivative (particularly, the compound represented by any of the formulas (G) to (Q)). Therefore, in the present invention, it is preferable to use a variant enzyme having enhanced enzymatic activity on the allylic diphosphate derivative.
- variant enzyme biological cells (transformant) transformed by a genetic engineering approach so as to express the variant enzyme can be prepared.
- the present inventors have prepared variant enzymes of the Micrococcus luteus B-P 26-derived undecaprenyl diphosphate synthase and successfully enhanced the enzymatic activity on the allylic diphosphate derivative.
- the three-dimensional structure of the Micrococcus luteus B-P 26-derived undecaprenyl diphosphate synthase has already been known in the art (database PDB (RCSB Protein Data Bank), ID: 1f75).
- database PDB RCSB Protein Data Bank
- the present inventors have conducted docking simulation based on this three-dimensional structure information and prepared variant enzymes on the basis of the design philosophy that the enzymatic activity on the allylic diphosphate derivative can be enhanced by mutation of an amino acid positioned in the vicinity of the hydrocarbon moiety around the diphosphate moiety of the allylic diphosphate so as to change the length of the side chain or the charge.
- variant enzyme N31A asparagine at position 31 was substituted by alanine (its base sequence and amino acid sequence are shown in SEQ ID NOs: 3 and 4, respectively, in the Sequence Listing);
- variant enzyme N77A asparagine at position 77 was substituted by alanine (its base sequence and amino acid sequence are shown in SEQ ID NOs: 5 and 6, respectively, in the Sequence Listing);
- variant enzyme L91N leucine at position 91 was substituted by asparagine (its base sequence and amino acid sequence are shown in SEQ ID NOs: 7 and 8, respectively, in the Sequence Listing);
- variant enzyme L91D leucine at position 91 was substituted by aspartic acid (its base sequence and amino acid sequence are shown in SEQ ID NOs: 9 and 10, respectively, in the Sequence Listing);
- variant enzyme N31Q asparagine at position 31 was substituted by glutamine (its base sequence and amino acid sequence are shown in SEQ ID NOs: 11 and 12, respectively, in the Sequence Listing);
- variant enzyme N77Q asparagine at position 77 was substituted by glutamine (its base sequence and amino acid sequence are shown in SEQ ID NOs: 13 and 14, respectively, in the Sequence Listing);
- L91G leucine at position 91 was substituted by glycine (its base sequence and amino acid sequence are shown in SEQ ID NOs: 15 and 16, respectively, in the Sequence Listing);
- variant enzyme L91K leucine at position 91 was substituted by lysine (its base sequence and amino acid sequence are shown in SEQ ID NOs: 17 and 18, respectively, in the Sequence Listing);
- variant enzyme F95A phenylalanine at position 95 was substituted by alanine (its base sequence and amino acid sequence are shown in SEQ ID NOs: 19 and 20, respectively, in the Sequence Listing);
- variant enzyme F95W phenylalanine at position 95 was substituted by tryptophan (its base sequence and amino acid sequence are shown in SEQ ID NOs: 21 and 22, respectively, in the Sequence Listing).
- variant enzyme N77A variant enzyme L91D, and variant enzyme L91K are preferred.
- Micrococcus luteus B-P 26-derived undecaprenyl diphosphate synthase as a wild-type enzyme is described herein, variant enzymes can be prepared by similar approaches using other enzymes having prenyltransferase activity as wild-type enzymes.
- enzyme having prenyltransferase activity include the following protein [1]:
- enzymes having an amino acid sequence derived from the original amino acid sequence by substitution, deletion, insertion, or addition of one or more amino acids may have enzymatic activity.
- specific examples of the enzyme having prenyltransferase activity also include the following protein [2]:
- p represents an integer of 1 to 10.
- the amino acid sequence should contain substitution, deletion, insertion, or addition of preferably one or more amino acids, more preferably 1 to 100 amino acids, even more preferably 1 to 75 amino acids, particularly preferably 1 to 50 amino acids, further preferably 1 to 25 amino acids, further preferably 1 to 12 amino acids, further preferably 1 to 5 amino acids, and most preferably 1 to 3 amino acids.
- proteins having an amino acid sequence having high sequence identity to the amino acid sequence of the enzyme having prenyltransferase activity may have similar activity.
- specific examples of the enzyme having prenyltransferase activity also include the following protein [3]:
- sequence identity to the amino acid sequence represented by any of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22 is preferably 45% or higher, more preferably 60% or higher, even more preferably 70% or higher, particularly preferably 80% or higher, further preferably 90% or higher, further preferably 95% or higher, further preferably 98% or higher, and most preferably 99% or higher.
- amino acid sequence or base sequence identity can be determined using the algorithm BLAST by Karlin and Altschul [Pro. Natl. Acad. Sci. USA, 90, 5873 (1993)] or FASTA [Methods Enzymol., 183, 63 (1990)].
- Examples of the method for confirming that a protein has activity of catalyzing the reaction between the allylic diphosphate derivative and isopentenyl diphosphate include a method involving preparing a transformant expressing the protein by a method conventionally known in the art, producing the protein using the transformant, and then quantitatively or qualitatively analyzing the substrate or product by HPLC (high-performance liquid chromatography), TLC (thin-layer chromatography), or the like to confirm whether or not the protein can catalyze the reaction between the allylic diphosphate derivative and isopentenyl diphosphate.
- HPLC high-performance liquid chromatography
- TLC thin-layer chromatography
- DNA encoding the enzyme having prenyltransferase activity include the following DNAs [1] to [3]:
- hybridizing means a step in which the DNA hybridizes to DNA having a specific base sequence or a portion of the DNA.
- the base sequence of the DNA having a specific base sequence or the portion of the DNA may be DNA of length that is useful as a probe in Northern or Southern blot analysis or can be used as an oligonucleotide primer in PCR (polymerase chain reaction) analysis.
- the DNA used as a probe include DNA of at least 100 bases or longer, preferably of 200 bases or longer, and more preferably of 500 bases or longer. DNA of at least 10 bases or longer, preferably of 15 bases or longer, may be used.
- Hybridization conditions can be determined according to the description of, for example, Molecular Cloning, 2nd ed. and 3rd ed. (2001), Methods for General and Molecular Bacteriology, ASM Press (1994), or Immunology methods manual, Academic press (Molecular) as well as many other standard textbooks to conduct the experiment.
- Examples of the stringent conditions include conditions involving, for example, incubating a DNA-immobilized filter and probe DNA overnight at 42° C. in a solution containing 50% formamide, 5 ⁇ SSC (750 mM sodium chloride and 75 mM sodium citrate), 50 mM sodium phosphate (pH 7.6), 5 ⁇ Denhardt's solution, 10% dextran sulfate, and 20 ⁇ g/l denatured salmon sperm DNA, and then washing the filter in, for example, a 0.2 ⁇ SSC solution at approximately 65° C. Lower stringent conditions may be used. The stringent conditions can be changed by adjustment of the concentration of formamide (lower concentration of formamide gives lower stringent conditions) and change in salt concentration and temperature conditions.
- Examples of low stringent conditions include conditions involving, for example, overnight incubation at 37° C. in a solution containing 6 ⁇ SSCE (20 ⁇ SSCE corresponds to 3 mol/l sodium chloride, 0.2 mol/l sodium dihydrogen phosphate, and 0.02 mol/l EDTA, pH 7.4), 0.5% SDS, 30% formamide, and 100 ⁇ g/l denatured salmon sperm DNA, followed by washing using a solution of 1 ⁇ SSC and 0.1% SDS at 50° C.
- examples of lower stringent conditions include conditions involving hybridization using a solution with a higher salt concentration (e.g., 5 ⁇ SSC) under the low stringent conditions, followed by washing.
- These various conditions may be set by the addition or change of a blocking reagent used for suppressing background in the hybridization experiment.
- the addition of the blocking reagent may be accompanied by change of the hybridization conditions in order to adapt the conditions to each experiment.
- DNA capable of hybridization under the stringent conditions described above include DNA having a base sequence having at least 80% or higher, preferably 90% or higher, more preferably 95% or higher, even more preferably 98% or higher, particularly preferably 99% or higher sequence identity to the base sequence represented by any of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21 when calculated on the basis of the parameters using a program such as BLAST and FASTA.
- Examples of the method for confirming that the DNA hybridizing under stringent conditions to the DNA encodes a protein having activity of catalyzing the reaction between the allylic diphosphate derivative and isopentenyl diphosphate include a method involving preparing recombinant DNA containing the DNA by a method conventionally known in the art, introducing the recombinant DNA into host cells, culturing the obtained biological cells, purifying the protein from the obtained culture, and then quantitatively or qualitatively analyzing the substrate or product by HPLC, TLC, or the like to confirm whether or not the protein can catalyze the reaction between the allylic diphosphate derivative and isopentenyl diphosphate.
- Each variant enzyme and DNA encoding the variant enzyme can be obtained by the site-directed mutagenesis of, for example, the base sequence represented by SEQ ID NO: 1 (base sequence of Micrococcus luteus B-P 26-derived undecaprenyl diphosphate synthase) using a site-directed mutagenesis method described in Molecular Cloning, A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press (1989), Current Protocols in Molecular Biology, John Wiley & Sons (1987-1997), Nucleic Acids Research, 10, 6487 (1982), Proc. Natl. Acad. Sci. USA, 79, 6409 (1982), Gene, 34, 315 (1985), Nucleic Acids Research, 13, 4431 (1985), Proc. Natl. Acad. Sci. USA, 82, 488 (1985), etc.
- SEQ ID NO: 1 base sequence of Micrococcus luteus B-P 26-derived undecaprenyl diphosphate synthase
- transformant transformed so as to express the enzyme having prenyltransferase activity
- a method for preparing a transformant that has been transformed so as to express the variant enzyme will be described briefly.
- Such a transformant can be prepared by a method conventionally known in the art as long as the design philosophy is determined.
- primers are designed so that they allow mutagenesis at a site of interest.
- Examples of the base sequences of the primers include base sequences described in Examples (see SEQ ID NOs: 23 to 42 in the Sequence Listing).
- mutagenized linear DNA is amplified by the PCR method or the like using DNA containing the base sequence represented by SEQ ID NO: 1 (base sequence of Micrococcus luteus B-P 26-derived undecaprenyl diphosphate synthase) as template DNA with the primers described above.
- SEQ ID NO: 1 base sequence of Micrococcus luteus B-P 26-derived undecaprenyl diphosphate synthase
- the obtained linear DNA is inserted downstream of a promoter in an appropriate expression vector using appropriate restriction enzymes or the like to prepare recombinant DNA.
- the recombinant DNA is introduced into host cells compatible with the expression vector, whereby a transformant can be obtained.
- DNA containing the base sequence represented by SEQ ID NO: 1 is inserted downstream of a promoter in an appropriate expression vector using appropriate restriction enzymes or the like.
- Mutagenized DNA which is obtained by the PCR method or the like using the expression vector as template DNA with the primers described above, is rendered cyclic by polymerase to prepare recombinant DNA. Then, the recombinant DNA is introduced into host cells compatible with the expression vector, whereby a transformant can be obtained.
- DNA containing the base sequence represented by SEQ ID NO: 1 (base sequence of Micrococcus luteus B-P 26-derived undecaprenyl diphosphate synthase) is inserted downstream of a promoter in an appropriate expression vector using appropriate restriction enzymes or the like to prepare recombinant DNA. Then, the recombinant DNA is introduced into host cells compatible with the expression vector, whereby a transformant can be obtained.
- DNA encoding any of other prenyltransferase activity-having enzymes derived from the organism or prenyltransferase activity-having enzymes derived from organisms other than the organism may be used.
- screening can be performed by a known approach using, for example, a portion of the base sequence represented by SEQ ID NO: 1 as a probe to identify DNA encoding the enzyme having prenyltransferase activity, followed by isolation.
- the method for isolating the DNA molecule of interest using the DNA molecule as a probe is described in, for example, Molecular Cloning, 2nd edition, Cold Spring Harbor Press (1989).
- the organism-derived enzyme having prenyltransferase activity is purified by the purification operation as described above, and the amino acid sequence of the purified enzyme is determined to identify DNA encoding the enzyme, followed by isolation.
- microorganisms yeasts, animal cells, insect cells, plant cells, and the like can be used as host cells as long as they are capable of expressing the gene of interest.
- Examples of usable expression vectors include those which are capable of autonomously replicating in the host cells or being incorporated into the chromosome and contain a promoter at a position that allows transcription of the recombinant DNA.
- the recombinant DNA should be recombinant DNA that is capable of autonomously replicating in the prokaryotic organism and is also composed of a promoter, a ribosomal binding sequence, DNA encoding the enzyme having prenyltransferase activity, and a transcription termination sequence.
- the recombinant DNA may further contain a gene controlling the promoter.
- Examples of the expression vector include pCold I (manufactured by Takara Bio Inc.), pCDF-1b and pRSF-1b (all manufactured by Novagen), pMAL-c2x (manufactured by New England Biolabs Inc.), pGEX-4T-1 (manufactured by GE Healthcare Biosciences Inc.), pTrcHis (manufactured by Invitrogen Corp.), pSE280 (manufactured by Invitrogen Corp.), pGEMEX-1 (manufactured by Promega Corp.), pQE-30 (manufactured by Qiagen), pET-3 to pET-52 (manufactured by Novagen), pKYP10 (JP 58-110600 A), pKYP200 [Agric.
- Any promoter that functions in host cells such as Escherichia coli can be used.
- Examples thereof include: promoters derived from E. coli , phages, etc., such as trp promoter (P trp ), T7 promoter, lac promoter (P lac ), P L promoter, P R promoter, and P SE promoter; and SPO1 promoter, SPO2 promoter, and penP promoter.
- artificially designed or modified promoters such as a promoter having two P trp sequences arranged in series, tac promoter, lacT7 promoter, and let I promoter, may be used.
- xylA promoter for expression in microorganisms belonging to the genus Bacillus Appl. Microbiol. Biotechnol., 35, 594-599 (1991)
- P54-6 promoter for expression in microorganisms belonging to the genus Corynebacterium Appl. Microbiol. Biotechnol., 53, 674-679 (2000)
- the like may be used.
- a plasmid having an appropriately adjusted distance e.g., 6 to 18 bases
- a Shine-Dalgarno sequence ribosomal binding sequence
- prokaryotic organism examples include microorganisms belonging to the genera Escherichia, Serratia, Bacillus, Brevibacterium, Corynebacterium, Microbacterium, Pseudomonas, Agrobacterium, Alicyclobacillus, Anabaena, Anacystis, Arthrobacter, Azotobacter, Chromatium, Erwinia, Methylobacterium, Phormidium, Rhodobacter, Rhodopseudomonas, Rhodospirillum, Scenedesmus, Streptomyces, Synechoccus , and Zymomonas , for example, Escherichia coli XL1-Blue, Escherichia coli XL2-Blue, Escherichia coli DH1, Escherichia coli DH5 ⁇ , Escherichia coli MC1000, Escherichia coli KY3276, Escherichia coli W1485, Escherichia coli
- Agrobacterium radiobacter Agrobacterium rhizogenes, Agrobacterium rubi, Anabaena cylindrica, Anabaena doliolum, Anabaena flos - aquae, Arthrobacter aurescens, Arthrobacter citreus, Arthrobacter globiformis, Arthrobacter hydrocarboglutamicus, Arthrobacter mysorens, Arthrobacter nicotianae, Arthrobacter paraffineus, Arthrobacter protophormiae, Arthrobacter roseoparaffinus, Arthrobacter sulfureus, Arthrobacter ureafaciens, Chromatium buderi, Chromatium tepidum, Chromatium vinosum, Chromatium warmingii, Chromatium fluviatile, Erwinia uredovora, Erwinia carotovora, Erwinia ananas, Erwinia herbicola, Erwinia punctata, Erwinia terreus
- Rhodobacter capsulatus Rhodobacter sphaeroides, Rhodopseudomonas blastica, Rhodopseudomonas marina, Rhodopseudomonas palustris, Rhodospirillum rubrum, Rhodospirillum salexigens, Rhodospirillum salinarum, Streptomyces ambofaciens, Streptomyces aureofaciens, Streptomyces aureus, Streptomyces fungicidicus, Streptomyces griseochromogenes, Streptomyces griseus, Streptomyces lividans, Streptomyces olivogriseus, Streptomyces rameus, Streptomyces tanashiensis, Streptomyces vinaceus , and Zymomonas mobilis.
- the recombinant DNA can be introduced by any method for introducing DNA into such host cells.
- Examples thereof include a method using calcium ions [Proc. Natl. Acad. Sci., USA, 69, 2110 (1972)], a protoplast method (JP 63-248394 A), an electroporation method [Nucleic Acids Res., 16, 6127 (1988)], and a heat shock method.
- YEp13 ATCC37115
- YEp24 ATCC37051
- YCp50 ATCC37419
- pHS19 pHS15
- pHS15 pHS15
- any promoter that functions in the yeast strain can be used.
- promoters such as PHO5 promoter, PGK promoter, GAP promoter, ADH promoter, gal 1 promoter, gal 10 promoter, heat-shock polypeptide promoter, MF ⁇ 1 promoter, and CUP 1 promoter.
- the recombinant DNA can be introduced by any method for introducing DNA into yeast. Examples thereof include an electroporation method [Methods Enzymol., 194, 182 (1990)], a spheroplast method [Proc. Natl. Acad. Sci., USA, 81, 4889 (1984)], and a lithium acetate method [J. Bacteriol., 153, 163 (1983)].
- pcDNAI, pcDM8 (commercially available from Funakoshi Corp.), pAGE107 (JP 3-22979 A), pAS3-3 (JP 2-227075 A), pCDM8 [Nature, 329, 840 (1987)], pcDNAI/Amp (manufactured by Invitrogen Corp.), pREP4 (manufactured by Invitrogen Corp.), pAGE103 [J. Biochem, 101, 1307 (1987)], pAGE210, pAMo, or pAMoA, for example, can be used as an expression vector.
- any promoter that functions in the animal cells can be used.
- examples thereof include cytomegalovirus (CMV) IE (immediate early) gene promoter, SV40 early promoter, metallothionein promoter, retrovirus promoter, heat-shock promoter, and SR ⁇ promoter. These promoters may be used in combination with human CMV IE gene enhancer.
- CMV cytomegalovirus
- Examples of the host cells include mouse myeloma cells, rat myeloma cells, mouse hybridoma cells, human Namalwa cells or Namalwa KJM-1 cells, human embryonic kidney cells, human leukemia cells, African green monkey kidney cells, Chinese hamster ovary (CHO) cells, and HBT5637 (JP 63-299 A).
- mouse myeloma cells such as SP2/0 and NSO
- rat myeloma cells such as YB2/0
- human embryonic kidney cells such as HEK293 (ATCC CRL-1573)
- human leukemia cells such as BALL-1
- African green monkey kidney cells such as COS-1 and COS-7.
- the recombinant DNA can be introduced by any method for introducing DNA into animal cells. Examples thereof include an electroporation method [Cytotechnology, 3, 133 (1990)], a calcium phosphate method (JP 2-227075 A), a lipofection method [Proc. Natl. Acad. Sci., USA, 84, 7413 (1987)], and a method described in Virology, 52, 456 (1973).
- the protein can be produced by a method described in, for example, Baculovirus Expression Vectors, A Laboratory Manual, W. H. Freeman and Company, New York (1992), Current Protocols in Molecular Biology, or Molecular Biology, A Laboratory Manual, Bio/Technology, 6, 47 (1988).
- insect cells are cotransfected with a vector for transferring the recombinant gene and baculovirus, so that recombinant virus is obtained in the culture supernatant of the insect cells. Then, insect cells are further infected with the recombinant virus, whereby the protein can be produced.
- Examples of the gene transfer vector used in this method include pVL1392, pVL1393, and pBlueBac III (all manufactured by Invitrogen Corp.).
- baculovirus examples include Autographa californica nuclear polyhedrosis virus, which infects insects of the family Noctuidae.
- insect cells examples include Spodoptera frugiperda ovary cells, Trichoplusia ni ovary cells, and silkworm ovary-derived cultured cells.
- Spodoptera frugiperda ovary cells such as Sf9 and Sf21 (Baculovirus Expression Vectors: A Laboratory Manual); Trichoplusia ni ovary cells such as High 5 and BTI-TN-5B1-4 (manufactured by Invitrogen Corp.); and silkworm ovary-derived cultured cells such as Bombyx mori N4.
- Examples of the method for cotransfecting insect cells with the vector for transferring the recombinant gene and the baculovirus to prepare the recombinant virus include a calcium phosphate method (JP 2-227075 A) and a lipofection method [Proc. Natl. Acad. Sci., USA, 84, 7413 (1987)].
- a Ti plasmid or tobacco mosaic virus vector for example, can be used as an expression vector.
- any promoter that functions in the plant cells can be used.
- Examples thereof include cauliflower mosaic virus (CaMV) 35S promoter and rice actin-1 promoter.
- Examples of the host cells include cells of plants such as tobacco, potato, tomato, carrot, soybean, oilseed rape, alfalfa, rice, wheat, and barley.
- the recombinant vector can be introduced by any method for introducing DNA into plant cells. Examples thereof include a method using Agrobacterium (JP 59-140885 A, JP 60-70080 A, and WO94/00977), an electroporation method (JP 60-251887 A), and a method using a particle gun (gene gun) (Japanese Patent Nos. 2606856 and 2517813).
- the host may be any of microorganisms, yeasts, animal cells, insect cells, plant cells, and the like and may be preferably any of microorganisms, more preferably microorganisms belonging to the genus Escherichia , and even more preferably microorganisms belonging to Escherichia coli.
- sugar- or sugar chain-added proteins When expressed by yeasts, animal cells, insect cells, and plant cells, sugar- or sugar chain-added proteins can be obtained.
- the obtained transformant is cultured in a medium and the enzyme having prenyltransferase activity is then generated and accumulated in the culture, whereby the enzyme having prenyltransferase activity can be produced. If necessary, the enzyme may be purified by the purification operation described above.
- the transformant can be cultured in a medium according to a usual method used for culturing host cells.
- the culture can be performed in the composition of the medium and the culture conditions described above.
- the polyisoprene of the present invention contains a trans structural moiety and a cis structural moiety as represented by the formula (4) shown below, wherein at least one atom or group contained in the trans structural moiety is replaced by another atom or group.
- the trans structural moiety means a moiety of repeated isoprene units with a trans structure (moiety C in the formula (4) shown below).
- the cis structural moiety means a moiety of repeated isoprene units with a cis structure (moiety ( ) q (moiety D) in the formula (4) shown below).
- n represents an integer of 1 to 10
- q represents an integer of 30 to 40000
- Y represents a hydroxy group, a formyl group, a carboxy group, an ester group, a carbonyl group, or a group represented by the following formula (2).
- the polyisoprene of the present invention is structurally similar to natural rubber and is highly compatible with rubber molecules. Moreover, the polyisoprene of the present invention has been modified substantially only at a terminal site of the molecule. Specifically, the polyisoprene of the present invention contains a hydroxy group, a formyl group, a carboxy group, an ester group, a carbonyl group, or a group represented by the formula (2), positioned at the end of the cis structural moiety, and at least one atom or group contained in the trans structural moiety is replaced by another atom or group. Thus, the polyisoprene of the present invention strongly interacts with filler such as silica while the original properties of polyisoprene are not impaired.
- the polyisoprene of the present invention is highly compatible with rubber and strongly interacts with filler such as silica as described above, a rubber composition containing this polyisoprene is obtained as a rubber composition in which rubber molecules are combined with filler in a level higher than ever.
- the resulting rubber composition can have, for example, improved low-heat-build-up properties, wet grip performance, and abrasion resistance.
- the polyisoprene of the present invention contains a polar group or the like only at the terminal site of the cis structural moiety and a site close to the end of the trans structural moiety.
- the polyisoprene therefore offers high dispersibility of filler such as silica and has a large effect of improving, for example, low-heat-build-up properties, wet grip performance, and abrasion resistance while the original properties of polyisoprene are not impaired, compared with polyisoprenes containing a polar group or the like in the main chain moiety or only at the terminal site of the cis structural moiety.
- n is as defined for n in the formula (1).
- q represents an integer of 30 to 40000 (preferably 15000 to 30000, more preferably 15000 to 20000).
- Y is as defined for Y in the formula (1).
- Y is preferably a hydroxy group or a carboxy group, because the resulting polyisoprene strongly interacts with filler such as silica.
- Examples of the atom or group (atom or group before replacement) contained in the trans structural moiety include the same as those exemplified as the atom or group (atom or group before replacement) contained in the trans structural moiety in the formula (1).
- Examples of the another atom or group include the same as those exemplified as the another atom or the another group described about the formula (1).
- At least one atom or group contained in the trans structural moiety is replaced by another atom or group.
- n, q, and Y are as defined for n, q, and Y in the formula (4).
- trans structural moiety in the formula (4) include structures represented by the formulas (a) to (s) mentioned above.
- structures represented by the formulas (c), (d), (e), (f), (k), (l), and (r) are preferred because the resulting polyisoprene more strongly interacts with filler such as silica and has a large effect of improving low-heat-build-up properties, wet grip performance, and abrasion resistance.
- Examples of the process for producing the polyisoprene of the present invention include a process including performing biosynthesis from the isoprene oligomer of the present invention and isopentenyl diphosphate.
- the polyisoprene of the present invention is obtained by biosynthesis except for the organic synthesis of the allylic diphosphate derivative as an initiating substrate, and can thus take into account the exhaustion of petroleum resources or environmental issues.
- natural rubber latex contains an enzyme, a rubber elongation factor, and the like having activity of catalyzing the condensation reaction between an isoprene oligomer and isopentenyl diphosphate and catalyzing a reaction as shown below through which isopentenyl diphosphate is sequentially linked in a Z form (newly added isoprene unit has a cis structure) starting from the isoprene oligomer to produce a polyisoprene.
- an enzyme a rubber elongation factor, and the like having activity of catalyzing the condensation reaction between an isoprene oligomer and isopentenyl diphosphate and catalyzing a reaction as shown below through which isopentenyl diphosphate is sequentially linked in a Z form (newly added isoprene unit has a cis structure) starting from the isoprene oligomer to produce a polyisoprene.
- the polyisoprene can be produced using this enzyme, rubber elongation factor, or the like.
- examples of the method for biosynthesizing the polyisoprene of the present invention from the isoprene oligomer of the present invention and isopentenyl diphosphate include a method using the enzyme, the rubber elongation factor, or the like contained in natural rubber latex.
- the enzyme, the rubber elongation factor, or the like cloned from natural rubber latex may be used.
- the isoprene oligomer of the present invention and isopentenyl diphosphate can be allowed to react with each other in the presence of the enzyme and/or the rubber elongation factor. More specifically, for example, natural rubber latex or the enzyme, the rubber elongation factor, or the like separated from the natural rubber latex can be added into a solution containing the isoprene oligomer of the present invention and isopentenyl diphosphate to perform the reaction.
- the reaction temperature can be set to, for example, 20 to 40° C.; the reaction time can be set to, for example, 1 to 72 hours; and the pH can be set to, for example, 6 to 8. If necessary, magnesium chloride, a surfactant, 2-mercaptoethanol, and the like may further be added thereto.
- the polyisoprene of the present invention obtained by the reaction is usually represented by the formula (4) wherein Y is a group represented by the formula (2) or a hydroxy group. This hydroxy group is formed through the hydrolysis of the group represented by the formula (2).
- polyisoprene represented by the formula (4) wherein Y is a formyl group can be obtained, for example, by the oxidation of the polyisoprene of the formula (4) wherein Y is a group represented by the formula (2).
- polyisoprene represented by the formula (4) wherein Y is a carboxy group can be obtained, for example, by the oxidation of the polyisoprene of the formula (4) wherein Y is a group represented by the formula (2).
- polyisoprene represented by the formula (4) wherein Y is an ester group can be obtained, for example, by the oxidation and esterification of the polyisoprene of the formula (4) wherein Y is a group represented by the formula (2).
- polyisoprene represented by the formula (4) wherein Y is a carbonyl group can be obtained, for example, by the oxidation and esterification of the polyisoprene of the formula (4) wherein Y is a group represented by the formula (2).
- the natural rubber latex is not particularly limited in its origin. Examples thereof include Hevea brasiliensis, Ficus elastica, Ficus lyrata, Ficus benjamina, Ficus religiosa, Ficus benghalensis , and Lactarius chrysorrheus . Among them, Hevea brasiliensis is preferred because it produces rubber having a large molecular weight and its latex contains a large quantity of rubber.
- the trunk of, for example, Hevea brasiliensis is cut in grooves (tapped) using a knife or the like, and natural rubber latex flowing out from the cleaved latex vessels is collected, whereby natural rubber latex can be obtained.
- Examples of the enzyme and the rubber elongation factor separated from the natural rubber latex include a serum, a bottom fraction, and a rubber fraction separated by centrifugation of natural rubber latex.
- the serum, the bottom fraction, and the rubber fraction contain the enzyme, the rubber elongation factor, or the like.
- the rubber composition of the present invention includes the isoprene oligomer of the present invention and/or the polyisoprene of the present invention. Accordingly, the rubber composition of the present invention is excellent in low-heat-build-up properties, wet grip performance, and abrasion resistance.
- the polyisoprene of the present invention can be used as a rubber component.
- the content of the polyisoprene of the present invention is preferably 20% by mass or higher, more preferably 40% by mass or higher, and even more preferably 60% by mass or higher, with respect to 100% by mass of rubber components, and may be 100% by mass.
- Examples of rubber components that can be used in addition to the polyisoprene of the present invention include diene rubbers such as isoprene rubber (IR), natural rubber (NR), butadiene rubber (BR), styrene-butadiene rubber (SBR), styrene-isoprene-butadiene rubber (SIBR), chloroprene rubber (CR), and acrylonitrile-butadiene rubber (NBR). These rubber components may be used alone or in combination of two or more thereof. Among them, NR and BR are preferred.
- NR is a rubber component because it is highly compatible with isoprene oligomers.
- the combined use of the isoprene oligomer of the present invention and NR is more favorable for the effects of the addition of the isoprene oligomer of the present invention.
- the content of NR is preferably 20% by mass or higher, more preferably 40% by mass or higher, and even more preferably 60% by mass or higher, with respect to 100% by mass of rubber components, and may be 100% by mass.
- the content of the isoprene oligomer of the present invention is preferably 1 part by mass or higher, and more preferably 2 parts by mass or higher, with respect to 100 parts by mass of rubber components. If the content is less than 1 part by mass, the effects of the addition of the isoprene oligomer of the present invention might be achieved insufficiently. Also, the content of the isoprene oligomer is preferably 20 parts by mass or lower, and more preferably 15 parts by mass or lower. If the content exceeds 20 parts by mass, the strength and, by extension, abrasion resistance of the resulting rubber composition may be reduced.
- filler examples include silica, carbon black, clay, and calcium carbonate.
- silica as filler.
- the rubber composition further containing silica ensures sufficient achievement of the effects of the addition of the isoprene oligomer of the present invention and/or the polyisoprene of the present invention.
- the silica include, but not particularly limited to, dry silica (silicic anhydride) and wet silica (hydrous silicic acid). Wet silica is preferred because of being rich in silanol groups.
- the rubber composition of the present invention may appropriately contain, in addition to the components described above, compounding ingredients generally used in the production of rubber compositions, for example, a silane coupling agent, zinc oxide, stearic acid, various antioxidants, a softener (e.g., oil), wax, a vulcanizing agent (e.g., sulfur), and a vulcanization accelerator.
- compounding ingredients generally used in the production of rubber compositions, for example, a silane coupling agent, zinc oxide, stearic acid, various antioxidants, a softener (e.g., oil), wax, a vulcanizing agent (e.g., sulfur), and a vulcanization accelerator.
- the rubber composition of the present invention can be produced using a process known in the art and can be produced, for example, by a process involving kneading the components using a rubber kneading apparatus such as an open roll mill or a Banbury mixer, followed by vulcanization.
- a rubber kneading apparatus such as an open roll mill or a Banbury mixer
- the rubber composition of the present invention can be used suitably in various tire components (e.g., treads, sidewalls, undertread, plies, breakers, and carcass) and the like.
- the pneumatic tire of the present invention can be produced by a usual process using the rubber composition.
- the unvulcanized rubber composition is extruded and processed into a shape appropriate for a tire component (e.g., treads and sidewalls), arranged by a usual method in a tire building machine, and assembled with other tire components to form an unvulcanized tire.
- This unvulcanized tire is heated and pressurized in a vulcanizer, whereby a tire can be produced.
- the secondary hydroxy group was protected by acetylation with acetic anhydride in the presence of dimethylaminopyridine in an anhydrous dichloromethane solvent to obtain an ester form (compound represented by (av) below) (yield: 81%).
- the TBDPS protective group was deprotected using tetra-n-butylammonium hydrate in anhydrous tetrahydrofuran to obtain a primary alcohol form (compound represented by (avi) below) (yield: 82%).
- the primary hydroxy group was replaced by chlorine using N-chlorosuccinimide and dimethyl sulfide in an anhydrous dichloromethane solvent at ⁇ 40° C.
- the TBDPS protective group was then deprotected using tetra-n-butylammonium hydrate in anhydrous tetrahydrofuran to obtain a diol form (compound represented by (dvi) below) (yield: 80%).
- the primary hydroxy group was replaced by chlorine using N-chlorosuccinimide and dimethyl sulfide in an anhydrous dichloromethane solvent at ⁇ 40° C. or lower to obtain a chloride (compound represented by (dvii) below) (yield: 80%).
- the TBDPS protective group was then deprotected using tetra-n-butylammonium hydrate in anhydrous tetrahydrofuran to obtain a diol form (compound represented by (evi) below) (yield: 91%).
- the primary hydroxy group was replaced by chlorine using N-chlorosuccinimide and dimethyl sulfide in an anhydrous dichloromethane solvent at ⁇ 40° C. or lower to obtain a chloride (compound represented by (evii) below) (yield: 70%).
- the epoxy was subjected to periodic acid oxidation using orthoperiodic acid in a mixed solvent of ether and tetrahydrofuran to obtain an aldehyde form (fiii) (yield: 73%).
- a Grignard reagent was prepared from ethyl iodide and magnesium in an anhydrous ether solvent and then reacted with the aldehyde to form an alcohol form (fiv) (yield: 80%).
- the TBDPS group in the compound (fiv) was removed using tetrabutylammonium fluoride in an anhydrous tetrahydrofuran solvent to form a diol form (fv) (yield: 93%).
- the hydroxy group present at an allylic position in the diol form (fv) was chlorinated using N-chlorosuccinimide and dimethyl sulfide in an anhydrous dichloromethane solvent at ⁇ 40° C. or lower to form a chloride (fvi) (yield: 69%).
- the chloride (fvi) was diphosphorylated using tris(tetra-N-butyl)ammonium hydrogen pyrophosphate in an anhydrous acetonitrile solvent and applied to an ion-exchange column to synthesize a compound (fvii) (compound represented by the formula (R)) as the substance of interest (yield: 28%).
- the compound was hydrolyzed with potassium hydroxide to obtain an alcohol form (compound represented by (giv) below) (yield: 78%).
- the alcohol form was chlorinated by the N-chlorosuccinimide method to obtain a chloride (compound represented by (gv) below) (yield: 40%).
- the chloride was mixed with n-butylammonium hydrogen diphosphate in anhydrous acetonitrile to obtain a compound represented by (gvi) below (compound represented by the formula (P)) as the substance of interest (yield: 26%).
- the alcohol form was subjected to reaction using chloromethyl ethyl ether and diisopropylethylamine in dichloromethane to obtain a compound represented by (hiii) below in which a methoxymethyl ether group was introduced in the hydroxy group at position 8 (yield: 76%).
- the acetyl group was converted to a hydroxy group using potassium hydroxide to obtain an alcohol form (compound represented by (hiv) below) (yield: 95%).
- the hydroxy group in the alcohol form was chlorinated using N-chlorosuccinimide to obtain a chloride (compound represented by (hv) below) (yield: 30%).
- the alcohol form was chlorinated using N-chlorosuccinimide in dichloromethane to obtain a compound represented by (iiii) below (yield: 92%).
- n-propanethiol was added to a solution of metallic sodium dissolved in ethanol and the resulting solution was reacted with the compound to obtain a thioether (compound represented by (iiv) below) (yield: 28%).
- p-toluenesulfonic acid was allowed to act thereon in methanol to obtain an alcohol form (compound represented by (iv) below) (yield: 75%).
- the alcohol form was chlorinated by the N-chlorosuccinimide method to obtain a chloride (compound represented by (ivi) below) (yield: 40%).
- the chloride was mixed with n-butylammonium hydrogen diphosphate in anhydrous acetonitrile to obtain a compound represented by (ivii) below (compound represented by the formula (M)) as the substance of interest (yield: 32%).
- the epoxy was oxidized with orthoperiodic acid in anhydrous tetrahydrofuran to obtain an aldehyde form (compound represented by (kiii) below) (yield: 66%).
- the aldehyde was reductively aminated using n-butylamine and sodium cyanoborohydride in anhydrous methanol to obtain a secondary amine (compound represented by (kiv) below) (yield: 66%).
- the amine was acetylated with acetic anhydride in the presence of dimethylaminopyridine in an anhydrous dichloromethane solvent to obtain a secondary amide (compound represented by (kv) below) (yield: 38%).
- the ester site was irreversibly hydrolyzed with potassium hydroxide in anhydrous methanol to obtain a primary alcohol form (compound represented by (kvi) below) (yield: 76%).
- the primary hydroxy group was replaced by chlorine using N-chlorosuccinimide and dimethyl sulfide in an anhydrous dichloromethane solvent at ⁇ 40° C. or lower to obtain a chloride (compound represented by (kvii) below) (yield: 67%).
- the reagent used was QuikChange Site-Directed Mutagenesis Kit from Stratagene Corp. Primers were designed so that they allowed mutagenesis at a site of interest. Primers for mutagenesis were purchased from Medical & Biological Laboratories, Co., Ltd. (manufacturer: XX IDT). The designed primers are as follows.
- Antisense primer 5′-cat cgg cct gct ccg tcc ata atg a-3′ SEQ ID NO: 24;
- Antisense primer 5′-gag acc atg ctt cag ttg aaa atg c-3′ (SEQ ID NO: 26);
- Antisense primer 5′-cac ccg ggt ttt tca tca agt aat ta-3′ (SEQ ID NO: 28);
- Antisense primer 5′-cac ccg gat ctt tca tca agt aat ta-3′ (SEQ ID NO: 30);
- Antisense primer 5′-cca tcg gcc ttg tcc gtc cat aat-3′ (SEQ ID NO: 32);
- Antisense primer 5′-cga gac cat gct tca gtt gaa aat gc-3′ (SEQ ID NO: 34);
- Antisense primer 5′-gtt taa tgc atc acc cgg tag ttt ca-3′ (SEQ ID NO: 40);
- Antisense primer 5′-gtt taa cca atc acc cgg tag ttt ca-3′ (SEQ ID NO: 42).
- the dsDNA template used was pET22b containing the base sequence of Micrococcus luteus B-P 26-derived undecaprenyl diphosphate synthase (hereinafter, also referred to as the wild-type enzyme) (this template is referred to as pET22b/MLU-UPS).
- This pET22b/MLU-UPS was kindly provided by Professor Tanetoshi Koyama (Institute of Multidisciplinary Research for Advanced Materials Tohoku University).
- 2 ⁇ l of 10 ⁇ Pfu polymerase buffer was mixed with 2-20 ng of the dsDNA template, 50 ng of the sense primer, 50 ng of the antisense primer, 0.4 ⁇ l of dNTPs (2.5 mM each), ddH 2 O up to 20 ⁇ l, 0.4 ml of Pfu polymerase (2.5 U/ ⁇ l) and PCR reaction was then performed.
- the PCR reaction was performed under the following conditions: 1 cycle of 95° C. for 30 sec; 15 cycles of 95° C. for 30 sec, 55° C. for 1 min, 68° C. for 8 min. After PCR, 0.4 ⁇ l of DpnI was added to the PCR reaction solution and DpnI treatment was performed at 37° C.
- E. coli DH5 ⁇ was transformed by the heat shock method using 1-10 ⁇ l of the DpnI-treated solution, and the transformant was applied to an LB agar medium containing 50 ⁇ g/mL ampicillin and then cultured overnight at 37° C., and then the transformed strain was selected. The transformant was cultured all night in an LB medium containing 50 ⁇ g/ml ampicillin.
- a plasmid was prepared by the alkali-SDS method from the obtained culture solution. Mutagenesis in the plasmid was confirmed using a sequencer.
- E. coli BL21 (DE3) was transformed with each plasmid pET22b/MLU-UPS (wild-type and variant).
- the obtained E. coli BL21(DE3)/pET22b/MLU-UPS (wild-type and variant) was inoculated into a test tube containing 3 mL of an LB medium containing 50 ⁇ g/mL ampicillin and shake-cultured at 37° C. for 5 hours.
- a 1 mL aliquot of the obtained culture solution was inoculated into a 500-mL Erlenmeyer flask containing 100 mL of an LB medium containing 50 ⁇ g/mL ampicillin and shake-cultured at 37° C. for 3 hours.
- IPTG was added thereto at a concentration of 0.1 mmol/L, and the bacterial cells were shake-cultured at 30° C. for 18 hours.
- the culture solution was centrifuged to obtain wet bacterial cells.
- the wet bacterial cells thus obtained were disrupted by sonication and then centrifuged.
- a protein having prenyltransferase activity was purified from the obtained supernatant using HisTrap (manufactured by Amersham Biosciences Corp.). The purification of the purified protein was confirmed by SDS-PAGE.
- a reaction solution containing 10 mg of each purified protein, 50 mM Tris-HCl buffer (pH 7.5), 40 mM magnesium chloride, 40 mM Triton X-100, 25 mM 2-mercaptoethanol, 1 mM of an initiating substrate (farnesyl diphosphate or each of the initiating substrates prepared in Production Examples 1 to 11), and 1 mM isopentenyl diphosphate was prepared and reacted for 1 hour in a water bath at 37° C.
- n and m in the formula (1) were calculated on the basis of information about the initiating substrate used and the length of the isoprene chain determined by TLC. Also, Y was structurally identified by NMR or IR.
- Reaction was performed under conditions shown below using each of the initiating substrates prepared in Production Examples 1 to 11 or farnesyl diphosphate.
- the activity of each variant enzyme on each initiating substrate was indicated by index with the activity of the wild-type enzyme ( Micrococcus luteus B-P 26-derived undecaprenyl diphosphate synthase) as 100.
- a reaction solution containing 500 ng of each purified protein, 50 mM Tris-HCl buffer (pH 7.5), 40 mM magnesium chloride, 40 mM Triton X-100, 25 mM 2-mercaptoethanol, 12.5 ⁇ M of an initiating substrate, and 50 ⁇ M [1- 14 C] isopentenyl diphosphate was prepared and reacted for 1 hour in a water bath at 37° C. After the reaction, liquid scintillation counting and TLC quantification were performed to measure the activity of each enzyme.
- a reaction solution containing 10 ⁇ l of a latex component, 50 mM Tris-HCl buffer (pH 7.5), 25 mM magnesium chloride, 40 mM 2-mercaptoethanol, 40 mM potassium fluoride, 50 ⁇ M of an isoprene oligomer, and 1 mM isopentenyl diphosphate was prepared and reacted for 3 days in a water bath at 30° C. After the reaction, the molecular weight was measured by GPC. Then, n and q in the formula (4) were calculated on the basis of the measured molecular weight and information about the initiating substrate used. The details (n and q in the formula (4)) of the thus obtained polyisoprenes are as shown in Tables 4 and 5.
- Y was a hydroxy group or a group represented by the formula (2). Also, Y was identified in the same way as in Examples (Preparation of isoprene oligomer).
- the latex component used was a serum prepared by the ultracentrifugation of latex taken from Hevea brasiliensis.
- Each isoprene oligomer used was an isoprene oligomer obtained using the variant enzyme N31A or the like and each initiating substrate (farnesyl diphosphate or each of the initiating substrates prepared in Production Examples 1 to 11) under the same conditions as in Examples (Preparation of isoprene oligomer).
- the isoprene oligomers obtained using the variant enzyme N31A or the like together with farnesyl diphosphate the compound represented by the formula (S), the compound represented by the formula (B), the compound represented by the formula (C), the compound represented by the formula (D), the compound represented by the formula (E), the compound represented by the formula (R), the compound represented by the formula (P), the compound represented by the formula (H), the compound represented by the formula (M), the compound represented by the formula (N), and the compound represented by the formula (K) as initiating substrates under the same conditions as in Examples (Preparation of isoprene oligomer) are referred to as isoprene oligomer (0), isoprene oligomer (S), isoprene oligomer (B), isoprene oligomer (C), isoprene oligomer (D), isoprene oligomer (E), isoprene oligomer (R), isoprene oligo
- isoprene oligomers obtained using the variant enzyme N31A under the same conditions as in Examples (Preparation of isoprene oligomer).
- the isoprene oligomers used were the isoprene oligomer (0), the isoprene oligomer (S), the isoprene oligomer (B), the isoprene oligomer (C), the isoprene oligomer (D), the isoprene oligomer (E), the isoprene oligomer (R), the isoprene oligomer (P), the isoprene oligomer (H), the isoprene oligomer (M), the isoprene oligomer (N), and the isoprene oligomer (K).
- Gram-positive bacteria Staphylococcus aureus (13276) and Bacillus subtilis (3134)
- Gram-negative bacteria Echerichia coli (3972), Salmonella enteric (100797), Peudomonas aeruginosa (13275), and Klebsiella pneumonia (3512)
- NBRC National Institute of Technology and Evaluation, Biological Resource Center. All the microbial strains used were purchased from NBRC.
- the Staphylococcus aureus strain was inoculated into a test tube containing 2 ml of a liquid medium (10 g/L polypeptone, 2 g/L yeast extract, and 1 g/L MgSO 4 .7H 2 O, pH 7.0) and cultured at 150 rpm at 30° C. for 5 hours.
- the microbial strain was inoculated into a solid medium (10 g/L polypeptone, 2 g of yeast extract, 1 g/L MgSO 4 .7H 2 O, and 15 g/L agar, pH 7.0) and cultured overnight at 30° C. On the next day, colonies were confirmed.
- One of the colonies on the solid medium was inoculated into a test tube containing 4 ml of the liquid medium and cultured (i.e., precultured) overnight at 30° C.
- 100 ⁇ l of the preculture solution was added to a new test tube containing 4 ml of the liquid medium and cultured at 150 rpm at 30° C.
- the culture solution was adjusted to 10 5 cfu/ml by the dilution method and used in the antimicrobial test.
- the minimum inhibitory concentration (MIC) was measured by the MIC method, which is a general experimental approach for examining the activity of anti-microorganism substances.
- the microbial culture solution thus adjusted to 10 5 cfu/ml and each isoprene oligomer adjusted to 0.5-5 mM were added into a 1.5-ml tube, mixed with each other, and cultured overnight at 150 rpm at 30° C. After the culture, each concentration of the culture solution was applied to the solid medium using a spreader and cultured at 30° C. for 1-4 days. After the culture, the presence or absence of growth of the microbe was examined by visual observation, and the minimum addition concentration of the terminally modified isoprene oligomer at which the microbe did not survive was defined as MIC.
- MIC was determined for the other microbes in the same way as above.
- Example 1 Example 2
- Example 3 Example 4
- Example 6 Isoprene Isoprene Isoprene Isoprene Isoprene oligomer oligomer oligomer oligomer oligomer oligomer oligomer oligomer oligomer oligomer oligomer oligomer oligomer oligomer oligomer MIC( ⁇ g/ml) (O) (S) (B) (C) (D) (E) (R) Staphylococcus aureus 13276 * — 260 160 560 460 58 Bacillus subtilis 3134 * — 260 160 560 320 58 Echerichia coli 3972 * — 180 — 240 — 130 Salmonella enteric 100797 * — — — — — — — Peudomonas aeruginosa 13275 * 93 — — — — Klebsiella pneumonia 3512 *
- the isoprene oligomer (0) of Comparative Example isoprene oligomer obtained from farnesyl diphosphate in which at least one atom or group contained in the trans structural moiety was not replaced by another atom or group did not exhibit antimicrobial activity (antimicrobial activity was not observed at 800 ppm or lower).
- the isoprene oligomers of Examples in which at least one atom or group contained in the trans structural moiety was replaced by another atom or group exhibited antimicrobial activity.
- the isoprene oligomer (F) was prepared from the compound represented by the formula (F) as an initiating substrate. This reaction was performed by adjusting the conditions described above in (Preparation of isoprene oligomer) in order to adjust the molecular weight of the isoprene oligomer to be obtained.
- the isoprene oligomer (K) was prepared from the compound represented by the formula (K) as an initiating substrate. This reaction was performed by adjusting the conditions described above in (Preparation of isoprene oligomer) in order to adjust the molecular weight of the isoprene oligomer to be obtained.
- the isoprene oligomer (0) was prepared from farnesyl diphosphate as an initiating substrate. This reaction was performed by adjusting the conditions described above in (Preparation of isoprene oligomer) in order to adjust the molecular weight of the isoprene oligomer to be obtained.
- polyisoprenes were prepared from the isoprene oligomers obtained in Production Examples 14 to 16 (the isoprene oligomer (F), the isoprene oligomer (K), and the isoprene oligomer (0)).
- the details (n, q, and Y in the formula (4)) of the obtained polyisoprenes were determined in the same way as in Examples (Preparation of polyisoprene).
- the polyisoprene (F) was prepared from the isoprene oligomer (F) prepared in Production Example 14. This reaction was performed by adjusting the conditions described above in (Preparation of polyisoprene) in order to adjust the molecular weight of the polyisoprene to be obtained.
- the polyisoprene (K-1) was prepared from the isoprene oligomer (K) prepared in Production Example 15. This reaction was performed by adjusting the conditions described above in (Preparation of polyisoprene) in order to adjust the molecular weight of the polyisoprene to be obtained.
- the polyisoprene (K-2) was prepared from the isoprene oligomer (K) prepared in Production Example 15. This reaction was performed by adjusting the conditions described above in (Preparation of polyisoprene) in order to adjust the molecular weight of the polyisoprene to be obtained.
- the polyisoprene (0) was prepared from the isoprene oligomer (0) prepared in Production Example 16. This reaction was performed by adjusting the conditions described above in (Preparation of polyisoprene) in order to adjust the molecular weight of the polyisoprene to be obtained.
- Carbon black Diablack (N220) manufactured by Mitsubishi Chemical Corp.
- Zinc oxide zinc oxide No. 1 manufactured by Mitsui Mining & Smelting Co., Ltd.
- Stearic acid stearic acid manufactured by NOF Corp.
- Nocrac 6C N-(1,3-dimethylbutyl)-N′-phenyl-p-phenylenediamine manufactured by Ouchi Shinko Chemical Industrial Co., Ltd.
- Wax Sannoc wax manufactured by Ouchi Shinko Chemical Industrial Co., Ltd.
- Sulfur sulfur powder manufactured by Tsurumi Chemical Industry Co., Ltd.
- Vulcanization accelerator NS Nocceler NS (N-tert-butyl-2-benzothiazolesulfenamide) manufactured by Ouchi Shinko Chemical Industrial Co., Ltd.
- Silane coupling agent Si266 (bis(3-triethoxysilylpropyl) disulfide) manufactured by Degussa
- Vulcanization accelerator DPG Nocceler D (N,N-diphenylguanidine) manufactured by Ouchi Shinko Chemical Industrial Co., Ltd.
- the materials other than sulfur and vulcanization accelerators were kneaded using a 1.7-L Banbury mixer according to the formulation shown in Table 8 or 9 to obtain a kneaded mixture.
- sulfur and vulcanization accelerator(s) were added to the obtained kneaded mixture and kneaded thereinto using an open roll mill to obtain an unvulcanized rubber composition.
- the obtained unvulcanized rubber composition was vulcanized at a pressure of 80 kgf/cm 2 at 150° C. for 30 minutes using a steam vulcanization press to obtain a vulcanized rubber composition.
- the tan ⁇ was measured under conditions of 70° C. and 2% strain (initial elongation) using a viscoelasticity spectrometer manufactured by Iwamoto Seisakusho Co., Ltd. and indicated by index with the tan ⁇ of the reference formulation as 100.
- a larger index represents larger heat build-up.
- a rubber composition having an index of 100 or less was regarded as having improved in resistance to heat build-up (low-heat-build-up properties). This means that a rubber composition having a smaller index is more excellent in low-heat-build-up properties.
- An abrasion test was carried out for 5 minutes under conditions of 3 kg load, 40% slip ratio, and sand falling at a rate of 15 g/min using a Lambourn abrasion tester manufactured by Iwamoto Seisakusho Co., Ltd.
- the shape of each sample was set to a thickness of 5 mm and a diameter of 50 mm, and the grindstone used was GC-type abrasive grains having a particle size of #80.
- the test results were converted to an index with the value of the reference formulation as 100 (reference). A larger index represents more excellent abrasion resistance.
- a rubber composition having an index exceeding 100 was regarded as having improved in abrasion resistance.
- a tensile test was carried out according to JIS K6251 “Rubber, vulcanized or thermoplastic—Determination of tensile stress-strain properties” using No. 3 dumbbell test pieces from the vulcanized rubber sheet, and the tensile strength at break (TB) (MPa) and elongation at break (EB) (%) were measured. Elongation at break less than 480% tends to cause rubber separation during use in large tires and thus requires improvement. Also as for tensile strength at break, its reduction is responsible for the destruction of tires and thus it is necessary to prevent a reduction due to the change in materials.
- the rubber compositions of Examples including the isoprene oligomers in which at least one atom or group contained in the trans structural moiety was replaced by another atom or group were excellent in low-heat-build-up properties, abrasion resistance, and elongation at break.
- the rubber compositions of Examples including the polyisoprenes in which at least one atom or group contained in the trans structural moiety was replaced by another atom or group were excellent in low-heat-build-up properties, abrasion resistance, and tensile strength at break.
- the ester was hydrolyzed with potassium hydroxide and methanol to obtain a carboxylic acid (compound represented by (iii) below) (yield: 92%).
- the carboxylic acid was decarboxylated with dimethyl sulfoxide and common salt to obtain a nitrile form (compound represented by (iv) below) (yield: 40%).
- the nitrile was reduced with lithium diisobutyl hydride and saturated ammonium chloride in anhydrous dichloromethane to obtain an aldehyde form (compound represented by (v) below) (yield: 89%).
- the aldehyde was treated with sodium hydride and ethyl diethylphosphonoacetate in anhydrous tetrahydrofuran to obtain a trans ester form (compound represented by (vi) below) (yield: 84%).
- the ester was reduced using lithium diisobutyl hydride and methanol in anhydrous dichloromethane and anhydrous hexane to obtain an alcohol form (compound represented by (vii) below) (yield: 19%).
- the primary hydroxy group was replaced by chlorine using N-chlorosuccinimide and dimethyl sulfide in an anhydrous dichloromethane solvent at ⁇ 40° C.
- the ester was hydrolyzed with potassium hydroxide and methanol to obtain a carboxylic acid (compound represented by (iii) below) (yield: 95%).
- the carboxylic acid was decarboxylated with dimethyl sulfoxide and common salt to obtain a nitrile form (compound represented by (iv) below) (yield: 40%).
- the nitrile was reduced with lithium diisobutyl hydride and saturated ammonium chloride in anhydrous dichloromethane to obtain an aldehyde form (compound represented by (v) below) (yield: 91%).
- the aldehyde was treated with sodium hydride and ethyl diethylphosphonoacetate in anhydrous tetrahydrofuran to obtain a trans ester form (compound represented by (vi) below) (yield: 82%).
- the ester was reduced using lithium diisobutyl hydride and methanol in anhydrous dichloromethane and anhydrous hexane to obtain an alcohol form (compound represented by (vii) below) (yield: 19%).
- the aldehyde was treated with sodium hydride and ethyl diethylphosphonoacetate in anhydrous tetrahydrofuran to obtain a trans ester form (compound represented by (vi) below) (yield: 84%).
- the ester was reduced using lithium diisobutyl hydride and methanol in anhydrous dichloromethane and anhydrous hexane to obtain an alcohol form (compound represented by (vii) below) (yield: 30%).
- reaction was performed under conditions shown below using Micrococcus luteus B-P 26-derived undecaprenyl diphosphate synthase as an enzyme and each of the initiating substrates 1 to 4, the compound represented by the formula (B), the compound represented by the formula (C), the compound represented by the formula (G), the compound represented by the formula (K), and farnesyl diphosphate (FPP).
- the results were indicated in Table 10 by the relative activity of the enzyme on the initiating substrates 1 to 4, the compound represented by the formula (B), the compound represented by the formula (C), the compound represented by the formula (G), and the compound represented by the formula (K) with the activity of the enzyme on farnesyl diphosphate as 100.
- a reaction solution containing 500 ng of the enzyme, 50 mM Tris-HCl buffer (pH 7.5), 40 mM magnesium chloride, 40 mM Triton X-100, 25 mM 2-mercaptoethanol, 12.5 ⁇ M of an initiating substrate, and 50 ⁇ M [1- 14 C] isopentenyl diphosphate was prepared and reacted for 1 hour in a water bath at 37° C. After the reaction, liquid scintillation counting and TLC quantification were performed to measure the activity of the enzyme on each initiating substrate.
- Bacillus stearothermophilus -derived farnesyl diphosphate synthase was prepared.
- E. coli BL21 (DE3) was transformed in the same way as above, with a plasmid pET22b containing the base sequence of Bacillus stearothermophilus -derived farnesyl diphosphate synthase (this plasmid is referred to as pET22b/BsFPS).
- This pET22b/BsFPS was kindly provided by Professor Koyama (Institute of Multidisciplinary Research for Advanced Materials Tohoku University).
- the E. coli BL21(DE3)/pET22b/BsFPS was inoculated into a test tube containing 3 mL of an LB medium containing 50 ⁇ g/mL ampicillin and shake-cultured at 37° C. for 5 hours.
- a 1 mL aliquot of the obtained culture solution was inoculated into a 500-mL Erlenmeyer flask containing 100 mL of an LB medium containing 50 ⁇ g/mL ampicillin and shake-cultured at 37° C. for 3 hours.
- IPTG was added thereto at a concentration of 0.1 mmol/L, and the bacterial cells were shake-cultured at 30° C. for 18 hours.
- the culture solution was centrifuged to obtain wet bacterial cells.
- the wet bacterial cells thus obtained were disrupted by sonication and then centrifuged.
- a protein having prenyltransferase activity Bacillus stearothermophilus -derived farnesyl diphosphate synthase was purified from the obtained supernatant using HisTrap (manufactured by Amersham Biosciences Corp.). The purification of the purified protein was confirmed by SDS-PAGE.
- E. coli BL21 (DE3) was transformed in the same way as above, with a plasmid pET22b containing the base sequence of Sulfolobus acidocaldarius -derived geranylgeranyl diphosphate synthase (this plasmid is referred to as pET22b/SaGGPS).
- This pET22b/SaGGPS was kindly provided by Professor Tokuzo Nishino (School of Engineering, Tohoku University).
- the E. coli BL21(DE3)/pET22b/SaGGPS was inoculated into a test tube containing 3 mL of an LB medium containing 50 ⁇ g/mL ampicillin and shake-cultured at 37° C. for 5 hours.
- a 1 mL aliquot of the obtained culture solution was inoculated into a 500-mL Erlenmeyer flask containing 100 mL of an LB medium containing 50 ⁇ g/mL ampicillin and shake-cultured at 37° C. for 3 hours.
- IPTG was added thereto at a concentration of 0.1 mmol/L, and the bacterial cells were shake-cultured at 30° C. for 18 hours.
- the culture solution was centrifuged to obtain wet bacterial cells.
- the wet bacterial cells thus obtained were disrupted by sonication and then centrifuged.
- a protein having prenyltransferase activity Sulfolobus acidocaldarius -derived geranylgeranyl diphosphate synthase
- HisTrap manufactured by Amersham Biosciences Corp.
- the purification of the purified protein was confirmed by SDS-PAGE.
- a reaction solution containing 500 ng of the purified enzyme, 50 mM Tris-HCl buffer (pH 8.5), 40 mM magnesium chloride, 50 mM ammonium chloride, 40 mM Triton X-100, 25 mM 2-mercaptoethanol, 12.5 ⁇ M of an initiating substrate, and 50 ⁇ M [1- 14 C] isopentenyl diphosphate was prepared and reacted for 1 hour in a water bath at 55° C. After the reaction, liquid scintillation counting and TLC quantification were performed to measure the activity of the enzyme on each initiating substrate.
- reaction was performed under conditions shown below using Sulfolobus acidocaldarius -derived geranylgeranyl diphosphate synthase and each of the initiating substrates 1 to 4, the compound represented by the formula (B), the compound represented by the formula (C), the compound represented by the formula (G), the compound represented by the formula (K), the compound represented by the formula (F), the compound represented by the formula (I), the compound represented by the formula (Q), farnesyl diphosphate (FPP), and geranyl diphosphate (GPP).
- a reaction solution containing 500 ng of the purified enzyme, 50 mM Tris-HCl buffer (pH 5.8), 40 mM magnesium chloride, 50 mM ammonium chloride, 40 mM Triton X-100, 25 mM 2-mercaptoethanol, 12.5 ⁇ M of an initiating substrate, and 50 ⁇ M [1- 14 C] isopentenyl diphosphate was prepared and reacted for 1 hour in a water bath at 55° C. After the reaction, liquid scintillation counting and TLC quantification were performed to measure the activity of the enzyme on each initiating substrate.
- SEQ ID NO: 1 Base sequence of Micrococcus luteus B-P 26-derived undecaprenyl diphosphate synthase (wild-type enzyme)
- SEQ ID NO: 2 Amino acid sequence of Micrococcus luteus B-P 26-derived undecaprenyl diphosphate synthase (wild-type enzyme)
- SEQ ID NO: 3 Base sequence of variant enzyme N31A
- SEQ ID NO: 4 Amino acid sequence of variant enzyme N31A
- SEQ ID NO: 5 Base sequence of variant enzyme N77A
- SEQ ID NO: 6 Amino acid sequence of variant enzyme N77A
- SEQ ID NO: 7 Base sequence of variant enzyme L91N
- SEQ ID NO: 8 Amino acid sequence of variant enzyme L91N
- SEQ ID NO: 9 Base sequence of variant enzyme L91D
- SEQ ID NO: 10 Amino acid sequence of variant enzyme L91D
- SEQ ID NO: 11 Base sequence of variant enzyme N31Q
- SEQ ID NO: 12 Amino acid sequence of variant enzyme N31Q
- SEQ ID NO: 13 Base sequence of variant enzyme N77Q
- SEQ ID NO: 14 Amino acid sequence of variant enzyme N77Q
- SEQ ID NO: 15 Base sequence of variant enzyme L91G
- SEQ ID NO: 16 Amino acid sequence of variant enzyme L91G
- SEQ ID NO: 17 Base sequence of variant enzyme L91K
- SEQ ID NO: 18 Amino acid sequence of variant enzyme L91K
- SEQ ID NO: 19 Base sequence of variant enzyme F95A
- SEQ ID NO: 20 Amino acid sequence of variant enzyme F95A
- SEQ ID NO: 21 Base sequence of variant enzyme F95W
- SEQ ID NO: 22 Amino acid sequence of variant enzyme F95W
- SEQ ID NO: 23 Sense primer for preparation of variant enzyme N31A
- SEQ ID NO: 24 Antisense primer for preparation of variant enzyme N31A
- SEQ ID NO: 25 Sense primer for preparation of variant enzyme N77A
- SEQ ID NO: 26 Antisense primer for preparation of variant enzyme N77A
- SEQ ID NO: 27 Sense primer for preparation of variant enzyme L91N
- SEQ ID NO: 28 Antisense primer for preparation of variant enzyme L91N
- SEQ ID NO: 29 Sense primer for preparation of variant enzyme L91D
- SEQ ID NO: 30 Antisense primer for preparation of variant enzyme L91D
- SEQ ID NO: 31 Sense primer for preparation of variant enzyme N31Q
- SEQ ID NO: 32 Antisense primer for preparation of variant enzyme N31Q
- SEQ ID NO: 33 Sense primer for preparation of variant enzyme N77Q
- SEQ ID NO: 34 Antisense primer for preparation of variant enzyme N77Q
- SEQ ID NO: 35 Sense primer for preparation of variant enzyme L91G
- SEQ ID NO: 36 Antisense primer for preparation of variant enzyme L91G
- SEQ ID NO: 37 Sense primer for preparation of variant enzyme L91K
- SEQ ID NO: 38 Antisense primer for preparation of variant enzyme L91K
- SEQ ID NO: 39 Sense primer for preparation of variant enzyme F95A
- SEQ ID NO: 40 Antisense primer for preparation of variant enzyme F95A
- SEQ ID NO: 41 Sense primer for preparation of variant enzyme F95W
- SEQ ID NO: 42 Antisense primer for preparation of variant enzyme F95W
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Mechanical Engineering (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Tires In General (AREA)
- Enzymes And Modification Thereof (AREA)
- Polyoxymethylene Polymers And Polymers With Carbon-To-Carbon Bonds (AREA)
Abstract
The invention relates to an isoprene oligomer that contains a trans structural moiety and a cis structural moiety, which can be represented by the following formula (1), wherein at least 1 atom or group in the trans structural moiety is replaced by another atom or group. The invention also relates to a polyisoprene, which is biosynthesized using the isoprene oligomer and isopentenyl diphosphate. Further, this invention provides a rubber composition comprising the isoprene oligomer and/or the polyisoprene, and a pneumatic tire, including tire components (e.g., treads and sidewalls) formed from the rubber composition.
wherein n represents an integer from 1 to 10; m represents an integer from 1 to 30; and Y represents a hydroxy group, a formyl group, a carboxy group, an ester group, a carbonyl group, or a group represented by the following formula (2):
Description
This application is a Divisional of copending application Ser. No. 13/809,616, filed on Jan. 11, 2013, which was filed as PCT International Application No. PCT/JP2011/064774 on Jun. 28, 2011, which claims the benefit under 35 U.S.C. §119(a) to Patent Application No. 2010-160120, filed in Japan on Jul. 14, 2010 and Patent Application No. 2010-277384, filed in Japan on Dec. 13, 2010, all of which are hereby expressly incorporated by reference into the present application.
The present invention relates to an isoprene oligomer and a polyisoprene; processes for producing these materials; a rubber composition including the isoprene oligomer and/or the polyisoprene; and a pneumatic tire formed from the rubber composition.
Conventionally, in order to impart novel properties, in addition to the original properties of rubber, to rubber products, filler and the like of various materials or shapes are introduced into rubber compositions according to the uses to achieve the desired properties. For automobile tires, for example, in order to improve properties such as abrasion resistance, low-heat-build-up properties, or wet grip performance, filler (e.g., silica, carbon black) is introduced into the organic rubber fraction.
When filler or the like is mixed with the rubber fraction in such a rubber composition, for the purpose of enhancing the affinity between the two to improve low-heat-build-up properties, wet grip performance, etc., a modified rubber (modified diene polymer) has been used in which a functional group having affinity for the filler is introduced in rubber molecules in the rubber fraction as a result of, for example, a treatment involving reacting rubber molecules with, for example, a compound containing both a nitrogen atom-containing group and a chlorosulfenyl group (see, for example, Patent Literatures 1 and 2).
It is however known that, depending on methods for introduction, a predetermined functional group is difficult to introduce to a predetermined position in the rubber molecule and is consequently introduced to, particularly, a random position in the main chain constituting the rubber molecule. Use of such rubber molecules containing a predetermined functional group introduced in the main chain is less likely to produce the desired effects due to the random bonds between the rubber molecules and filler. In addition, the functional group-introduced sites have deteriorated rubber properties, which disadvantageously results in deterioration in the properties of the whole rubber.
- Patent Literature 1: JP 2000-001573 A
- Patent Literature 2: JP 2000-001575 A
An object of the present invention is to solve the problems described above and to provide an isoprene oligomer and a polyisoprene which have been modified substantially only at a terminal site of the molecule. Another object of the present invention is to provide a rubber composition including the isoprene oligomer and/or the polyisoprene, and pneumatic tires including various tire components (e.g., treads and sidewalls) formed from the rubber composition.
The present invention relates to an isoprene oligomer including a trans structural moiety and a cis structural moiety, which is represented by the following formula (1), wherein at least 1 atom or group in the trans structural moiety is replaced by another atom or group:
wherein n represents an integer from 1 to 10; m represents an integer from 1 to 30; and Y represents a hydroxy group, a formyl group, a carboxy group, an ester group, a carbonyl group, or a group represented by the following formula (2):
It is preferable that at least 1 atom or group in moiety II in the following formula (1-1) should be replaced, and no atom or group in moiety III should be replaced:
It is preferable that the trans structural moiety should be represented by any of the following formulas (a) to (s):
It is preferable that the isoprene oligomer should be biosynthesized using an allylic diphosphate and isopentenyl diphosphate; the allylic diphosphate is represented by the following formula (3), wherein at least 1 atom or group in the isoprene units in formula (3) is replaced by another atom or group:
wherein p represents an integer from 1 to 10.
It is preferable that the biosynthesis should be carried out using an enzyme that shows prenyltransferase activity.
It is preferable that the enzyme that shows prenyltransferase activity should be any of the following proteins:
[1] a protein having an amino acid sequence represented by any of the following SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22;
[2] a protein having an amino sequence that is derived from the amino acid sequence represented by any of the following SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22 by substitution, deletion, insertion, or addition of 1 or more amino acids, and possessing the ability to catalyze a reaction between an allylic diphosphate and isopentenyl diphosphate, wherein the allylic diphosphate can be represented by the following formula (3), wherein at least 1 atom or group in the isoprene units in formula (3) is replaced by another atom or group;
[3] a protein having an amino acid sequence that shows 45% or higher sequence identity to the amino acid sequence represented by any of the following SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22 and possessing the ability to catalyze a reaction between an allylic diphosphate and isopentenyl diphosphate, wherein the allylic diphosphate can be represented by the following formula (3), wherein at least 1 atom or group in the isoprene units in formula (3) is replaced by another atom or group:
[3] a protein having an amino acid sequence that shows 45% or higher sequence identity to the amino acid sequence represented by any of the following SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22 and possessing the ability to catalyze a reaction between an allylic diphosphate and isopentenyl diphosphate, wherein the allylic diphosphate can be represented by the following formula (3), wherein at least 1 atom or group in the isoprene units in formula (3) is replaced by another atom or group:
wherein p represents an integer from 1 to 10.
The present invention also relates to a process for producing the isoprene oligomer, which involves the biosynthesis of isoprene oligomer by using an allylic diphosphate and isopentenyl diphosphate, wherein the allylic diphosphate can be represented by the following formula (3), wherein at least 1 atom or group in the isoprene units in formula (3) is replaced by another atom or group:
wherein p represents an integer from 1 to 10.
It is preferable that the biosynthesis should be carried out using an enzyme showing prenyltransferase activity.
The present invention further relates to a polyisoprene including a trans structural moiety and a cis structural moiety, which is represented by the following formula (4), wherein at least 1 atom or group in the trans structural moiety is replaced by another atom or group:
wherein n represents an integer from 1 to 10; q represents an integer from 30 to 40 000; and Y represents a hydroxy group, a formyl group, a carboxy group, an ester group, a carbonyl group, or a group represented by the following formula (2):
It is preferable that at least 1 atom or group in moiety VI in the following formula (4-1) should be replaced, and no atom or group in moiety VII should be replaced:
It is preferable that the polyisoprene should be biosynthesized using the isoprene oligomer and isopentenyl diphosphate.
The present invention further relates to a process for producing the polyisoprene, which involves the biosynthesis of the polyisoprene by using the isoprene oligomer and isopentenyl diphosphate.
The present invention further relates to a rubber composition including at least 1 of the isoprene oligomers and the polyisoprene.
The present invention further relates to a pneumatic tire formed from the rubber composition.
The isoprene oligomer of the present invention is an isoprene oligomer containing a trans structural moiety and a cis structural moiety represented by the formula (1), wherein at least one atom or group contained in the trans structural moiety is replaced by another atom or group. Moreover, the polyisoprene of the present invention is a polyisoprene containing a trans structural moiety and a cis structural moiety represented by the formula (4), wherein at least one atom or group contained in the trans structural moiety is replaced by another atom or group. Thus, the isoprene oligomer of the present invention and the polyisoprene of the present invention have been modified substantially only at a terminal site of the molecule (rubber molecule) and therefore are excellent in affinity for filler such as silica while the original properties of the molecules (rubber molecules) are not impaired. Accordingly, a rubber composition containing the isoprene oligomer of the present invention and/or the polyisoprene of the present invention is obtained as a rubber composition in which rubber molecules are combined with filler in a level higher than ever. Thus, the present invention can provide a rubber composition excellent in, for example, low-heat-build-up properties, and wet grip performance. Use of the rubber composition in various tire components (e.g., treads and sidewalls) can provide pneumatic tires excellent in, for example, low-heat-build-up properties, and wet grip performance.
In the process of artificially biosynthesizing a rubber molecule (polyisoprene), an enzyme such as prenyltransferase is allowed to act on a mixture of an initiating substrate such as farnesyl diphosphate (FPP) and monomer such as isopentenyl diphosphate to produce an isoprene oligomer having approximately 8 isoprene units addition-polymerized to the initiating substrate. It is known that the isoprene oligomer is then further mixed with a latex component containing an enzyme for addition-polymerizing isopentenyl diphosphate to produce a polyisoprene having a large number of isopentenyl diphosphate units linked to the oligomer.
As described above, the addition polymerization mediated by natural enzymes is indispensable to various steps for sequentially linking the monomers starting from the initiating substrate to form a rubber molecule.
For this reason, the biosynthesis of a rubber molecule (polyisoprene) requires using an initiating substrate and monomer whose reaction can be catalyzed by the enzyme used, which results in limitations to the structures of the initiating substrate and monomer used as raw materials for the rubber molecule (polyisoprene). Particularly, the initiating substrate is limited to naturally occurring dimethylallyl diphosphate, geranyl diphosphate, farnesyl diphosphate, geranylgeranyl diphosphate, and the like due to restrictions attributed to the enzyme for producing the oligomer.
As a result, the artificially biosynthesized rubber molecule (polyisoprene) is also limited in the degree of freedom of its structure. Thus, free molecular design for imparting functionality that is absent in natural rubber is made difficult.
Conventionally, in order to obtain, for example, a rubber molecule (polyisoprene) in which a functional group or the like is introduced, a functional group having affinity for filler is introduced into a rubber molecule, for example, by a treatment including reacting a rubber molecule (polyisoprene) biosynthesized in advance with, for example, a compound containing both a nitrogen atom-containing group and a chlorosulfenyl group, similarly as in the case of using synthetic rubber as a raw material.
In contrast, the present invention is based on the findings that an isoprene oligomer or polyisoprene having a terminal site to which functionality has been imparted can be produced by using partially structurally modified farnesyl diphosphate or the like as an initiating substrate for the isoprene oligomer or polyisoprene production.
In particular, the present invention is based on the findings that by maintaining the structure of moiety I in the following formula (I) in the naturally occurring initiating substrate farnesyl diphosphate or the like, even when a desired structure is introduced in a moiety other than moiety I, it is possible to produce isoprene oligomers in the presence of the naturally occurring oligomer-producing enzyme prenyltransferase or any enzyme obtained by partial mutation thereof. This is probably, albeit not absolutely clear, because prenyltransferase is adsorbed on the structure of moiety I in the formula (I) of the initiating substrate and is relatively insensitive to the structures of other moieties.
On the basis of these findings, an isoprene oligomer or polyisoprene having a terminal site having desired properties can be provided. In other words, isoprene oligomers or polyisoprenes having various functions can be provided without impairing the properties of isoprene oligomer or polyisoprene itself.
(Isoprene Oligomer)
The isoprene oligomer of the present invention is an isoprene oligomer containing a trans structural moiety and a cis structural moiety represented by the formula (1) shown below, wherein at least one atom or group contained in the trans structural moiety is replaced by another atom or group. In this context, the trans structural moiety means a moiety of repeated isoprene units with a trans structure (moiety A in the formula (1) shown below). Also, the cis structural moiety means a moiety of repeated isoprene units with a cis structure (moiety ( )m (moiety B) in the formula (1) shown below). In the present specification, the group represented by the formula (2) shown below has three hydroxy groups bonded to a phosphorus atom, and some (or one) or all of these hydroxy groups are dissociated in an aqueous solution (for example, a group represented by the formula (5) shown below is then formed). In the present specification, the group represented by the formula (2) also conceptually encompasses such groups in which some (or one) or all of the hydroxy groups have been dissociated.
In the present specification, the modification of a terminal site of the molecule (rubber molecule) refers to the introduction of a desired functional group into a predetermined site in the trans structural moiety present at an end of the molecule (rubber molecule), or the introduction of a different structure into a predetermined site in the trans structural moiety present at an end of the molecule (rubber molecule).
wherein n represents an integer of 1 to 10; m represents an integer of 1 to 30; and Y represents a hydroxy group, a formyl group, a carboxy group, an ester group, a carbonyl group, or a group represented by the following formula (2).
The isoprene oligomer of the present invention is structurally similar to natural rubber and is highly compatible with rubber molecules. Moreover, the isoprene oligomer of the present invention has been modified substantially only at a terminal site of the molecule. Specifically, the isoprene oligomer of the present invention contains a hydroxy group, a formyl group, a carboxy group, an ester group, a carbonyl group, or a group represented by the formula (2), positioned at the end of the cis structural moiety, and at least one atom or group contained in the trans structural moiety is replaced by another atom or group. Thus, the isoprene oligomer of the present invention strongly interacts with filler such as silica while the original properties of isoprene oligomer are not impaired. Since the isoprene oligomer of the present invention is highly compatible with rubber and strongly interacts with filler such as silica, as described above, a rubber composition containing this isoprene oligomer is obtained as a rubber composition in which rubber molecules are combined with filler in a level higher than ever. The resulting rubber composition can have, for example, improved low-heat-build-up properties, wet grip performance, and abrasion resistance.
The isoprene oligomer of the present invention contains a polar group or the like only at the terminal site of the cis structural moiety and a site close to the end of the trans structural moiety. The isoprene oligomer therefore offers high dispersibility of filler such as silica and has a large effect of improving, for example, low-heat-build-up properties, wet grip performance, and abrasion resistance while the original properties of isoprene oligomer are not impaired, compared with isoprene oligomers containing a polar group or the like in the main chain moiety or only at the terminal site of the cis structural moiety.
Furthermore, the isoprene oligomer of the present invention has excellent antimicrobial activity. This is presumably because the isoprene oligomer of the present invention, in which at least one atom or group contained in the trans structural moiety is replaced by another atom or group, structurally differs from usual isoprene oligomers present in the natural world and thus has effects such as the inhibition of enzymes or coenzymes, the inhibition of nucleic acid synthesis, the inhibition of cell membrane synthesis, the inhibition of cytoplasmic membrane synthesis, cell membrane disruption, and cytoplasmic membrane disruption in microbes.
In the formula (1), n represents an integer of 1 to 10 (preferably 1 to 4, more preferably 1 to 3).
In the formula (1), m represents an integer of 1 to 30 (preferably 1 to 10, more preferably 1 to 8).
In the formula (1), Y represents a hydroxy group (—OH), a formyl group (—CHO), a carboxy group (—COOH), an ester group (—COOR), a carbonyl group (—COR), or a group represented by the formula (2).
In the ester group (—COOR) or the carbonyl group (—COR), R represents an alkyl group having 1 to 30 (preferably 1 to 17) carbon atoms. Examples of the alkyl group having 1 to 30 carbon atoms include methyl, ethyl, propyl, butyl, and pentyl groups.
In the formula (1), Y is preferably a hydroxy group or a carboxy group, because the resulting isoprene oligomer has excellent antimicrobial properties and strongly interacts with filler such as silica.
At least one atom or group contained in the trans structural moiety in the formula (1) has been replaced by another atom or group.
Examples of the atom or group (atom or group before replacement) contained in the trans structural moiety include a hydrogen atom, a methyl group, a methylene group, a carbon atom, and a methine group.
Examples of the another atom include nitrogen, oxygen, sulfur, silicon, and carbon atoms. Among them, a nitrogen atom has a strong intermolecular force and causes strong interaction with enzymes or cell membranes. For this reason, a nitrogen atom is preferred in terms of antimicrobial properties.
Examples of the another group include an acetoxy group, alkoxy groups (preferably, alkoxy groups having 1 to 3 carbon atoms, more preferably a methoxy group), a hydroxy group, aryl groups (preferably, a phenyl group), alkyl groups (preferably, alkyl groups having 1 to 5 carbon atoms, more preferably an ethyl group and a tert-butyl group), an acetyl group, N-alkyl-acetamino groups (whose alkyl preferably has 1 to 5 carbon atoms), and an azide group.
Particularly, since a nitrogen atom has a strong intermolecular force and causes strong interaction with enzymes or cell membranes, N-alkyl-acetamino groups (more preferably, N-methyl-acetamino and N-butyl-acetamino groups) and azide group are preferred in terms of antimicrobial properties.
As described above, at least one atom or group contained in the trans structural moiety has been replaced by another atom or group. For this replacement, it is preferable that in the moiety of repeated isoprene units in the trans structural moiety, at least one atom or group contained in moiety II in the formula (1-1) shown below should be replaced while no atom or group contained in moiety III in the formula (1-1) should be replaced. This is based on the findings by the present inventors that by maintaining the structure of moiety I in the formula (I) in the naturally occurring initiating substrate farnesyl diphosphate or the like, even when a desired structure is introduced in a moiety other than moiety I, it is possible to produce isoprene oligomers in the presence of the naturally occurring oligomer-producing enzyme prenyltransferase or any enzyme obtained by partial mutation thereof.
wherein n, m, and Y are as defined for n, m, and Y in the formula (1).
Specific examples of the trans structural moiety in the formula (1) include structures represented by the formulas (a) to (s) shown below. Among them, structures represented by the formulas (c), (d), (e), (f), (k), (l), and (r) are preferred, because the resulting isoprene oligomer has a large effect of improving low-heat-build-up properties, wet grip performance, and abrasion resistance. Also, structures represented by the formulas (g) to (q) are preferred, with structures represented by the formulas (k), (l), and (q) being more preferred, because the resulting isoprene oligomer is excellent in antimicrobial properties.
Examples of the process for producing the isoprene oligomer of the present invention include a process including performing biosynthesis from an allylic diphosphate and isopentenyl diphosphate, the allylic diphosphate (hereinafter, also referred to as an allylic diphosphate derivative) being represented by the formula (3) shown below, wherein at least one atom or group contained in isoprene units in the formula (3) is replaced by another atom or group. In the present specification, the allylic diphosphate derivative has three hydroxy groups bonded to a phosphorus atom, and some (or one) or all of these hydroxy groups are dissociated in an aqueous solution (for example, a group represented by the formula (5) is then formed). In the present specification, the allylic diphosphate derivative also conceptually encompasses such groups in which some (or one) or all of the hydroxy groups have been dissociated.
wherein p represents an integer of 1 to 10.
In the formula (3), p represents an integer of 1 to 10 (preferably 1 to 4, more preferably 1 to 3).
In the present specification, examples of the atom or group (atom or group before replacement) contained in isoprene units in the formula (3) include the same as those exemplified as the atom or group (atom or group before replacement) contained in the trans structural moiety in the formula (1).
In the present specification, examples of the another atom or group for replacing the atom or group contained in isoprene units in the formula (3) include the same as those exemplified as the another atom or the another group described for the formula (1).
For the replacement, it is preferable that the structure of moiety I in the formula (I) should be maintained after the replacement, as described above. Specifically, it is preferable that at least one atom or group contained in moiety IV in the formula (3-1) shown below should be replaced while no atom or group contained in moiety V in the formula (3-1) should be replaced. This allows favorable production of isoprene oligomers using the naturally occurring oligomer-producing enzyme prenyltransferase or any enzyme obtained by partial mutation thereof.
wherein p is as defined for p in the formula (3).
Specific examples of the allylic diphosphate derivative include compounds represented by the following formulas (A) to (S).
In the present specification, OPP has three hydroxy groups bonded to a phosphorus atom, and some (or one) or all of these hydroxy groups are dissociated in an aqueous solution (for example, a group represented by the formula (5) is then formed). In the present specification, OPP also conceptually encompasses such groups in which some (or one) or all of the hydroxy groups have been dissociated.
Allylic diphosphate derivatives represented by the formulas (A) to (S) and the like can be produced by those skilled in the art with reference to the processes described in Examples, using, for example, dimethylallyl diphosphate, geranyl diphosphate, farnesyl diphosphate, geranylgeranyl diphosphate, geraniol, farnesol, or geranylgeraniol.
Examples of the process for biosynthesizing the isoprene oligomer of the present invention from the allylic diphosphate derivative and isopentenyl diphosphate include a process using an enzyme having prenyltransferase activity. Specifically, the allylic diphosphate derivative and isopentenyl diphosphate may be allowed to react with each other in the presence of an enzyme having prenyltransferase activity.
In the present specification, the enzyme having prenyltransferase activity means an enzyme having activity of catalyzing the condensation reaction between an allylic substrate (allylic diphosphate) and isopentenyl diphosphate to synthesize a new allylic diphosphate in which one isoprene unit is added, and catalyzing a reaction through which isopentenyl diphosphate is sequentially linked in a Z form (newly added isoprene unit has a cis structure) starting from the allylic substrate (allylic diphosphate). Examples thereof include enzymes for catalyzing the following reaction:
The presence of many such enzymes having prenyltransferase activity has already been confirmed (e.g., Z-nonaprenyl diphosphate synthase (Ishii, K. et al., (1986) Biochem, J., 233, 773) and undecaprenyl diphosphate (UPP) synthase (Takahashi, I. and Ogura, K. (1982) J. Biochem., 92, 1527; and Keenman, M. V. and Allen, C. M. (1974) Arch. Biochem. Biophys., 161, 375)). Since the maximum number of isoprene units (m in the formula (1)) each enzyme can produce is predetermined, the enzyme to be used can be changed according to the number of isoprene units (m in the formula (1)) of interest.
Examples of organisms containing the enzyme having prenyltransferase activity include Micrococcus luteus B-P 26, Escherichia coli, Saccharomyces cerevisiae, Arabidopsis thaliana, Hevea brasiliensis, Periploca sepium, Bacillus Stearothermophilus, and Sulfolobus acidocaldarius (ATCC49426).
The isoprene oligomer of the present invention can be obtained by reacting the allylic diphosphate derivative with isopentenyl diphosphate in the presence of the enzyme having prenyltransferase activity. The phrase “in the presence of the enzyme having prenyltransferase activity” means the presence of a culture of the organism, biological cells separated from the culture, a treated product of the biological cells, the enzyme purified from the culture or the biological cells, a culture of biological cells (transformant) transformed by a genetic engineering approach so as to express the enzyme having prenyltransferase activity (this enzyme also encompasses variant enzymes described later), biological cells separated from the culture, a treated product of the biological cells, the enzyme purified from the culture or the biological cells, or the like.
In this context, the biological cells transformed so as to express the enzyme having prenyltransferase activity refer to a transformant prepared by a genetic engineering approach conventionally known in the art. The preparation method will be described later.
In order to obtain biological cells of the organism, the organism can be cultured in an appropriate medium. The medium for this purpose is not particularly limited as long as the organism can proliferate therein. A usual medium containing usual carbon source, nitrogen source and inorganic ions, and optionally organic nutrient sources can be used.
For example, any carbon sources that can be utilized by the organism can be used. Specific examples of usable carbon sources include: sugars such as glucose, fructose, maltose, and amylose; alcohols such as sorbitol, ethanol, and glycerol; organic acids such as fumaric acid, citric acid, acetic acid, and propionic acid, and salts thereof; carbohydrates such as paraffin; and mixtures thereof.
Examples of usable nitrogen sources include: inorganic ammonium salts such as ammonium sulfate and ammonium chloride; ammonium salts of organic acids such as ammonium fumarate and ammonium citrate; nitrates such as sodium nitrate and potassium nitrate; organic nitrogen compounds such as peptone, yeast extracts, meat extracts, and corn steep liquor; and mixtures thereof.
In addition, nutrient sources used in usual media, such as inorganic salts, trace metal salts, vitamins, and hormones, can be mixed appropriately for use.
The culture conditions are not particularly limited and culture can be performed at pH and temperature appropriately controlled in the ranges of pH 5 to 8 and temperature 20 to 60° C., for approximately 12 to 480 hours under aerobic conditions.
Examples of the culture of the organism include a culture solution obtained by culturing the organism under the culture conditions described above, and a culture filtrate (culture supernatant) obtained by separating the organism (biological cells) from the culture solution by filtration or the like. Also, examples of the biological cells separated from the culture include biological cells (organism) separated from the culture solution by filtration, centrifugation, or the like.
Examples of the treated product of the biological cells include disrupted biological cells obtained by homogenizing the biological cells separated from the culture, and disrupted biological cells obtained by sonicating the biological cells separated from the culture.
The enzyme purified from the culture or the biological cells may be obtained, for example, by a known purification operation, such as salting out, ion-exchange chromatography, affinity chromatography, or gel-filtration chromatography, for the enzyme present in the culture or the biological cells. The purified enzyme is not particularly limited in its purity.
As described above, the isoprene oligomer of the present invention can be obtained by reacting the allylic diphosphate derivative with isopentenyl diphosphate in the presence of the enzyme having prenyltransferase activity. Specifically, for example, the culture of the biological cells, the purified enzyme or the like can be added into a solution containing the allylic diphosphate derivative and isopentenyl diphosphate to perform the reaction. The reaction temperature can be set to, for example, 20 to 60° C.; the reaction time can be set to, for example, 1 to 16 hours; and the pH can be set to, for example, 5 to 8. If necessary, magnesium chloride, a surfactant, 2-mercaptoethanol, and the like may further be added thereto.
The isoprene oligomer of the present invention obtained by the reaction is usually represented by the formula (1) wherein Y is a group represented by the formula (2) or a hydroxy group. This hydroxy group is formed through the hydrolysis of the group represented by the formula (2).
Further, the isoprene oligomer represented by the formula (1) wherein Y is a formyl group can be obtained, for example, by the oxidation of the isoprene oligomer of the formula (1) wherein Y is a group represented by the formula (2).
Further, the isoprene oligomer represented by the formula (1) wherein Y is a carboxy group can be obtained, for example, by the oxidation of the isoprene oligomer of the formula (1) wherein Y is a group represented by the formula (2).
Further, the isoprene oligomer represented by the formula (1) wherein Y is an ester group can be obtained, for example, by the oxidation and esterification of the isoprene oligomer of the formula (1) wherein Y is a group represented by the formula (2).
Further, the isoprene oligomer represented by the formula (1) wherein Y is a carbonyl group can be obtained, for example, by the oxidation and esterification of the isoprene oligomer of the formula (1) wherein Y is a group represented by the formula (2).
The isoprene oligomer of the present invention is obtained by biosynthesis except for the organic synthesis of the allylic diphosphate derivative as an initiating substrate, and can thus take into account the exhaustion of petroleum resources and environmental issues.
(Enzyme Having Prenyltransferase Activity)
Next, the enzyme having prenyltransferase activity will be described.
As an example of the enzyme having prenyltransferase activity derived from the organism, the base sequence and the amino acid sequence of Micrococcus luteus B-P 26 (available from Dr. L. Jeffries, Walton Oaks Experimental Station Vitamins, Ltd.)-derived undecaprenyl diphosphate synthase are shown in SEQ ID NOs: 1 and 2, respectively, in the Sequence Listing. The base sequence and the amino acid sequence of Micrococcus luteus B-P 26-derived undecaprenyl diphosphate synthase are known in the art and included in the database DDBJ (DNA Data Bank of Japan) (Accession No. AB004319 (base sequence) and Accession No. BAA31993.1 (amino acid sequence)).
The original substrate (initiating substrate) for the enzyme (enzyme having prenyltransferase activity) derived from this organism is an allylic diphosphate. Then, the allylic diphosphate derivative used as an initiating substrate in the present invention originally functions as an inhibitor of the enzyme produced by the organism. Thus, the enzyme produced by the organism often has low enzymatic activity on the allylic diphosphate derivative (particularly, the compound represented by any of the formulas (G) to (Q)). Therefore, in the present invention, it is preferable to use a variant enzyme having enhanced enzymatic activity on the allylic diphosphate derivative.
In the case of using the variant enzyme, biological cells (transformant) transformed by a genetic engineering approach so as to express the variant enzyme can be prepared.
The present inventors have prepared variant enzymes of the Micrococcus luteus B-P 26-derived undecaprenyl diphosphate synthase and successfully enhanced the enzymatic activity on the allylic diphosphate derivative.
The three-dimensional structure of the Micrococcus luteus B-P 26-derived undecaprenyl diphosphate synthase has already been known in the art (database PDB (RCSB Protein Data Bank), ID: 1f75). Thus, the present inventors have conducted docking simulation based on this three-dimensional structure information and prepared variant enzymes on the basis of the design philosophy that the enzymatic activity on the allylic diphosphate derivative can be enhanced by mutation of an amino acid positioned in the vicinity of the hydrocarbon moiety around the diphosphate moiety of the allylic diphosphate so as to change the length of the side chain or the charge. Specifically, it is preferable to perform any of the following mutations (1) to (4):
(1) Substitution of asparagine at position 31 by alanine, glutamine, glycine, or aspartic acid;
(2) Substitution of leucine at position 91 by asparagine, aspartic acid, glycine, or lysine;
(3) Substitution of asparagine at position 77 by alanine, glutamine, glycine, or aspartic acid;
(4) Substitution of phenylalanine at position 95 by alanine, tryptophan, glycine, aspartic acid, or arginine.
Specifically, the following variant enzymes were prepared:
variant enzyme N31A: asparagine at position 31 was substituted by alanine (its base sequence and amino acid sequence are shown in SEQ ID NOs: 3 and 4, respectively, in the Sequence Listing);
variant enzyme N77A: asparagine at position 77 was substituted by alanine (its base sequence and amino acid sequence are shown in SEQ ID NOs: 5 and 6, respectively, in the Sequence Listing);
variant enzyme L91N: leucine at position 91 was substituted by asparagine (its base sequence and amino acid sequence are shown in SEQ ID NOs: 7 and 8, respectively, in the Sequence Listing);
variant enzyme L91D: leucine at position 91 was substituted by aspartic acid (its base sequence and amino acid sequence are shown in SEQ ID NOs: 9 and 10, respectively, in the Sequence Listing);
variant enzyme N31Q: asparagine at position 31 was substituted by glutamine (its base sequence and amino acid sequence are shown in SEQ ID NOs: 11 and 12, respectively, in the Sequence Listing);
variant enzyme N77Q: asparagine at position 77 was substituted by glutamine (its base sequence and amino acid sequence are shown in SEQ ID NOs: 13 and 14, respectively, in the Sequence Listing);
variant enzyme L91G: leucine at position 91 was substituted by glycine (its base sequence and amino acid sequence are shown in SEQ ID NOs: 15 and 16, respectively, in the Sequence Listing);
variant enzyme L91K: leucine at position 91 was substituted by lysine (its base sequence and amino acid sequence are shown in SEQ ID NOs: 17 and 18, respectively, in the Sequence Listing);
variant enzyme F95A: phenylalanine at position 95 was substituted by alanine (its base sequence and amino acid sequence are shown in SEQ ID NOs: 19 and 20, respectively, in the Sequence Listing);
variant enzyme F95W: phenylalanine at position 95 was substituted by tryptophan (its base sequence and amino acid sequence are shown in SEQ ID NOs: 21 and 22, respectively, in the Sequence Listing).
Among them, variant enzyme N77A, variant enzyme L91D, and variant enzyme L91K are preferred.
Although the use of the Micrococcus luteus B-P 26-derived undecaprenyl diphosphate synthase as a wild-type enzyme is described herein, variant enzymes can be prepared by similar approaches using other enzymes having prenyltransferase activity as wild-type enzymes.
Specific examples of the enzyme having prenyltransferase activity include the following protein [1]:
[1] a protein having an amino acid sequence represented by any of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22.
It is also known that enzymes having an amino acid sequence derived from the original amino acid sequence by substitution, deletion, insertion, or addition of one or more amino acids may have enzymatic activity. Thus, specific examples of the enzyme having prenyltransferase activity also include the following protein [2]:
[2] a protein having an amino acid sequence derived from the amino acid sequence represented by any of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22 by substitution, deletion, insertion, or addition of one or more amino acids, and having activity of catalyzing a reaction between an allylic diphosphate (allylic diphosphate derivative) and isopentenyl diphosphate, the allylic diphosphate being represented by the following formula (3), wherein at least one atom or group contained in isoprene units in the formula (3) is replaced by another atom or group:
wherein p represents an integer of 1 to 10.
For maintaining the activity of catalyzing the reaction between the allylic diphosphate derivative and isopentenyl diphosphate, it is preferable that the amino acid sequence should contain substitution, deletion, insertion, or addition of preferably one or more amino acids, more preferably 1 to 100 amino acids, even more preferably 1 to 75 amino acids, particularly preferably 1 to 50 amino acids, further preferably 1 to 25 amino acids, further preferably 1 to 12 amino acids, further preferably 1 to 5 amino acids, and most preferably 1 to 3 amino acids.
It is also known that proteins having an amino acid sequence having high sequence identity to the amino acid sequence of the enzyme having prenyltransferase activity may have similar activity. Thus, specific examples of the enzyme having prenyltransferase activity also include the following protein [3]:
[3] a protein having an amino acid sequence having 45% or higher sequence identity to the amino acid sequence represented by any of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22, and having activity of catalyzing a reaction between the allylic diphosphate derivative and isopentenyl diphosphate.
For maintaining the activity of catalyzing the reaction between the allylic diphosphate derivative and isopentenyl diphosphate, the sequence identity to the amino acid sequence represented by any of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22 is preferably 45% or higher, more preferably 60% or higher, even more preferably 70% or higher, particularly preferably 80% or higher, further preferably 90% or higher, further preferably 95% or higher, further preferably 98% or higher, and most preferably 99% or higher.
The amino acid sequence or base sequence identity can be determined using the algorithm BLAST by Karlin and Altschul [Pro. Natl. Acad. Sci. USA, 90, 5873 (1993)] or FASTA [Methods Enzymol., 183, 63 (1990)].
Examples of the method for confirming that a protein has activity of catalyzing the reaction between the allylic diphosphate derivative and isopentenyl diphosphate include a method involving preparing a transformant expressing the protein by a method conventionally known in the art, producing the protein using the transformant, and then quantitatively or qualitatively analyzing the substrate or product by HPLC (high-performance liquid chromatography), TLC (thin-layer chromatography), or the like to confirm whether or not the protein can catalyze the reaction between the allylic diphosphate derivative and isopentenyl diphosphate.
(DNA Encoding Enzyme Having Prenyltransferase Activity)
Examples of DNA encoding the enzyme having prenyltransferase activity include the following DNAs [1] to [3]:
[1] DNA encoding any of the proteins [1] to [3];
[2] DNA having a base sequence represented by any of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21; and
[3] DNA hybridizing under stringent conditions to DNA having a base sequence complementary to the base sequence represented by any of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21; and encoding a protein having activity of catalyzing a reaction between the allylic diphosphate derivative and isopentenyl diphosphate.
In this context, the term “hybridizing” means a step in which the DNA hybridizes to DNA having a specific base sequence or a portion of the DNA. Thus, the base sequence of the DNA having a specific base sequence or the portion of the DNA may be DNA of length that is useful as a probe in Northern or Southern blot analysis or can be used as an oligonucleotide primer in PCR (polymerase chain reaction) analysis. Examples of the DNA used as a probe include DNA of at least 100 bases or longer, preferably of 200 bases or longer, and more preferably of 500 bases or longer. DNA of at least 10 bases or longer, preferably of 15 bases or longer, may be used.
Methods for DNA hybridization experiment are well known. Hybridization conditions can be determined according to the description of, for example, Molecular Cloning, 2nd ed. and 3rd ed. (2001), Methods for General and Molecular Bacteriology, ASM Press (1994), or Immunology methods manual, Academic press (Molecular) as well as many other standard textbooks to conduct the experiment.
Examples of the stringent conditions include conditions involving, for example, incubating a DNA-immobilized filter and probe DNA overnight at 42° C. in a solution containing 50% formamide, 5×SSC (750 mM sodium chloride and 75 mM sodium citrate), 50 mM sodium phosphate (pH 7.6), 5×Denhardt's solution, 10% dextran sulfate, and 20 μg/l denatured salmon sperm DNA, and then washing the filter in, for example, a 0.2×SSC solution at approximately 65° C. Lower stringent conditions may be used. The stringent conditions can be changed by adjustment of the concentration of formamide (lower concentration of formamide gives lower stringent conditions) and change in salt concentration and temperature conditions. Examples of low stringent conditions include conditions involving, for example, overnight incubation at 37° C. in a solution containing 6×SSCE (20×SSCE corresponds to 3 mol/l sodium chloride, 0.2 mol/l sodium dihydrogen phosphate, and 0.02 mol/l EDTA, pH 7.4), 0.5% SDS, 30% formamide, and 100 μg/l denatured salmon sperm DNA, followed by washing using a solution of 1×SSC and 0.1% SDS at 50° C. Also, examples of lower stringent conditions include conditions involving hybridization using a solution with a higher salt concentration (e.g., 5×SSC) under the low stringent conditions, followed by washing.
These various conditions may be set by the addition or change of a blocking reagent used for suppressing background in the hybridization experiment. The addition of the blocking reagent may be accompanied by change of the hybridization conditions in order to adapt the conditions to each experiment.
Examples of DNA capable of hybridization under the stringent conditions described above include DNA having a base sequence having at least 80% or higher, preferably 90% or higher, more preferably 95% or higher, even more preferably 98% or higher, particularly preferably 99% or higher sequence identity to the base sequence represented by any of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21 when calculated on the basis of the parameters using a program such as BLAST and FASTA.
Examples of the method for confirming that the DNA hybridizing under stringent conditions to the DNA encodes a protein having activity of catalyzing the reaction between the allylic diphosphate derivative and isopentenyl diphosphate include a method involving preparing recombinant DNA containing the DNA by a method conventionally known in the art, introducing the recombinant DNA into host cells, culturing the obtained biological cells, purifying the protein from the obtained culture, and then quantitatively or qualitatively analyzing the substrate or product by HPLC, TLC, or the like to confirm whether or not the protein can catalyze the reaction between the allylic diphosphate derivative and isopentenyl diphosphate.
Each variant enzyme and DNA encoding the variant enzyme can be obtained by the site-directed mutagenesis of, for example, the base sequence represented by SEQ ID NO: 1 (base sequence of Micrococcus luteus B-P 26-derived undecaprenyl diphosphate synthase) using a site-directed mutagenesis method described in Molecular Cloning, A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press (1989), Current Protocols in Molecular Biology, John Wiley & Sons (1987-1997), Nucleic Acids Research, 10, 6487 (1982), Proc. Natl. Acad. Sci. USA, 79, 6409 (1982), Gene, 34, 315 (1985), Nucleic Acids Research, 13, 4431 (1985), Proc. Natl. Acad. Sci. USA, 82, 488 (1985), etc.
(Transformant)
Next, the method for preparing biological cells (transformant) transformed so as to express the enzyme having prenyltransferase activity will be described briefly. Here, mainly, a method for preparing a transformant that has been transformed so as to express the variant enzyme will be described briefly. Such a transformant can be prepared by a method conventionally known in the art as long as the design philosophy is determined.
For the mutagenesis, first, primers are designed so that they allow mutagenesis at a site of interest. Examples of the base sequences of the primers include base sequences described in Examples (see SEQ ID NOs: 23 to 42 in the Sequence Listing). Next, for example, mutagenized linear DNA is amplified by the PCR method or the like using DNA containing the base sequence represented by SEQ ID NO: 1 (base sequence of Micrococcus luteus B-P 26-derived undecaprenyl diphosphate synthase) as template DNA with the primers described above. Then, the obtained linear DNA is inserted downstream of a promoter in an appropriate expression vector using appropriate restriction enzymes or the like to prepare recombinant DNA. Then, the recombinant DNA is introduced into host cells compatible with the expression vector, whereby a transformant can be obtained.
Alternatively, for example, DNA containing the base sequence represented by SEQ ID NO: 1 (base sequence of Micrococcus luteus B-P 26-derived undecaprenyl diphosphate synthase) is inserted downstream of a promoter in an appropriate expression vector using appropriate restriction enzymes or the like. Mutagenized DNA, which is obtained by the PCR method or the like using the expression vector as template DNA with the primers described above, is rendered cyclic by polymerase to prepare recombinant DNA. Then, the recombinant DNA is introduced into host cells compatible with the expression vector, whereby a transformant can be obtained.
When such mutagenesis is unnecessary, for example, DNA containing the base sequence represented by SEQ ID NO: 1 (base sequence of Micrococcus luteus B-P 26-derived undecaprenyl diphosphate synthase) is inserted downstream of a promoter in an appropriate expression vector using appropriate restriction enzymes or the like to prepare recombinant DNA. Then, the recombinant DNA is introduced into host cells compatible with the expression vector, whereby a transformant can be obtained.
Although the description above is about the case using the DNA containing the known base sequence represented by SEQ ID NO: 1 (base sequence of Micrococcus luteus B-P 26-derived undecaprenyl diphosphate synthase), DNA encoding any of other prenyltransferase activity-having enzymes derived from the organism or prenyltransferase activity-having enzymes derived from organisms other than the organism may be used. In this case, screening can be performed by a known approach using, for example, a portion of the base sequence represented by SEQ ID NO: 1 as a probe to identify DNA encoding the enzyme having prenyltransferase activity, followed by isolation. The method for isolating the DNA molecule of interest using the DNA molecule as a probe is described in, for example, Molecular Cloning, 2nd edition, Cold Spring Harbor Press (1989).
Alternatively, the following method may be used: the organism-derived enzyme having prenyltransferase activity is purified by the purification operation as described above, and the amino acid sequence of the purified enzyme is determined to identify DNA encoding the enzyme, followed by isolation.
Any of microorganisms, yeasts, animal cells, insect cells, plant cells, and the like can be used as host cells as long as they are capable of expressing the gene of interest.
Examples of usable expression vectors include those which are capable of autonomously replicating in the host cells or being incorporated into the chromosome and contain a promoter at a position that allows transcription of the recombinant DNA.
When a prokaryotic organism such as bacteria is used as host cells, it is preferable that the recombinant DNA should be recombinant DNA that is capable of autonomously replicating in the prokaryotic organism and is also composed of a promoter, a ribosomal binding sequence, DNA encoding the enzyme having prenyltransferase activity, and a transcription termination sequence. The recombinant DNA may further contain a gene controlling the promoter.
Examples of the expression vector include pCold I (manufactured by Takara Bio Inc.), pCDF-1b and pRSF-1b (all manufactured by Novagen), pMAL-c2x (manufactured by New England Biolabs Inc.), pGEX-4T-1 (manufactured by GE Healthcare Biosciences Inc.), pTrcHis (manufactured by Invitrogen Corp.), pSE280 (manufactured by Invitrogen Corp.), pGEMEX-1 (manufactured by Promega Corp.), pQE-30 (manufactured by Qiagen), pET-3 to pET-52 (manufactured by Novagen), pKYP10 (JP 58-110600 A), pKYP200 [Agric. Biol. Chem., 48, 669 (1984)], pLSA1 [Agric. Biol. Chem., 53, 277 (1989)], pGEL1 [Proc. Natl. Acad. Sci., USA, 82, 4306 (1985)], pBluescript II SK(+) and pBluescript II KS(−) (manufactured by Stratagene Corp.), pTrS30 [prepared from Escherichia coli JM109/pTrS30 (FERM BP-5407)], pTrS32 [prepared from Escherichia coli JM109/pTrS32 (FERM BP-5408)], pPAC31 (WO98/12343), pUC19 [Gene, 33, 103 (1985)], pSTV28 (manufactured by Takara Bio Inc.), pUC118 (manufactured by Takara Bio Inc.), and pPA1 (JP 63-233798 A).
Any promoter that functions in host cells such as Escherichia coli can be used. Examples thereof include: promoters derived from E. coli, phages, etc., such as trp promoter (Ptrp), T7 promoter, lac promoter (Plac), PL promoter, PR promoter, and PSE promoter; and SPO1 promoter, SPO2 promoter, and penP promoter. Also, for example, artificially designed or modified promoters such as a promoter having two Ptrp sequences arranged in series, tac promoter, lacT7 promoter, and let I promoter, may be used.
Furthermore, xylA promoter for expression in microorganisms belonging to the genus Bacillus [Appl. Microbiol. Biotechnol., 35, 594-599 (1991)], P54-6 promoter for expression in microorganisms belonging to the genus Corynebacterium [Appl. Microbiol. Biotechnol., 53, 674-679 (2000)], and the like may be used.
It is preferable to use a plasmid having an appropriately adjusted distance (e.g., 6 to 18 bases) between a Shine-Dalgarno sequence (ribosomal binding sequence) and an initiation codon.
Examples of the prokaryotic organism include microorganisms belonging to the genera Escherichia, Serratia, Bacillus, Brevibacterium, Corynebacterium, Microbacterium, Pseudomonas, Agrobacterium, Alicyclobacillus, Anabaena, Anacystis, Arthrobacter, Azotobacter, Chromatium, Erwinia, Methylobacterium, Phormidium, Rhodobacter, Rhodopseudomonas, Rhodospirillum, Scenedesmus, Streptomyces, Synechoccus, and Zymomonas, for example, Escherichia coli XL1-Blue, Escherichia coli XL2-Blue, Escherichia coli DH1, Escherichia coli DH5α, Escherichia coli MC1000, Escherichia coli KY3276, Escherichia coli W1485, Escherichia coli JM109, Escherichia coli HB101, Escherichia coli No. 49, Escherichia coli W3110, Escherichia coli NY49, Escherichia coli MP347, Escherichia coli NM522, Escherichia coli BL21, Bacillus subtilis ATCC33712, Bacillus megaterium, Brevibacterium ammoniagenes, Brevibacterium immariophilum ATCC14068, Brevibacterium saccharolyticum ATCC14066, Brevibacterium flavum ATCC14067, Brevibacterium lactofermentum ATCC13869, Corynebacterium glutamicum ATCC13032, Corynebacterium glutamicum ATCC14297, Corynebacterium acetoacidophilum ATCC13870, Microbacterium ammoniaphilum ATCC15354, Serratia ficaria, Serratia fonticola, Serratia liquefaciens, Serratia marcescens, Pseudomonas sp. D-0110, Agrobacterium radiobacter, Agrobacterium rhizogenes, Agrobacterium rubi, Anabaena cylindrica, Anabaena doliolum, Anabaena flos-aquae, Arthrobacter aurescens, Arthrobacter citreus, Arthrobacter globiformis, Arthrobacter hydrocarboglutamicus, Arthrobacter mysorens, Arthrobacter nicotianae, Arthrobacter paraffineus, Arthrobacter protophormiae, Arthrobacter roseoparaffinus, Arthrobacter sulfureus, Arthrobacter ureafaciens, Chromatium buderi, Chromatium tepidum, Chromatium vinosum, Chromatium warmingii, Chromatium fluviatile, Erwinia uredovora, Erwinia carotovora, Erwinia ananas, Erwinia herbicola, Erwinia punctata, Erwinia terreus, Methylobacterium rhodesianum, Methylobacterium extorquens, Phormidium sp. ATCC29409, Rhodobacter capsulatus, Rhodobacter sphaeroides, Rhodopseudomonas blastica, Rhodopseudomonas marina, Rhodopseudomonas palustris, Rhodospirillum rubrum, Rhodospirillum salexigens, Rhodospirillum salinarum, Streptomyces ambofaciens, Streptomyces aureofaciens, Streptomyces aureus, Streptomyces fungicidicus, Streptomyces griseochromogenes, Streptomyces griseus, Streptomyces lividans, Streptomyces olivogriseus, Streptomyces rameus, Streptomyces tanashiensis, Streptomyces vinaceus, and Zymomonas mobilis.
The recombinant DNA can be introduced by any method for introducing DNA into such host cells. Examples thereof include a method using calcium ions [Proc. Natl. Acad. Sci., USA, 69, 2110 (1972)], a protoplast method (JP 63-248394 A), an electroporation method [Nucleic Acids Res., 16, 6127 (1988)], and a heat shock method.
When a yeast strain is used as host cells, YEp13 (ATCC37115), YEp24 (ATCC37051), YCp50 (ATCC37419), pHS19, or pHS15, for example, can be used as an expression vector.
In this case, any promoter that functions in the yeast strain can be used. Examples thereof include promoters such as PHO5 promoter, PGK promoter, GAP promoter, ADH promoter, gal 1 promoter, gal 10 promoter, heat-shock polypeptide promoter, MFα1 promoter, and CUP 1 promoter.
Examples of the host cells include yeast strains belonging to the genera Saccharomyces, Schizosaccharomyces, Kluyveromyces, Trichosporon, Schwanniomyces, Pichia, Candida and the like and specifically include Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces lactis, Trichosporon pullulans, Schwanniomyces alluvius, Pichia pastoris, and Candida utilis.
The recombinant DNA can be introduced by any method for introducing DNA into yeast. Examples thereof include an electroporation method [Methods Enzymol., 194, 182 (1990)], a spheroplast method [Proc. Natl. Acad. Sci., USA, 81, 4889 (1984)], and a lithium acetate method [J. Bacteriol., 153, 163 (1983)].
When animal cells are used as a host, pcDNAI, pcDM8 (commercially available from Funakoshi Corp.), pAGE107 (JP 3-22979 A), pAS3-3 (JP 2-227075 A), pCDM8 [Nature, 329, 840 (1987)], pcDNAI/Amp (manufactured by Invitrogen Corp.), pREP4 (manufactured by Invitrogen Corp.), pAGE103 [J. Biochem, 101, 1307 (1987)], pAGE210, pAMo, or pAMoA, for example, can be used as an expression vector.
In this case, any promoter that functions in the animal cells can be used. Examples thereof include cytomegalovirus (CMV) IE (immediate early) gene promoter, SV40 early promoter, metallothionein promoter, retrovirus promoter, heat-shock promoter, and SRα promoter. These promoters may be used in combination with human CMV IE gene enhancer.
Examples of the host cells include mouse myeloma cells, rat myeloma cells, mouse hybridoma cells, human Namalwa cells or Namalwa KJM-1 cells, human embryonic kidney cells, human leukemia cells, African green monkey kidney cells, Chinese hamster ovary (CHO) cells, and HBT5637 (JP 63-299 A).
Specific examples thereof include: mouse myeloma cells such as SP2/0 and NSO; rat myeloma cells such as YB2/0; human embryonic kidney cells such as HEK293 (ATCC CRL-1573); human leukemia cells such as BALL-1; and African green monkey kidney cells such as COS-1 and COS-7.
The recombinant DNA can be introduced by any method for introducing DNA into animal cells. Examples thereof include an electroporation method [Cytotechnology, 3, 133 (1990)], a calcium phosphate method (JP 2-227075 A), a lipofection method [Proc. Natl. Acad. Sci., USA, 84, 7413 (1987)], and a method described in Virology, 52, 456 (1973).
When insect cells are used as a host, the protein can be produced by a method described in, for example, Baculovirus Expression Vectors, A Laboratory Manual, W. H. Freeman and Company, New York (1992), Current Protocols in Molecular Biology, or Molecular Biology, A Laboratory Manual, Bio/Technology, 6, 47 (1988).
Specifically, insect cells are cotransfected with a vector for transferring the recombinant gene and baculovirus, so that recombinant virus is obtained in the culture supernatant of the insect cells. Then, insect cells are further infected with the recombinant virus, whereby the protein can be produced.
Examples of the gene transfer vector used in this method include pVL1392, pVL1393, and pBlueBac III (all manufactured by Invitrogen Corp.).
Examples of the baculovirus include Autographa californica nuclear polyhedrosis virus, which infects insects of the family Noctuidae.
Examples of the insect cells include Spodoptera frugiperda ovary cells, Trichoplusia ni ovary cells, and silkworm ovary-derived cultured cells.
Specific examples thereof include: Spodoptera frugiperda ovary cells such as Sf9 and Sf21 (Baculovirus Expression Vectors: A Laboratory Manual); Trichoplusia ni ovary cells such as High 5 and BTI-TN-5B1-4 (manufactured by Invitrogen Corp.); and silkworm ovary-derived cultured cells such as Bombyx mori N4.
Examples of the method for cotransfecting insect cells with the vector for transferring the recombinant gene and the baculovirus to prepare the recombinant virus include a calcium phosphate method (JP 2-227075 A) and a lipofection method [Proc. Natl. Acad. Sci., USA, 84, 7413 (1987)].
When plant cells are used as host cells, a Ti plasmid or tobacco mosaic virus vector, for example, can be used as an expression vector.
In this case, any promoter that functions in the plant cells can be used. Examples thereof include cauliflower mosaic virus (CaMV) 35S promoter and rice actin-1 promoter.
Examples of the host cells include cells of plants such as tobacco, potato, tomato, carrot, soybean, oilseed rape, alfalfa, rice, wheat, and barley.
The recombinant vector can be introduced by any method for introducing DNA into plant cells. Examples thereof include a method using Agrobacterium (JP 59-140885 A, JP 60-70080 A, and WO94/00977), an electroporation method (JP 60-251887 A), and a method using a particle gun (gene gun) (Japanese Patent Nos. 2606856 and 2517813).
The host may be any of microorganisms, yeasts, animal cells, insect cells, plant cells, and the like and may be preferably any of microorganisms, more preferably microorganisms belonging to the genus Escherichia, and even more preferably microorganisms belonging to Escherichia coli.
When expressed by yeasts, animal cells, insect cells, and plant cells, sugar- or sugar chain-added proteins can be obtained.
The obtained transformant is cultured in a medium and the enzyme having prenyltransferase activity is then generated and accumulated in the culture, whereby the enzyme having prenyltransferase activity can be produced. If necessary, the enzyme may be purified by the purification operation described above.
The transformant can be cultured in a medium according to a usual method used for culturing host cells. For example, the culture can be performed in the composition of the medium and the culture conditions described above.
(Polyisoprene)
Next, the polyisoprene of the present invention will be described. The polyisoprene of the present invention contains a trans structural moiety and a cis structural moiety as represented by the formula (4) shown below, wherein at least one atom or group contained in the trans structural moiety is replaced by another atom or group. In this context, the trans structural moiety means a moiety of repeated isoprene units with a trans structure (moiety C in the formula (4) shown below). Also, the cis structural moiety means a moiety of repeated isoprene units with a cis structure (moiety ( )q (moiety D) in the formula (4) shown below).
wherein n represents an integer of 1 to 10; q represents an integer of 30 to 40000; and Y represents a hydroxy group, a formyl group, a carboxy group, an ester group, a carbonyl group, or a group represented by the following formula (2).
The polyisoprene of the present invention is structurally similar to natural rubber and is highly compatible with rubber molecules. Moreover, the polyisoprene of the present invention has been modified substantially only at a terminal site of the molecule. Specifically, the polyisoprene of the present invention contains a hydroxy group, a formyl group, a carboxy group, an ester group, a carbonyl group, or a group represented by the formula (2), positioned at the end of the cis structural moiety, and at least one atom or group contained in the trans structural moiety is replaced by another atom or group. Thus, the polyisoprene of the present invention strongly interacts with filler such as silica while the original properties of polyisoprene are not impaired. Since the polyisoprene of the present invention is highly compatible with rubber and strongly interacts with filler such as silica as described above, a rubber composition containing this polyisoprene is obtained as a rubber composition in which rubber molecules are combined with filler in a level higher than ever. The resulting rubber composition can have, for example, improved low-heat-build-up properties, wet grip performance, and abrasion resistance.
The polyisoprene of the present invention contains a polar group or the like only at the terminal site of the cis structural moiety and a site close to the end of the trans structural moiety. The polyisoprene therefore offers high dispersibility of filler such as silica and has a large effect of improving, for example, low-heat-build-up properties, wet grip performance, and abrasion resistance while the original properties of polyisoprene are not impaired, compared with polyisoprenes containing a polar group or the like in the main chain moiety or only at the terminal site of the cis structural moiety.
In the formula (4), n is as defined for n in the formula (1).
In the formula (4), q represents an integer of 30 to 40000 (preferably 15000 to 30000, more preferably 15000 to 20000).
In the formula (4), Y is as defined for Y in the formula (1). Here, Y is preferably a hydroxy group or a carboxy group, because the resulting polyisoprene strongly interacts with filler such as silica.
Examples of the atom or group (atom or group before replacement) contained in the trans structural moiety include the same as those exemplified as the atom or group (atom or group before replacement) contained in the trans structural moiety in the formula (1).
Examples of the another atom or group include the same as those exemplified as the another atom or the another group described about the formula (1).
As described above, at least one atom or group contained in the trans structural moiety is replaced by another atom or group. For the replacement, it is preferable, as described for the isoprene oligomer, that at least one atom or group contained in moiety VI in the following formula (4-1) should be replaced while no atom or group contained in moiety VII in the formula (4-1) should be replaced:
wherein n, q, and Y are as defined for n, q, and Y in the formula (4).
Specific examples of the trans structural moiety in the formula (4) include structures represented by the formulas (a) to (s) mentioned above. Among them, structures represented by the formulas (c), (d), (e), (f), (k), (l), and (r) are preferred because the resulting polyisoprene more strongly interacts with filler such as silica and has a large effect of improving low-heat-build-up properties, wet grip performance, and abrasion resistance.
(Process for Producing Polyisoprene)
Examples of the process for producing the polyisoprene of the present invention include a process including performing biosynthesis from the isoprene oligomer of the present invention and isopentenyl diphosphate.
The polyisoprene of the present invention is obtained by biosynthesis except for the organic synthesis of the allylic diphosphate derivative as an initiating substrate, and can thus take into account the exhaustion of petroleum resources or environmental issues.
It has heretofore been known that natural rubber latex contains an enzyme, a rubber elongation factor, and the like having activity of catalyzing the condensation reaction between an isoprene oligomer and isopentenyl diphosphate and catalyzing a reaction as shown below through which isopentenyl diphosphate is sequentially linked in a Z form (newly added isoprene unit has a cis structure) starting from the isoprene oligomer to produce a polyisoprene.
In the present invention, the polyisoprene can be produced using this enzyme, rubber elongation factor, or the like.
Specifically, examples of the method for biosynthesizing the polyisoprene of the present invention from the isoprene oligomer of the present invention and isopentenyl diphosphate include a method using the enzyme, the rubber elongation factor, or the like contained in natural rubber latex. Alternatively, the enzyme, the rubber elongation factor, or the like cloned from natural rubber latex may be used.
Specifically, the isoprene oligomer of the present invention and isopentenyl diphosphate can be allowed to react with each other in the presence of the enzyme and/or the rubber elongation factor. More specifically, for example, natural rubber latex or the enzyme, the rubber elongation factor, or the like separated from the natural rubber latex can be added into a solution containing the isoprene oligomer of the present invention and isopentenyl diphosphate to perform the reaction. The reaction temperature can be set to, for example, 20 to 40° C.; the reaction time can be set to, for example, 1 to 72 hours; and the pH can be set to, for example, 6 to 8. If necessary, magnesium chloride, a surfactant, 2-mercaptoethanol, and the like may further be added thereto.
The polyisoprene of the present invention obtained by the reaction is usually represented by the formula (4) wherein Y is a group represented by the formula (2) or a hydroxy group. This hydroxy group is formed through the hydrolysis of the group represented by the formula (2).
Further, the polyisoprene represented by the formula (4) wherein Y is a formyl group can be obtained, for example, by the oxidation of the polyisoprene of the formula (4) wherein Y is a group represented by the formula (2).
Further, the polyisoprene represented by the formula (4) wherein Y is a carboxy group can be obtained, for example, by the oxidation of the polyisoprene of the formula (4) wherein Y is a group represented by the formula (2).
Further, the polyisoprene represented by the formula (4) wherein Y is an ester group can be obtained, for example, by the oxidation and esterification of the polyisoprene of the formula (4) wherein Y is a group represented by the formula (2).
Further, the polyisoprene represented by the formula (4) wherein Y is a carbonyl group can be obtained, for example, by the oxidation and esterification of the polyisoprene of the formula (4) wherein Y is a group represented by the formula (2).
The natural rubber latex is not particularly limited in its origin. Examples thereof include Hevea brasiliensis, Ficus elastica, Ficus lyrata, Ficus benjamina, Ficus religiosa, Ficus benghalensis, and Lactarius chrysorrheus. Among them, Hevea brasiliensis is preferred because it produces rubber having a large molecular weight and its latex contains a large quantity of rubber.
The trunk of, for example, Hevea brasiliensis is cut in grooves (tapped) using a knife or the like, and natural rubber latex flowing out from the cleaved latex vessels is collected, whereby natural rubber latex can be obtained.
Examples of the enzyme and the rubber elongation factor separated from the natural rubber latex include a serum, a bottom fraction, and a rubber fraction separated by centrifugation of natural rubber latex. The serum, the bottom fraction, and the rubber fraction contain the enzyme, the rubber elongation factor, or the like.
(Rubber Composition)
The rubber composition of the present invention includes the isoprene oligomer of the present invention and/or the polyisoprene of the present invention. Accordingly, the rubber composition of the present invention is excellent in low-heat-build-up properties, wet grip performance, and abrasion resistance. In this context, the polyisoprene of the present invention can be used as a rubber component.
The content of the polyisoprene of the present invention is preferably 20% by mass or higher, more preferably 40% by mass or higher, and even more preferably 60% by mass or higher, with respect to 100% by mass of rubber components, and may be 100% by mass.
Examples of rubber components that can be used in addition to the polyisoprene of the present invention include diene rubbers such as isoprene rubber (IR), natural rubber (NR), butadiene rubber (BR), styrene-butadiene rubber (SBR), styrene-isoprene-butadiene rubber (SIBR), chloroprene rubber (CR), and acrylonitrile-butadiene rubber (NBR). These rubber components may be used alone or in combination of two or more thereof. Among them, NR and BR are preferred.
For allowing a rubber composition to contain the isoprene oligomer of the present invention, it is preferable to use NR as a rubber component because it is highly compatible with isoprene oligomers. The combined use of the isoprene oligomer of the present invention and NR is more favorable for the effects of the addition of the isoprene oligomer of the present invention.
When the rubber composition contains the isoprene oligomer of the present invention, the content of NR is preferably 20% by mass or higher, more preferably 40% by mass or higher, and even more preferably 60% by mass or higher, with respect to 100% by mass of rubber components, and may be 100% by mass.
The content of the isoprene oligomer of the present invention is preferably 1 part by mass or higher, and more preferably 2 parts by mass or higher, with respect to 100 parts by mass of rubber components. If the content is less than 1 part by mass, the effects of the addition of the isoprene oligomer of the present invention might be achieved insufficiently. Also, the content of the isoprene oligomer is preferably 20 parts by mass or lower, and more preferably 15 parts by mass or lower. If the content exceeds 20 parts by mass, the strength and, by extension, abrasion resistance of the resulting rubber composition may be reduced.
Examples of filler that can be used in the present invention include silica, carbon black, clay, and calcium carbonate.
In the present invention, it is preferable to use silica as filler. The rubber composition further containing silica ensures sufficient achievement of the effects of the addition of the isoprene oligomer of the present invention and/or the polyisoprene of the present invention. Examples of the silica include, but not particularly limited to, dry silica (silicic anhydride) and wet silica (hydrous silicic acid). Wet silica is preferred because of being rich in silanol groups.
For the present invention, it is also preferable to use carbon black as filler. In this case as well, the effects of the addition of the isoprene oligomer of the present invention and/or the polyisoprene of the present invention can be achieved sufficiently.
The rubber composition of the present invention may appropriately contain, in addition to the components described above, compounding ingredients generally used in the production of rubber compositions, for example, a silane coupling agent, zinc oxide, stearic acid, various antioxidants, a softener (e.g., oil), wax, a vulcanizing agent (e.g., sulfur), and a vulcanization accelerator.
The rubber composition of the present invention can be produced using a process known in the art and can be produced, for example, by a process involving kneading the components using a rubber kneading apparatus such as an open roll mill or a Banbury mixer, followed by vulcanization.
The rubber composition of the present invention can be used suitably in various tire components (e.g., treads, sidewalls, undertread, plies, breakers, and carcass) and the like.
(Pneumatic Tire)
The pneumatic tire of the present invention can be produced by a usual process using the rubber composition. Specifically, the unvulcanized rubber composition is extruded and processed into a shape appropriate for a tire component (e.g., treads and sidewalls), arranged by a usual method in a tire building machine, and assembled with other tire components to form an unvulcanized tire. This unvulcanized tire is heated and pressurized in a vulcanizer, whereby a tire can be produced.
The present invention will be described more specifically with reference to Examples. However, the present invention is not intended to be limited to these Examples.
Synthesis was carried out with farnesol as a starting material. The hydroxy group of farnesol was protected using imidazole and tert-butylphenylchlorosilane (TBDPS) in anhydrous dichloromethane to obtain a TBDPS-protected form (compound represented by (ai) below) (yield: 92%). The olefin at position 10 was oxidized using m-chloroperbenzoic acid in anhydrous dichloromethane to obtain an epoxy form (compound represented by (aii) below) (yield: 9%). Next, the epoxy was oxidized with orthoperiodic acid in anhydrous tetrahydrofuran to obtain an aldehyde form (compound represented by (aiii) below) (yield: 28%). Next, a Grignard reagent was prepared from magnesium and butane bromide in anhydrous methanol, and the aldehyde form was added to the Grignard reagent to obtain a secondary alcohol form (compound represented by (aiv) below) (yield: 68%). The secondary hydroxy group was protected by acetylation with acetic anhydride in the presence of dimethylaminopyridine in an anhydrous dichloromethane solvent to obtain an ester form (compound represented by (av) below) (yield: 81%). The TBDPS protective group was deprotected using tetra-n-butylammonium hydrate in anhydrous tetrahydrofuran to obtain a primary alcohol form (compound represented by (avi) below) (yield: 82%). Next, the primary hydroxy group was replaced by chlorine using N-chlorosuccinimide and dimethyl sulfide in an anhydrous dichloromethane solvent at −40° C. or lower to obtain a chloride (compound represented by (avii) below) (yield: 82%). Next, the chloride was diphosphorylated using tris-tetra-n-butylammonium hydrogen pyrophosphate in anhydrous acetonitrile to obtain a compound represented by (aviii) below (compound represented by the formula (S)) as the substance of interest (yield: 42%).
The intermediate in each synthesis step and the final product were confirmed by TLC and instrumental analysis (IR, NMR).
Synthesis was carried out with geraniol as a starting material. Geraniol was acetylated using pyridine and acetic anhydride in anhydrous dichloromethane to obtain an acetate (compound represented by (bi) below) (yield: 95%). Next, the carbon atom at position 8 was subjected to selenium oxidation in ethanol to obtain an aldehyde form (compound represented by (bii) below) (yield: 24%). Next, the aldehyde was alkaline-hydrolyzed using potassium hydroxide to obtain an alcohol form (compound represented by (biii) below) (yield: 38%). Next, the alcohol was treated with imidazole and tert-butyldiphenylsilyl chloride (TBDPS) in anhydrous dichloromethane to obtain a compound represented by (biv) below (yield: 80%). Then, the compound was reacted with butyllithium in anhydrous ether to obtain a butyl alcohol form (compound represented by (bv) below) (yield: 73%). Next, the alcohol was converted to a sodium salt with sodium hydroxide in anhydrous tetrahydrofuran, and methyl iodide was then added thereto, followed by Williamson synthesis to obtain an ether form (compound represented by (bvi) below) (yield: 95%). Next, deprotection was carried out using tetra-n-butylammonium fluoride in anhydrous tetrahydrofuran to obtain an alcohol form (compound represented by (bvii) below) (yield: 87%). Next, the primary hydroxy group was replaced by chlorine using N-chlorosuccinimide and dimethyl sulfide in an anhydrous dichloromethane solvent at −40° C. or lower to obtain a chloride (compound represented by (bviii) below) (yield: 92%). Next, the chloride was diphosphorylated using tris-tetra-n-butylammonium hydrogen pyrophosphate in anhydrous acetonitrile to obtain a compound represented by (bix) below (compound represented by the formula (B)) as the substance of interest (yield: 26%).
The intermediate in each synthesis step and the final product were confirmed by TLC and instrumental analysis (IR, NMR).
Synthesis was carried out with geraniol as a starting material. Geraniol was acetylated using pyridine and acetic anhydride in anhydrous dichloromethane to obtain an acetate (compound represented by (ci) below) (yield: 97%). Next, the carbon atom at position 8 was subjected to selenium oxidation in ethanol to obtain an aldehyde form (compound represented by (cii) below) (yield: 20%). Next, the aldehyde was alkaline-hydrolyzed using potassium hydroxide to obtain an alcohol form (compound represented by (ciii) below) (yield: 42%). Next, the alcohol was treated with imidazole and tert-butyldiphenylsilyl chloride (TBDPS) in anhydrous dichloromethane to obtain a compound represented by (civ) below (yield: 80%). Then, the compound was reacted with butyllithium in anhydrous ether to obtain a butyl alcohol form (yield: 62%). Next, deprotection was carried out using tetra-n-butylammonium fluoride in anhydrous tetrahydrofuran to obtain a diol form (compound represented by (cvi) below) (yield: 94%). Next, the primary hydroxy group was replaced by chlorine using N-chlorosuccinimide and dimethyl sulfide in an anhydrous dichloromethane solvent at −40° C. or lower to obtain a chloride (compound represented by (cvii) below) (yield: 90%). Next, the chloride was diphosphorylated using tris-tetra-n-butylammonium hydrogen pyrophosphate in anhydrous acetonitrile to obtain a compound represented by (cviii) below (compound represented by the formula (C)) as the substance of interest (yield: 46%).
The intermediate in each synthesis step and the final product were confirmed by TLC and instrumental analysis (IR, NMR).
Synthesis was carried out with farnesol as a starting material. A protective group was bonded to the hydroxy group of farnesol using imidazole, anhydrous dimethylformamide, anhydrous dichloromethane, and tert-butyldiphenylsilyl chloride (TBDPS) to obtain a TBDPS-protected form (compound represented by (di) below) (yield: 99%). Next, this compound was reacted with m-chloroperbenzoic acid in an anhydrous dichloromethane solvent to obtain an epoxy form (compound represented by (dii) (below) (yield: 29%). Next, the epoxy was subjected to periodic acid oxidation using orthoperiodic acid in a mixed solvent of ether and tetrahydrofuran to obtain an aldehyde form (compound represented by (diii) below) (yield: 73%). A Grignard reagent was prepared from ethyl iodide and magnesium in an anhydrous ether solvent and then reacted with the aldehyde to form an alcohol form (compound represented by (div) below) (yield: 80%). The secondary hydroxy group of the racemic alcohol form and (S)-MaNP acid were subjected to reaction in the presence of N,N-dicyclohexylcarbodiimide, 4-dimethylaminopyridine, and (+)-10-camphorsulfonic acid in an anhydrous dichloromethane solvent to obtain diastereomers. Then, the diastereomers were optically resolved by HPLC, and the absolute configuration was determined by NMR to optically obtain a compound represented by (dv) below (yield: 80%). The TBDPS protective group was then deprotected using tetra-n-butylammonium hydrate in anhydrous tetrahydrofuran to obtain a diol form (compound represented by (dvi) below) (yield: 80%). Next, the primary hydroxy group was replaced by chlorine using N-chlorosuccinimide and dimethyl sulfide in an anhydrous dichloromethane solvent at −40° C. or lower to obtain a chloride (compound represented by (dvii) below) (yield: 80%). Next, the chloride was diphosphorylated using tris-tetra-n-butylammonium hydrogen pyrophosphate in anhydrous acetonitrile to obtain a compound represented by (dviii) below (compound represented by the formula (D)) as the substance of interest (yield: 46%).
The intermediate in each synthesis step and the final product were confirmed by TLC and instrumental analysis (IR, NMR).
Synthesis was carried out with farnesol as a starting material. A protective group was bonded to the hydroxy group of farnesol using imidazole, anhydrous dimethylformamide, anhydrous dichloromethane, and tert-butyldiphenylsilyl chloride (TBDPS) to obtain a TBDPS-protected form (compound represented by (ei) below) (yield: 99%). Next, this compound was reacted with m-chloroperbenzoic acid in an anhydrous dichloromethane solvent to obtain an epoxy form (compound represented by (eii) below) (yield: 29%). Next, the epoxy was subjected to periodic acid oxidation using orthoperiodic acid in a mixed solvent of ether and tetrahydrofuran to obtain an aldehyde form (compound represented by (eiii) below) (yield: 73%). A Grignard reagent was prepared from ethyl iodide and magnesium in an anhydrous ether solvent and then reacted with the aldehyde to form an alcohol form (compound represented by (eiv) below) (yield: 80%). The secondary hydroxy group of the racemic alcohol form and (S)-MaNP acid were subjected to reaction in the presence of N,N-dicyclohexylcarbodiimide, 4-dimethylaminopyridine, and (+)-10-camphorsulfonic acid in an anhydrous dichloromethane solvent to obtain diastereomers. Then, the diastereomers were optically resolved by HPLC, and the absolute configuration was determined by NMR to optically obtain a compound represented by (ev) below (yield: 84%). The TBDPS protective group was then deprotected using tetra-n-butylammonium hydrate in anhydrous tetrahydrofuran to obtain a diol form (compound represented by (evi) below) (yield: 91%). Next, the primary hydroxy group was replaced by chlorine using N-chlorosuccinimide and dimethyl sulfide in an anhydrous dichloromethane solvent at −40° C. or lower to obtain a chloride (compound represented by (evii) below) (yield: 70%). Next, the chloride was diphosphorylated using tris-tetra-n-butylammonium hydrogen pyrophosphate in anhydrous acetonitrile to obtain a compound represented by (eviii) below (compound represented by the formula (E)) as the substance of interest (yield: 59%).
The intermediate in each synthesis step and the final product were confirmed by TLC and instrumental analysis (IR, NMR).
Synthesis was carried out with farnesol as a starting material. A protective group was bonded to the hydroxy group of farnesol using imidazole, anhydrous dimethylformamide, anhydrous dichloromethane, and tert-butyldiphenylsilyl chloride (TBDPS) to obtain a TBDPS-protected form (fi) (yield: 99%). Next, this compound was reacted with m-chloroperbenzoic acid in an anhydrous dichloromethane solvent to obtain an epoxy form (fii) (yield: 29%). The epoxy was subjected to periodic acid oxidation using orthoperiodic acid in a mixed solvent of ether and tetrahydrofuran to obtain an aldehyde form (fiii) (yield: 73%). A Grignard reagent was prepared from ethyl iodide and magnesium in an anhydrous ether solvent and then reacted with the aldehyde to form an alcohol form (fiv) (yield: 80%). The TBDPS group in the compound (fiv) was removed using tetrabutylammonium fluoride in an anhydrous tetrahydrofuran solvent to form a diol form (fv) (yield: 93%).
The hydroxy group present at an allylic position in the diol form (fv) was chlorinated using N-chlorosuccinimide and dimethyl sulfide in an anhydrous dichloromethane solvent at −40° C. or lower to form a chloride (fvi) (yield: 69%). The chloride (fvi) was diphosphorylated using tris(tetra-N-butyl)ammonium hydrogen pyrophosphate in an anhydrous acetonitrile solvent and applied to an ion-exchange column to synthesize a compound (fvii) (compound represented by the formula (R)) as the substance of interest (yield: 28%).
The intermediate in each synthesis step and the final product were confirmed by TLC and instrumental analysis (IR, NMR).
Synthesis was carried out with geraniol as a starting material. Geraniol was acetylated using pyridine and acetic anhydride in anhydrous dichloromethane to obtain an acetate (compound represented by (gi) below) (yield: 97%). Next, the carbon atom at position 8 was subjected to selenium oxidation in ethanol to obtain an alcohol form (compound represented by (gii) below) (yield: 20%). The alcohol was reacted with tert-butyldimethylsilyl chloride in the presence of a basic catalyst using imidazole to obtain a compound represented by (giii) below (yield: 87%). Next, the compound was hydrolyzed with potassium hydroxide to obtain an alcohol form (compound represented by (giv) below) (yield: 78%). The alcohol form was chlorinated by the N-chlorosuccinimide method to obtain a chloride (compound represented by (gv) below) (yield: 40%). Next, the chloride was mixed with n-butylammonium hydrogen diphosphate in anhydrous acetonitrile to obtain a compound represented by (gvi) below (compound represented by the formula (P)) as the substance of interest (yield: 26%).
The intermediate in each synthesis step and the final product were confirmed by TLC and instrumental analysis (IR, NMR).
Synthesis was carried out with geraniol as a starting material. Geraniol was stirred together with acetic anhydride in pyridine to acetylate the hydroxy group, so that a compound represented by (hi) below was obtained (yield: 12%). Next, the compound was subjected to oxidation reaction with selenium dioxide and tert-butyl hydroperoxide to obtain a trans alcohol form (compound represented by (hii) below) (yield: 38%). The alcohol form was subjected to reaction using chloromethyl ethyl ether and diisopropylethylamine in dichloromethane to obtain a compound represented by (hiii) below in which a methoxymethyl ether group was introduced in the hydroxy group at position 8 (yield: 76%). Next, the acetyl group was converted to a hydroxy group using potassium hydroxide to obtain an alcohol form (compound represented by (hiv) below) (yield: 95%). The hydroxy group in the alcohol form was chlorinated using N-chlorosuccinimide to obtain a chloride (compound represented by (hv) below) (yield: 30%). Then, the chloride was diphosphorylated with tris(tetra-n-butyl)ammonium hydrogen diphosphate and applied to a cellulose column to obtain a compound represented by (hvi) below (compound represented by the formula (H)) as the substance of interest (yield: 77%).
The intermediate in each synthesis step and the final product were confirmed by TLC and instrumental analysis (IR, NMR).
Synthesis was carried out with geraniol as a starting material. Geraniol and dihydropyran were condensed in the presence of a pyridinium p-toluenesulfonate catalyst to obtain a compound represented by (ii) below in which the hydroxy group in geraniol was protected with a tetrahydropyran ring (yield: 85%). Next, the compound was subjected to oxidation reaction with selenium dioxide and tert-butyl hydroperoxide to obtain a trans alcohol form (compound represented by (iii) below) (yield: 47%). The alcohol form was chlorinated using N-chlorosuccinimide in dichloromethane to obtain a compound represented by (iiii) below (yield: 92%). Next, n-propanethiol was added to a solution of metallic sodium dissolved in ethanol and the resulting solution was reacted with the compound to obtain a thioether (compound represented by (iiv) below) (yield: 28%). Next, p-toluenesulfonic acid was allowed to act thereon in methanol to obtain an alcohol form (compound represented by (iv) below) (yield: 75%). The alcohol form was chlorinated by the N-chlorosuccinimide method to obtain a chloride (compound represented by (ivi) below) (yield: 40%). Next, the chloride was mixed with n-butylammonium hydrogen diphosphate in anhydrous acetonitrile to obtain a compound represented by (ivii) below (compound represented by the formula (M)) as the substance of interest (yield: 32%).
The intermediate in each synthesis step and the final product were confirmed by TLC and instrumental analysis (IR, NMR).
Synthesis was carried out with geraniol as a starting material. Geraniol and dihydropyran were condensed in the presence of a pyridinium p-toluenesulfonate catalyst to obtain a compound represented by (ji) below in which the hydroxy group in geraniol was protected with a tetrahydropyran ring (yield: 85%). Next, the compound was subjected to oxidation reaction with selenium dioxide and tert-butyl hydroperoxide to obtain a trans alcohol form (compound represented by (jii) below) (yield: 47%). Next, thereto were added benzyl bromide and sodium hydroxide in anhydrous tetrahydrofuran to obtain an ether (compound represented by (jiii) below) (yield: 87%). Next, p-toluenesulfonic acid was allowed to act thereon in methanol to obtain an alcohol form (compound represented by (jiv) below) (yield: 69%). The alcohol form was chlorinated by the N-chlorosuccinimide method to obtain a chloride (compound represented by (jv) below) (yield: 40%). Next, the chloride was mixed with n-butylammonium hydrogen diphosphate in anhydrous acetonitrile to obtain a compound represented by (jvi) below (compound represented by the formula (N)) as the substance of interest (yield: 26%).
The intermediate in each synthesis step and the final product were confirmed by TLC and instrumental analysis (IR, NMR).
Synthesis was carried out with geraniol as a starting material. Geraniol was acetylated with acetic anhydride in the presence of dimethylaminopyridine in anhydrous dichloromethane to obtain an ester form (compound represented by (ki) below) (yield: 96%). The olefin at position 6 was oxidized using m-chloroperbenzoic acid in anhydrous dichloromethane to obtain an epoxy form (compound represented by (kii) below) (yield: 92%). Next, the epoxy was oxidized with orthoperiodic acid in anhydrous tetrahydrofuran to obtain an aldehyde form (compound represented by (kiii) below) (yield: 66%). Next, the aldehyde was reductively aminated using n-butylamine and sodium cyanoborohydride in anhydrous methanol to obtain a secondary amine (compound represented by (kiv) below) (yield: 66%). The amine was acetylated with acetic anhydride in the presence of dimethylaminopyridine in an anhydrous dichloromethane solvent to obtain a secondary amide (compound represented by (kv) below) (yield: 38%). The ester site was irreversibly hydrolyzed with potassium hydroxide in anhydrous methanol to obtain a primary alcohol form (compound represented by (kvi) below) (yield: 76%). Next, the primary hydroxy group was replaced by chlorine using N-chlorosuccinimide and dimethyl sulfide in an anhydrous dichloromethane solvent at −40° C. or lower to obtain a chloride (compound represented by (kvii) below) (yield: 67%). Next, the chloride was diphosphorylated using tris-tetra-n-butylammonium hydrogen pyrophosphate in anhydrous acetonitrile to obtain the substance of interest (compound represented by (kviii) below (compound represented by the formula (K))) (yield: 50%).
The intermediate in each synthesis step and the final product were confirmed by TLC and instrumental analysis (IR, NMR).
The reagent used was QuikChange Site-Directed Mutagenesis Kit from Stratagene Corp. Primers were designed so that they allowed mutagenesis at a site of interest. Primers for mutagenesis were purchased from Medical & Biological Laboratories, Co., Ltd. (manufacturer: XX IDT). The designed primers are as follows.
Primers for preparation of variant enzyme N31A:
Sense primer 5′-gac gga gca ggc cga tgg gca aaa-3′ (SEQ ID NO: 23),
Antisense primer 5′-cat cgg cct gct ccg tcc ata atg a-3′ (SEQ ID NO: 24);
Primers for preparation of variant enzyme N77A:
Sense primer 5′-act gaa gca tgg tct cgt cct aaa g-3′ (SEQ ID NO: 25),
Antisense primer 5′-gag acc atg ctt cag ttg aaa atg c-3′ (SEQ ID NO: 26);
Primers for preparation of variant enzyme L91N:
Sense primer 5′-gat gaa aaa ccc ggg tga ttt ttt aa-3′ (SEQ ID NO: 27),
Antisense primer 5′-cac ccg ggt ttt tca tca agt aat ta-3′ (SEQ ID NO: 28);
Primers for preparation of variant enzyme L91D:
Sense primer 5′-gat gaa aga tcc ggg tga ttt ttt aa-3′ (SEQ ID NO: 29),
Antisense primer 5′-cac ccg gat ctt tca tca agt aat ta-3′ (SEQ ID NO: 30);
Primers for preparation of variant enzyme N31Q:
Sense primer 5′-gac gga caa ggc cga tgg gca aaa-3′ (SEQ ID NO: 31),
Antisense primer 5′-cca tcg gcc ttg tcc gtc cat aat-3′ (SEQ ID NO: 32);
Primers for preparation of variant enzyme N77Q:
Sense primer 5′-act gaa caa tgg tct cgt cct aaa g-3′ (SEQ ID NO: 33),
Antisense primer 5′-cga gac cat gct tca gtt gaa aat gc-3′ (SEQ ID NO: 34);
Primers for preparation of variant enzyme L91G:
Sense primer 5′-gat gaa agg acc ggg tga ttt ttt aa-3′ (SEQ ID NO: 35),
Antisense primer 5′-acc cgg tcc ttt cat caa gta att aac-3′ (SEQ ID NO: 36);
Primers for preparation of variant enzyme L91K:
Sense primer 5′-gat gaa aaa acc ggg tga ttt ttt aa-3′ (SEQ ID NO: 37),
Antisense primer 5′-acc cgg ttt ttt cat caa gta att aa-3′ (SEQ ID NO: 38);
Primers for preparation of variant enzyme F95A:
Sense primer 5′-ggg tga tgc gtt aaa cac att ttt ac-3′ (SEQ ID NO: 39),
Antisense primer 5′-gtt taa tgc atc acc cgg tag ttt ca-3′ (SEQ ID NO: 40);
Primers for preparation of variant enzyme F95W:
Sense primer 5′-ggg tga ttg gtt aaa cac att ttt ac-3′ (SEQ ID NO: 41),
Antisense primer 5′-gtt taa cca atc acc cgg tag ttt ca-3′ (SEQ ID NO: 42).
The dsDNA template used was pET22b containing the base sequence of Micrococcus luteus B-P 26-derived undecaprenyl diphosphate synthase (hereinafter, also referred to as the wild-type enzyme) (this template is referred to as pET22b/MLU-UPS). This pET22b/MLU-UPS was kindly provided by Professor Tanetoshi Koyama (Institute of Multidisciplinary Research for Advanced Materials Tohoku University). 2 μl of 10×Pfu polymerase buffer was mixed with 2-20 ng of the dsDNA template, 50 ng of the sense primer, 50 ng of the antisense primer, 0.4 μl of dNTPs (2.5 mM each), ddH2O up to 20 μl, 0.4 ml of Pfu polymerase (2.5 U/μl) and PCR reaction was then performed. The PCR reaction was performed under the following conditions: 1 cycle of 95° C. for 30 sec; 15 cycles of 95° C. for 30 sec, 55° C. for 1 min, 68° C. for 8 min. After PCR, 0.4 μl of DpnI was added to the PCR reaction solution and DpnI treatment was performed at 37° C. for 1 hour. E. coli DH5α was transformed by the heat shock method using 1-10 μl of the DpnI-treated solution, and the transformant was applied to an LB agar medium containing 50 μg/mL ampicillin and then cultured overnight at 37° C., and then the transformed strain was selected. The transformant was cultured all night in an LB medium containing 50 μg/ml ampicillin. A plasmid was prepared by the alkali-SDS method from the obtained culture solution. Mutagenesis in the plasmid was confirmed using a sequencer.
E. coli BL21 (DE3) was transformed with each plasmid pET22b/MLU-UPS (wild-type and variant). The obtained E. coli BL21(DE3)/pET22b/MLU-UPS (wild-type and variant) was inoculated into a test tube containing 3 mL of an LB medium containing 50 μg/mL ampicillin and shake-cultured at 37° C. for 5 hours. A 1 mL aliquot of the obtained culture solution was inoculated into a 500-mL Erlenmeyer flask containing 100 mL of an LB medium containing 50 μg/mL ampicillin and shake-cultured at 37° C. for 3 hours. Then, IPTG was added thereto at a concentration of 0.1 mmol/L, and the bacterial cells were shake-cultured at 30° C. for 18 hours. The culture solution was centrifuged to obtain wet bacterial cells.
The wet bacterial cells thus obtained were disrupted by sonication and then centrifuged. A protein having prenyltransferase activity was purified from the obtained supernatant using HisTrap (manufactured by Amersham Biosciences Corp.). The purification of the purified protein was confirmed by SDS-PAGE.
A reaction solution containing 10 mg of each purified protein, 50 mM Tris-HCl buffer (pH 7.5), 40 mM magnesium chloride, 40 mM Triton X-100, 25 mM 2-mercaptoethanol, 1 mM of an initiating substrate (farnesyl diphosphate or each of the initiating substrates prepared in Production Examples 1 to 11), and 1 mM isopentenyl diphosphate was prepared and reacted for 1 hour in a water bath at 37° C.
After the completion of reaction, 100 ml of saturated saline and 500 ml of 1-butanol were added thereto, and the mixture was stirred and then left at rest. Then, the supernatant (1-butanol layer) was concentrated to dryness by evaporation. A portion of the residue was structurally confirmed by NMR to obtain an isoprene oligomer.
The details (n and m in the formula (1)) of the thus obtained isoprene oligomers are as shown in Tables 1 and 2. Here, Y was a hydroxy group or a group represented by the formula (2).
In these examples, n and m in the formula (1) were calculated on the basis of information about the initiating substrate used and the length of the isoprene chain determined by TLC. Also, Y was structurally identified by NMR or IR.
TABLE 1 | ||
Initiating substrate |
Compound | Compound | Compound | Compound | Compound | Compound | ||
Farnesyl | of formula | of formula | of formula | of formula | of formula | of formula |
n | diphosphate | (S) | (B) | (C) | (D) | (E) | (R) |
Wild-type enzyme | 3 | 2 | 2 | 2 | 2 | 2 | 2 | |
Variant enzyme | N31A | 3 | 2 | 2 | 2 | 2 | 2 | 2 |
N77A | 3 | 2 | 2 | 2 | 2 | 2 | 2 | |
L91N | 3 | 2 | 2 | 2 | 2 | 2 | 2 | |
L91D | 3 | 2 | 2 | 2 | 2 | 2 | 2 | |
N31Q | 3 | 2 | 2 | 2 | 2 | 2 | 2 | |
N77Q | 3 | 2 | 2 | 2 | 2 | 2 | 2 | |
L91G | 3 | 2 | 2 | 2 | 2 | 2 | 2 | |
L91K | 3 | 2 | 2 | 2 | 2 | 2 | 2 | |
F95A | 3 | 2 | 2 | 2 | 2 | 2 | 2 | |
F95W | 3 | 2 | 2 | 2 | 2 | 2 | 2 | |
Initiating substrate |
Compound | Compound | Compound | Compound | Compound | |
of formula | of formula | of formula | of formula | of formula |
n | (P) | (H) | (M) | (N) | (K) | ||
Wild-type enzyme | 2 | 2 | 2 | 2 | 1 | |||
Variant enzyme | N31A | 2 | 2 | 2 | 2 | 1 | ||
N77A | 2 | 2 | 2 | 2 | 1 | |||
L91N | 2 | 2 | 2 | 2 | 1 | |||
L91D | 2 | 2 | 2 | 2 | 1 | |||
N31Q | 2 | 2 | 2 | 2 | 1 | |||
N77Q | 2 | 2 | 2 | 2 | 1 | |||
L91G | 2 | 2 | 2 | 2 | 1 | |||
L91K | 2 | 2 | 2 | 2 | 1 | |||
F95A | 2 | 2 | 2 | 2 | 1 | |||
F95W | 2 | 2 | 2 | 2 | 1 | |||
TABLE 2 | ||
Initiating substrate |
Compound | Compound | Compound | Compound | Compound | Compound | ||
Farnesyl | of formula | of formula | of formula | of formula | of formula | of formula |
m | diphosphate | (S) | (B) | (C) | (D) | (E) | (R) |
Wild-type enzyme | 7, 8, 9 | 3, 4, 5, 6, 7 | 5, 6, 7, 8, 9 | 4, 5, 6, 7 | 4, 5, 6, 7 | 4, 5, 6, 7 | 4, 5, 6, 7 | |
Variant enzyme | N31A | 7, 8, 9 | 4, 5, 6, 7 | 4, 5, 6, 7, 8, 9 | 4, 5, 6, 7 | 4, 5, 6, 7 | 4, 5, 6, 7 | 4, 5, 6, 7 |
N77A | 8, 9 | 1, 4, 5, 6 | 6, 7, 8, | 1, 4, 5, 6 | 5, 6 | 5, 6 | 5, 6 | |
L91N | 8, 9 | 3, 4, 5 | 6, 7, 8, | 3, 4, 5, 6 | 3, 4, 5 | 3, 4, 5 | 3, 4, 5 | |
L91D | 8, 9 | 3, 4, 5 | 5, 6, 7, 8 | 4, 5, 6 | 4, 5, 6 | 4, 5 | 4, 5, 6 | |
N31Q | 7, 8, 9 | 4, 5, 6, 7 | 4, 5, 6, 7, 8, 9 | 4, 5, 6, 7 | 4, 5, 6, 7 | 4, 5 | 4, 5, 6, 7 | |
N77Q | 8, 9 | 3, 4, 5 | 4, 5, 6, 7, 8, 9 | 4, 5, 6, 7, 8 | 4, 5, 6 | 4, 5 | 4, 5, 6, 7 | |
L91G | 7, 8, 9 | 3, 4, 5 | 6, 7, 8, | 3, 4, 5, 6 | 3, 4, 5 | 4, 5, 6, 7 | 4, 5, 6, 7 | |
L91K | 8, 9 | 3, 4, 5 | 6, 7, 8, | 3, 4, 5, 6 | 4, 5, 6, 7 | 4, 5 | 4, 5, 6, 7 | |
F95A | 8, 9, 10 | 3, 4, 5 | 5, 6, 7, 8 | 3, 4, 5, 6, 7 | 5, 6, 7, 8 | 4, 5, 6, 7, 8 | 3, 4, 5 | |
F95W | 8, 9, 10 | 3, 4, 5 | 5, 6, 7, 8 | 3, 4, 5, 6, 7 | 5, 6, 7, 8 | 4, 5, 6, 7, 8 | 3, 4, 5 | |
Initiating substrate |
Compound | Compound | Compound | Compound | Compound | |
of formula | of formula | of formula | of formula | of formula |
m | (P) | (H) | (M) | (N) | (K) | ||
Wild-type enzyme | 3, 4, 5, 6 | 7, 8, 9 | 4, 5, 6, 7 | 3, 4, 5, 6 | 3, 4, 5, 6 | |||
Variant enzyme | N31A | 3, 4, 5, 6 | 7, 8, 9 | 4, 5, 6 | 4, 5, 6, 7 | 5, 6, 7 | ||
N77A | 2, 3, 4, 5, 6 | 7, 8, 9 | 4, 5, 6 | 4, 5, 6 | 4, 5, 6 | |||
L91N | 2, 3, 4, 5, 6 | 8, 9 | 3, 4, 5, 6 | 3, 4, 5 | 3, 4, 5 | |||
L91D | 3, 4, 5, 6 | 8, 9 | 4, 5, 6 | 3, 4, 5 | 3, 4, 5 | |||
N31Q | 2, 3, 4, 5, 6 | 7, 8, 9 | 4, 5, 6, 7 | 5, 6, 7 | 5, 6, 7 | |||
N77Q | 2, 3, 4, 5, 6 | 8, 9 | 4, 5, 6 | 3, 4, 5 | 3, 4, 5 | |||
L91G | 4, 5, 6 | 7, 8, 9 | 3, 4, 5, 6 | 3, 4, 5, 6 | 4, 5, 6 | |||
L91K | 4, 5 | 8, 9 | 3, 4, 5, 6 | 3, 4, 5 | 3, 4, 5 | |||
F95A | 4, 5 | 7, 8, 9 | 3, 4, 5, 6, 7 | 3, 4, 5 | 3, 4, 5, 6 | |||
F95W | 4, 5 | 7, 8, 9 | 3, 4, 5, 6, 7 | 3, 4, 5 | 3, 4, 5, 6 | |||
Reaction was performed under conditions shown below using each of the initiating substrates prepared in Production Examples 1 to 11 or farnesyl diphosphate. The activity of each variant enzyme on each initiating substrate was indicated by index with the activity of the wild-type enzyme (Micrococcus luteus B-P 26-derived undecaprenyl diphosphate synthase) as 100.
A reaction solution containing 500 ng of each purified protein, 50 mM Tris-HCl buffer (pH 7.5), 40 mM magnesium chloride, 40 mM Triton X-100, 25 mM 2-mercaptoethanol, 12.5 μM of an initiating substrate, and 50 μM [1-14C] isopentenyl diphosphate was prepared and reacted for 1 hour in a water bath at 37° C. After the reaction, liquid scintillation counting and TLC quantification were performed to measure the activity of each enzyme.
TABLE 3 | ||
Initiating substrate |
Compound | Compound | Compound | Compound | Compound | Compound | ||
Farnesyl | of formula | of formula | of formula | of formula | of formula | of formula |
Relative activity | diphosphate | (S) | (B) | (C) | (D) | (E) | (R) |
Wild-type enzyme | 100 | 100 | 100 | 100 | 100 | 100 | 100 | |
Variant enzyme | N31A | 123 | 116 | 116 | 111 | 179 | 222 | 200 |
N77A | 213 | — | 319 | 234 | 208 | 396 | 254 | |
L91N | 156 | — | — | 108 | 103 | 271 | 137 | |
L91D | 231 | 227 | 231 | 155 | 125 | 320 | 230 | |
N31Q | — | — | — | — | 104 | 210 | 146 | |
N77Q | 121 | — | — | — | 124 | 194 | 156 | |
L91G | — | 130 | 149 | 146 | 134 | 170 | 110 | |
L91K | 133 | 147 | 156 | 130 | 101 | 163 | 165 | |
F95A | — | 163 | 128 | — | — | 120 | 140 | |
F95W | — | 130 | 140 | — | 120 | 114 | 121 | |
Initiating substrate |
Compound | Compound | Compound | Compound | Compound | |
of formula | of formula | of formula | of formula | of formula |
Relative activity | (P) | (H) | (M) | (N) | (K) | ||
Wild-type enzyme | 100 | 100 | 100 | 100 | 100 | |||
Variant enzyme | N31A | — | 152 | 149 | — | — | ||
N77A | — | 162 | 127 | 112 | — | |||
L91N | — | — | 139 | — | — | |||
L91D | 112 | — | 123 | — | — | |||
N31Q | — | 110 | 101 | — | — | |||
N77Q | — | — | — | 133 | — | |||
L91G | 104 | — | — | — | — | |||
L91K | — | — | 112 | — | 112 | |||
F95A | 104 | — | — | 132 | 136 | |||
F95W | 130 | — | — | 147 | 148 | |||
A reaction solution containing 10 μl of a latex component, 50 mM Tris-HCl buffer (pH 7.5), 25 mM magnesium chloride, 40 mM 2-mercaptoethanol, 40 mM potassium fluoride, 50 μM of an isoprene oligomer, and 1 mM isopentenyl diphosphate was prepared and reacted for 3 days in a water bath at 30° C. After the reaction, the molecular weight was measured by GPC. Then, n and q in the formula (4) were calculated on the basis of the measured molecular weight and information about the initiating substrate used. The details (n and q in the formula (4)) of the thus obtained polyisoprenes are as shown in Tables 4 and 5. Here, Y was a hydroxy group or a group represented by the formula (2). Also, Y was identified in the same way as in Examples (Preparation of isoprene oligomer).
The latex component used was a serum prepared by the ultracentrifugation of latex taken from Hevea brasiliensis.
Each isoprene oligomer used was an isoprene oligomer obtained using the variant enzyme N31A or the like and each initiating substrate (farnesyl diphosphate or each of the initiating substrates prepared in Production Examples 1 to 11) under the same conditions as in Examples (Preparation of isoprene oligomer). In the description below, the isoprene oligomers obtained using the variant enzyme N31A or the like together with farnesyl diphosphate, the compound represented by the formula (S), the compound represented by the formula (B), the compound represented by the formula (C), the compound represented by the formula (D), the compound represented by the formula (E), the compound represented by the formula (R), the compound represented by the formula (P), the compound represented by the formula (H), the compound represented by the formula (M), the compound represented by the formula (N), and the compound represented by the formula (K) as initiating substrates under the same conditions as in Examples (Preparation of isoprene oligomer) are referred to as isoprene oligomer (0), isoprene oligomer (S), isoprene oligomer (B), isoprene oligomer (C), isoprene oligomer (D), isoprene oligomer (E), isoprene oligomer (R), isoprene oligomer (P), isoprene oligomer (H), isoprene oligomer (M), isoprene oligomer (N), and isoprene oligomer (K), respectively.
TABLE 4 | ||
Isoprene oligomer |
Isoprene | Isoprene | Isoprene | Isoprene | Isoprene | Isoprene | Isoprene | ||
oligomer | oligomer | oligomer | oligomer | oligomer | oligomer | oligomer |
n | (O) | (S) | (B) | (C) | (D) | (E) | (R) |
Wild-type enzyme | 3 | 2 | 2 | 2 | 2 | 2 | 2 |
Variant enzyme | N31A | 3 | 2 | 2 | 2 | 2 | 2 | 2 |
N77A | 3 | 2 | 2 | 2 | 2 | 2 | 2 | |
L91N | 3 | 2 | 2 | 2 | 2 | 2 | 2 | |
L91D | 3 | 2 | 2 | 2 | 2 | 2 | 2 | |
N31Q | 3 | 2 | 2 | 2 | 2 | 2 | 2 | |
N77Q | 3 | 2 | 2 | 2 | 2 | 2 | 2 | |
L91G | 3 | 2 | 2 | 2 | 2 | 2 | 2 | |
L91K | 3 | 2 | 2 | 2 | 2 | 2 | 2 | |
F95A | 3 | 2 | 2 | 2 | 2 | 2 | 2 | |
F95W | 3 | 2 | 2 | 2 | 2 | 2 | 2 | |
Isoprene oligomer |
Isoprene | Isoprene | Isoprene | Isoprene | Isoprene | |||
oligomer | oligomer | oligomer | oligomer | oligomer |
n | (P) | (H) | (M) | (N) | (K) | ||
Wild-type enzyme | 2 | 2 | 2 | 2 | 1 |
Variant enzyme | N31A | 2 | 2 | 2 | 2 | 1 | ||
N77A | 2 | 2 | 2 | 2 | 1 | |||
L91N | 2 | 2 | 2 | 2 | 1 | |||
L91D | 2 | 2 | 2 | 2 | 1 | |||
N31Q | 2 | 2 | 2 | 2 | 1 | |||
N77Q | 2 | 2 | 2 | 2 | 1 | |||
L91G | 2 | 2 | 2 | 2 | 1 | |||
L91K | 2 | 2 | 2 | 2 | 1 | |||
F95A | 2 | 2 | 2 | 2 | 1 | |||
F95W | 2 | 2 | 2 | 2 | 1 | |||
TABLE 5 | ||
Isoprene oligomer |
Isoprene | Isoprene | Isoprene | Isoprene | Isoprene | Isoprene | Isoprene | ||
oligomer | oligomer | oligomer | oligomer | oligomer | oligomer | oligomer |
q | (O) | (S) | (B) | (C) | (D) | (E) | (R) |
Wild-type enzyme | 5000-30000 | 3000-10000 | 3000-15000 | 5000-30000 | 4500-15000 | 3000-12000 | 3000-12000 |
Variant enzyme | N31A | 3000-15000 | 1000-7350 | 3000-15000 | 3000-10000 | 3000-10000 | 3000-12000 | 3000-12000 |
N77A | 3000-10000 | 1000-7350 | 4000-12000 | 3000-10000 | 5000-20000 | 5000-10000 | 5000-10000 | |
L91N | 1000-12000 | 1000-6500 | 4000-12000 | 1000-12000 | 5000-20000 | 5000-8000 | 5000-8000 | |
L91D | 10000-30000 | 1000-6500 | 3000-10000 | 1000-12000 | 1000-12000 | 1500-7000 | 1500-7000 | |
N31Q | 3000-15000 | 2000-10000 | 3000-15000 | 3500-30000 | 1000-12000 | 2000-7500 | 2000-7500 | |
N77Q | 3000-15000 | 1000-7350 | 3000-15000 | 3000-15000 | 3500-10000 | 1500-6500 | 1500-6500 | |
L91G | 3000-15000 | 1000-7350 | 3000-10000 | 3000-20000 | 3000-15000 | 1500-7500 | 2000-7500 | |
L91K | 3000-15000 | 1500-7350 | 3000-10000 | 3000-15000 | 1500-8000 | 3000-12000 | 1500-6500 | |
F95A | 700-1000 | 3000-7350 | 5000-20000 | 2000-10000 | 1700-7500 | 1500-10000 | 1500-8000 | |
F95W | 700-1000 | 3000-7350 | 5000-20000 | 1500-8000 | 1500-7500 | 1500-10000 | 1000-8000 | |
Isoprene oligomer |
Isoprene | Isoprene | Isoprene | Isoprene | Isoprene | |||
oligomer | oligomer | oligomer | oligomer | oligomer |
q | (P) | (H) | (M) | (N) | (K) | ||
Wild-type enzyme | 1000-3500 | 1000-12000 | 4000-10000 | 1500-7000 | 100-1500 |
Variant enzyme | N31A | 800-5000 | 3000-12000 | 3000-10000 | 1500-5000 | 150-1500 | ||
N77A | 800-5000 | 1500-7000 | 2000-7000 | 3000-6000 | 200-1500 | |||
L91N | 1000-2000 | 2000-7500 | 2000-7500 | 3000-6000 | 200-1500 | |||
L91D | 1000-3000 | 1500-6500 | 1500-6500 | 1000-7500 | 150-2500 | |||
N31Q | 1500-4000 | 1500-7000 | 1000-7000 | 1500-6000 | 100-1500 | |||
N77Q | 1000-3000 | 2000-7500 | 2000-7500 | 2000-5000 | 250-2000 | |||
L91G | 1000-2500 | 1500-6500 | 1500-10000 | 1500-5000 | 250-1500 | |||
L91K | 1000-4500 | 2000-7500 | 2000-7500 | 2500-8000 | 100-1500 | |||
F95A | 450-1500 | 2000-7000 | 2000-6500 | 3000-8000 | 250-2500 | |||
F95W | 450-2000 | 1500-6500 | 1500-6500 | 3000-8000 | 250-2500 | |||
(Antimicrobial Test)
An antimicrobial test was conducted using isoprene oligomers obtained using the variant enzyme N31A under the same conditions as in Examples (Preparation of isoprene oligomer). The isoprene oligomers used were the isoprene oligomer (0), the isoprene oligomer (S), the isoprene oligomer (B), the isoprene oligomer (C), the isoprene oligomer (D), the isoprene oligomer (E), the isoprene oligomer (R), the isoprene oligomer (P), the isoprene oligomer (H), the isoprene oligomer (M), the isoprene oligomer (N), and the isoprene oligomer (K).
The following microbial strains were used in the antimicrobial test:
Gram-positive bacteria: Staphylococcus aureus (13276) and Bacillus subtilis (3134)
Gram-negative bacteria: Echerichia coli (3972), Salmonella enteric (100797), Peudomonas aeruginosa (13275), and Klebsiella pneumonia (3512)
Fungi: Candida albicans (1594)
The number in the parentheses represents NBRC No. from National Institute of Technology and Evaluation, Biological Resource Center. All the microbial strains used were purchased from NBRC.
Next, the recovery and culture conditions of the microbial strains used are shown in Table 6.
TABLE 6 | |||||
Culture | |||||
NBRC | Liquid | Solid | temperature | ||
No. | culture | medium | (° C.) | ||
1594 | 703 | 108 | 24 | ||
3134 | 702 | 802 | 30 | ||
3512 | 702 | 802 | 30 | ||
3972 | 702 | 802 | 30 | ||
13275 | 702 | 802 | 30 | ||
13276 | 702 | 802 | 30 | ||
100797 | 702 | 802 | 30 | ||
Composition of each medium (1 L solution each)
108: 10 g of glucose, 5 g of peptone, 3 g of yeast extract, 3 g of malt extract, and 15 g of agar, pH 5.6;
702: 10 g of polypeptone, 2 g of yeast extract, and 1 g of MgSO4.7H2O, pH 7.0;
703: 10 g of glucose, 5 g of peptone, 3 g of yeast extract, and 3 g of malt extract, pH 6.0;
802: 10 g of polypeptone, 2 g of yeast extract, 1 g of MgSO4.7H2O, and 15 g of agar, pH 7.0.
The Staphylococcus aureus strain was inoculated into a test tube containing 2 ml of a liquid medium (10 g/L polypeptone, 2 g/L yeast extract, and 1 g/L MgSO4.7H2O, pH 7.0) and cultured at 150 rpm at 30° C. for 5 hours. The microbial strain was inoculated into a solid medium (10 g/L polypeptone, 2 g of yeast extract, 1 g/L MgSO4.7H2O, and 15 g/L agar, pH 7.0) and cultured overnight at 30° C. On the next day, colonies were confirmed. One of the colonies on the solid medium was inoculated into a test tube containing 4 ml of the liquid medium and cultured (i.e., precultured) overnight at 30° C. Next, 100 μl of the preculture solution was added to a new test tube containing 4 ml of the liquid medium and cultured at 150 rpm at 30° C. During the culture, the turbidity was measured using a spectrophotometer, and the culture was continued until O.D.600=0.1 to 0.3. The culture solution was adjusted to 105 cfu/ml by the dilution method and used in the antimicrobial test.
The minimum inhibitory concentration (MIC) was measured by the MIC method, which is a general experimental approach for examining the activity of anti-microorganism substances. The microbial culture solution thus adjusted to 105 cfu/ml and each isoprene oligomer adjusted to 0.5-5 mM were added into a 1.5-ml tube, mixed with each other, and cultured overnight at 150 rpm at 30° C. After the culture, each concentration of the culture solution was applied to the solid medium using a spreader and cultured at 30° C. for 1-4 days. After the culture, the presence or absence of growth of the microbe was examined by visual observation, and the minimum addition concentration of the terminally modified isoprene oligomer at which the microbe did not survive was defined as MIC.
MIC was determined for the other microbes in the same way as above.
The isoprene oligomers used and their MICs are shown in Table 7.
TABLE 7 | ||
Isoprene oligomer |
Comparative | |||||||
Example 1 | Example 1 | Example 2 | Example 3 | Example 4 | Example 5 | Example 6 | |
Isoprene | Isoprene | Isoprene | Isoprene | Isoprene | Isoprene | Isoprene | |
oligomer | oligomer | oligomer | oligomer | oligomer | oligomer | oligomer |
MIC(μg/ml) | (O) | (S) | (B) | (C) | (D) | (E) | (R) |
Staphylococcus aureus | 13276 | * | — | 260 | 160 | 560 | 460 | 58 |
Bacillus subtilis | 3134 | * | — | 260 | 160 | 560 | 320 | 58 |
Echerichia coli | 3972 | * | — | 180 | — | 240 | — | 130 |
Salmonella enteric | 100797 | * | — | — | — | — | — | — |
Peudomonas aeruginosa | 13275 | * | 93 | — | — | — | — | — |
Klebsiella pneumonia | 3512 | * | 93 | 58 | — | — | — | — |
Candida albicans | 1594 | * | 93 | — | — | 240 | 90 | 130 |
Isoprene oligomer |
Example 7 | Example 8 | Example 9 | Example 10 | Example 11 | |
Isoprene | Isoprene | Isoprene | Isoprene | Isoprene | |
oligomer | oligomer | oligomer | oligomer | oligomer |
MIC(μg/ml) | (P) | (H) | (M) | (N) | (K) | ||
Staphylococcus aureus | 13276 | 140 | — | 190 | 560 | 45 | ||
Bacillus subtilis | 3134 | 140 | — | 760 | 560 | 30 | ||
Echerichia coli | 3972 | — | — | 420 | 240 | 30 | ||
Salmonella enteric | 100797 | — | — | 240 | 37 | 50 | ||
Peudomonas aeruginosa | 13275 | — | — | — | 37 | 56 | ||
Klebsiella pneumonia | 3512 | — | — | — | 130 | 75 | ||
Candida albicans | 1594 | — | 88 | — | 20 | 35 | ||
* Antimicrobial activity was not observed at 800 ppm or lower. |
(Discussion about Results of Table 7)
The isoprene oligomer (0) of Comparative Example (isoprene oligomer obtained from farnesyl diphosphate) in which at least one atom or group contained in the trans structural moiety was not replaced by another atom or group did not exhibit antimicrobial activity (antimicrobial activity was not observed at 800 ppm or lower). In contrast, the isoprene oligomers of Examples in which at least one atom or group contained in the trans structural moiety was replaced by another atom or group exhibited antimicrobial activity.
(Rubber Composition)
Next, a rubber composition containing the isoprene oligomer and/or the polyisoprene of the present invention was evaluated for its performance. First, the compound represented by the formula (F) was synthesized in the same way as in Production Examples 1 to 11.
Next, farnesyl diphosphate and the synthesized initiating substrates (the compound represented by the formula (K) and the compound represented by the formula (F)) were used to prepare isoprene oligomers. The details (n, m, and Y in the formula (1)) of the obtained isoprene oligomers were determined in the same way as in Examples (Preparation of isoprene oligomer).
The isoprene oligomer (F) was prepared from the compound represented by the formula (F) as an initiating substrate. This reaction was performed by adjusting the conditions described above in (Preparation of isoprene oligomer) in order to adjust the molecular weight of the isoprene oligomer to be obtained.
The details (n and m in the formula (1)) of the obtained isoprene oligomer (F) were n=2 and m=5 to 8. Here, Y was a hydroxy group or a group represented by the formula (2).
The isoprene oligomer (K) was prepared from the compound represented by the formula (K) as an initiating substrate. This reaction was performed by adjusting the conditions described above in (Preparation of isoprene oligomer) in order to adjust the molecular weight of the isoprene oligomer to be obtained.
The details (n and m in the formula (1)) of the obtained isoprene oligomer (K) were n=1 and m=5 to 7. Here, Y was a hydroxy group or a group represented by the formula (2).
The isoprene oligomer (0) was prepared from farnesyl diphosphate as an initiating substrate. This reaction was performed by adjusting the conditions described above in (Preparation of isoprene oligomer) in order to adjust the molecular weight of the isoprene oligomer to be obtained.
The details (n and m in the formula (1)) of the obtained isoprene oligomer (0) were n=3 and m=5 to 7. Here, Y was a hydroxy group or a group represented by the formula (2).
Next, polyisoprenes were prepared from the isoprene oligomers obtained in Production Examples 14 to 16 (the isoprene oligomer (F), the isoprene oligomer (K), and the isoprene oligomer (0)). The details (n, q, and Y in the formula (4)) of the obtained polyisoprenes were determined in the same way as in Examples (Preparation of polyisoprene).
The polyisoprene (F) was prepared from the isoprene oligomer (F) prepared in Production Example 14. This reaction was performed by adjusting the conditions described above in (Preparation of polyisoprene) in order to adjust the molecular weight of the polyisoprene to be obtained.
The details (n and q in the formula (4)) of the obtained polyisoprene (F) were n=2 and q=7000 to 12000. Here, Y was a hydroxy group or a group represented by the formula (2).
The polyisoprene (K-1) was prepared from the isoprene oligomer (K) prepared in Production Example 15. This reaction was performed by adjusting the conditions described above in (Preparation of polyisoprene) in order to adjust the molecular weight of the polyisoprene to be obtained.
The details (n and q in the formula (4)) of the obtained polyisoprene (K-1) were n=1 and q=3500 to 7000. Here, Y was a hydroxy group or a group represented by the formula (2).
The polyisoprene (K-2) was prepared from the isoprene oligomer (K) prepared in Production Example 15. This reaction was performed by adjusting the conditions described above in (Preparation of polyisoprene) in order to adjust the molecular weight of the polyisoprene to be obtained.
The details (n and q in the formula (4)) of the obtained polyisoprene (K-2) were n=1 and q=7000 to 12000. Here, Y was a hydroxy group or a group represented by the formula (2).
The polyisoprene (0) was prepared from the isoprene oligomer (0) prepared in Production Example 16. This reaction was performed by adjusting the conditions described above in (Preparation of polyisoprene) in order to adjust the molecular weight of the polyisoprene to be obtained.
The details (n and q in the formula (4)) of the obtained polyisoprene (0) were n=3 and q=7000 to 12000. Here, Y was a hydroxy group or a group represented by the formula (2).
Hereinafter, various agents used in Examples 12 to 21 and Comparative Examples 2 to 6 will be summarized.
NR: TSR20
BR: BR01 manufactured by JSR Corp.
Carbon black: Diablack (N220) manufactured by Mitsubishi Chemical Corp.
Isoprene oligomer (F), isoprene oligomer (K), and isoprene oligomer (0): isoprene oligomers obtained in Production Examples 14 to 16
Polyisoprene (F), polyisoprene (K-1), polyisoprene (K-2), and polyisoprene (0): polyisoprenes obtained in Production Examples 17 to 20
Zinc oxide: zinc oxide No. 1 manufactured by Mitsui Mining & Smelting Co., Ltd.
Stearic acid: stearic acid manufactured by NOF Corp.
Antioxidant: Nocrac 6C (N-(1,3-dimethylbutyl)-N′-phenyl-p-phenylenediamine) manufactured by Ouchi Shinko Chemical Industrial Co., Ltd.
Wax: Sannoc wax manufactured by Ouchi Shinko Chemical Industrial Co., Ltd.
Sulfur: sulfur powder manufactured by Tsurumi Chemical Industry Co., Ltd.
Vulcanization accelerator NS: Nocceler NS (N-tert-butyl-2-benzothiazolesulfenamide) manufactured by Ouchi Shinko Chemical Industrial Co., Ltd.
Silica: Nipsil AQ (wet silica) manufactured by Nippon
Silica Industrial Co., Ltd.
Silane coupling agent: Si266 (bis(3-triethoxysilylpropyl) disulfide) manufactured by Degussa
Vulcanization accelerator DPG: Nocceler D (N,N-diphenylguanidine) manufactured by Ouchi Shinko Chemical Industrial Co., Ltd.
The materials other than sulfur and vulcanization accelerators were kneaded using a 1.7-L Banbury mixer according to the formulation shown in Table 8 or 9 to obtain a kneaded mixture. Next, sulfur and vulcanization accelerator(s) were added to the obtained kneaded mixture and kneaded thereinto using an open roll mill to obtain an unvulcanized rubber composition. The obtained unvulcanized rubber composition was vulcanized at a pressure of 80 kgf/cm2 at 150° C. for 30 minutes using a steam vulcanization press to obtain a vulcanized rubber composition.
The thus obtained vulcanized rubber compositions were evaluated as shown below. The results are shown in Tables 8 and 9. The formulations of Comparative Examples 4 and 5 were used as reference formulations in Tables 8 and 9, respectively.
(Viscoelasticity Test)
The tan δ was measured under conditions of 70° C. and 2% strain (initial elongation) using a viscoelasticity spectrometer manufactured by Iwamoto Seisakusho Co., Ltd. and indicated by index with the tan δ of the reference formulation as 100. A larger index represents larger heat build-up. A rubber composition having an index of 100 or less was regarded as having improved in resistance to heat build-up (low-heat-build-up properties). This means that a rubber composition having a smaller index is more excellent in low-heat-build-up properties.
(Lambourn Abrasion Test)
An abrasion test was carried out for 5 minutes under conditions of 3 kg load, 40% slip ratio, and sand falling at a rate of 15 g/min using a Lambourn abrasion tester manufactured by Iwamoto Seisakusho Co., Ltd. The shape of each sample was set to a thickness of 5 mm and a diameter of 50 mm, and the grindstone used was GC-type abrasive grains having a particle size of #80. The test results were converted to an index with the value of the reference formulation as 100 (reference). A larger index represents more excellent abrasion resistance. A rubber composition having an index exceeding 100 was regarded as having improved in abrasion resistance.
(Tensile Test)
A tensile test was carried out according to JIS K6251 “Rubber, vulcanized or thermoplastic—Determination of tensile stress-strain properties” using No. 3 dumbbell test pieces from the vulcanized rubber sheet, and the tensile strength at break (TB) (MPa) and elongation at break (EB) (%) were measured. Elongation at break less than 480% tends to cause rubber separation during use in large tires and thus requires improvement. Also as for tensile strength at break, its reduction is responsible for the destruction of tires and thus it is necessary to prevent a reduction due to the change in materials.
TABLE 8 | ||||||||
Comparative | Comparative | Comparative | ||||||
Example 12 | Example 13 | Example 14 | Example 15 | Example 2 | Example 3 | Example 4 | ||
Formulation | NR | 80 | 80 | 80 | 80 | 80 | 80 | 80 |
(Part(s) by mass) | BR | 20 | 20 | 20 | 20 | 20 | 20 | 20 |
Carbon black | 50 | 50 | 50 | 50 | 50 | 50 | 50 | |
Isoprene oligomer (F) | 3 | 10 | — | — | — | — | — | |
Isoprene oligomer (K) | — | — | 3 | 10 | — | — | — | |
Isoprene oligomer (O) | — | — | — | — | 3 | 10 | — | |
Zinc oxide | 3 | 3 | 3 | 3 | 3 | 3 | 3 | |
Stearic acid | 2 | 2 | 2 | 2 | 2 | 2 | 2 | |
Antioxidant | 2 | 2 | 2 | 2 | 2 | 2 | 2 | |
Wax | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | |
Sulfur | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | |
Vulcanization accelerator NS | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
Performance | Viscoelasticity tan δ (index) | 97 | 94 | 96 | 93 | 102 | 104 | 100 |
evaluation | Lambourn abrasion (index) | 104 | 106 | 103 | 106 | 98 | 96 | 100 |
Elongation at break (%) | 520 | 570 | 520 | 580 | 530 | 570 | 510 | |
TABLE 9 | |||||||||
Comparative | Comparative | ||||||||
Example 16 | Example 17 | Example 18 | Example 19 | Example 20 | Example 21 | Example 5 | Example 6 | ||
Formulation | Polyisoprene (F) | 100 | — | — | 80 | 60 | — | — | — |
(Part(s) by | Polyisoprene (K-1) | — | 100 | — | — | — | 60 | — | — |
mass) | Polyisoprene (K-2) | — | — | 100 | — | — | — | — | — |
Polyisoprene (O) | — | — | — | — | — | — | 60 | — | |
NR | — | — | — | 20 | 40 | 40 | 40 | 100 | |
Silica | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | |
Silane coupling | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | |
agent | |||||||||
Stearic acid | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | |
Antioxidant | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | |
Zinc oxide | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | |
Sulfur | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | |
Vulcanization | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
accelerator NS | |||||||||
Vulcanization | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
accelerator DPG | |||||||||
Performance | Viscoelasticity | 89 | 93 | 88 | 91 | 94 | 93 | 100 | 101 |
evaluation | tan δ (index) | ||||||||
Lambourn abrasion | 112 | 106 | 111 | 108 | 105 | 106 | 100 | 102 | |
(index) | |||||||||
Tensile strength | 25.8 | 25.5 | 25.2 | 25.5 | 25.2 | 25.3 | 25.6 | 24.8 | |
at break (MPa) | |||||||||
As is evident from Table 8, the rubber compositions of Examples including the isoprene oligomers in which at least one atom or group contained in the trans structural moiety was replaced by another atom or group were excellent in low-heat-build-up properties, abrasion resistance, and elongation at break.
As is evident from Table 9, the rubber compositions of Examples including the polyisoprenes in which at least one atom or group contained in the trans structural moiety was replaced by another atom or group were excellent in low-heat-build-up properties, abrasion resistance, and tensile strength at break.
Next, the following experiment was conducted in order to demonstrate the fact that by maintaining the structure of moiety I in the formula (I) in the naturally occurring initiating substrate farnesyl diphosphate or the like, even when a desired structure is introduced in a moiety other than moiety I, it is possible to produce isoprene oligomers in the presence of the naturally occurring oligomer-producing enzyme prenyltransferase or any enzyme obtained by partial mutation thereof, whereas this enzymatic reaction does not proceed in the case of using initiating substrates not maintaining the structure of moiety I in the formula (I).
First, the following initiating substrates 1 to 4 not maintaining the structure of moiety I in the formula (I) were synthesized.
Synthesis was carried out with crotyl alcohol as a starting material. The primary hydroxy group was replaced by chlorine using N-chlorosuccinimide and dimethyl sulfide in an anhydrous dichloromethane solvent to obtain a chloride (compound represented by (i) below) (yield: 78%). Next, the chloride was diphosphorylated using tris-tetra-n-butylammonium hydrogen pyrophosphate in anhydrous acetonitrile to obtain a compound represented by (ii) below (initiating substrate 1) as the substance of interest (yield: 50%). The intermediate in each synthesis step and the final product were confirmed by TLC and instrumental analysis (IR, NMR).
Synthesis was carried out with 3-methyl-2-buten-1-ol as a starting material. The hydroxy group of 3-methyl-2-buten-1-ol was chlorinated using N-chlorosuccinimide (NCS) and dimethyl sulfide (DMS) in anhydrous dichloromethane in a nitrogen atmosphere to obtain a chloride (compound represented by (i) below) (yield: 90%). Next, the chloride was reacted with ethyl cyanoacetate in the presence of lithium hydroxide in anhydrous N,N-dimethylformamide to obtain an ester form (compound represented by (ii) below) (yield: 44%). Next, the ester was hydrolyzed with potassium hydroxide and methanol to obtain a carboxylic acid (compound represented by (iii) below) (yield: 92%). Next, the carboxylic acid was decarboxylated with dimethyl sulfoxide and common salt to obtain a nitrile form (compound represented by (iv) below) (yield: 40%). The nitrile was reduced with lithium diisobutyl hydride and saturated ammonium chloride in anhydrous dichloromethane to obtain an aldehyde form (compound represented by (v) below) (yield: 89%). The aldehyde was treated with sodium hydride and ethyl diethylphosphonoacetate in anhydrous tetrahydrofuran to obtain a trans ester form (compound represented by (vi) below) (yield: 84%). Next, the ester was reduced using lithium diisobutyl hydride and methanol in anhydrous dichloromethane and anhydrous hexane to obtain an alcohol form (compound represented by (vii) below) (yield: 19%). Next, the primary hydroxy group was replaced by chlorine using N-chlorosuccinimide and dimethyl sulfide in an anhydrous dichloromethane solvent at −40° C. or lower to obtain a chloride (compound represented by (viii) below) (yield: 82%). Next, the chloride was diphosphorylated using tris-tetra-n-butylammonium hydrogen pyrophosphate in anhydrous acetonitrile to obtain a compound represented by (ix) below (initiating substrate 2) as the substance of interest (yield: 50%). The intermediate in each synthesis step and the final product were confirmed by TLC and instrumental analysis (IR, NMR).
Synthesis was carried out with geraniol as a starting material. The hydroxy group of geraniol was chlorinated using N-chlorosuccinimide (NCS) and dimethyl sulfide (DMS) in anhydrous dichloromethane in a nitrogen atmosphere to obtain a chloride (compound represented by (i) below) (yield: 94%). Next, the chloride was reacted with ethyl cyanoacetate in the presence of lithium hydroxide in anhydrous N,N-dimethylformamide to obtain an ester form (compound represented by (ii) below) (yield: 34%). Next, the ester was hydrolyzed with potassium hydroxide and methanol to obtain a carboxylic acid (compound represented by (iii) below) (yield: 95%). Next, the carboxylic acid was decarboxylated with dimethyl sulfoxide and common salt to obtain a nitrile form (compound represented by (iv) below) (yield: 40%). The nitrile was reduced with lithium diisobutyl hydride and saturated ammonium chloride in anhydrous dichloromethane to obtain an aldehyde form (compound represented by (v) below) (yield: 91%). The aldehyde was treated with sodium hydride and ethyl diethylphosphonoacetate in anhydrous tetrahydrofuran to obtain a trans ester form (compound represented by (vi) below) (yield: 82%). Next, the ester was reduced using lithium diisobutyl hydride and methanol in anhydrous dichloromethane and anhydrous hexane to obtain an alcohol form (compound represented by (vii) below) (yield: 19%). Next, the primary hydroxy group was replaced by chlorine using N-chlorosuccinimide and dimethyl sulfide in an anhydrous dichloromethane solvent to obtain a chloride (compound represented by (viii) below) (yield: 82%). Next, the chloride was diphosphorylated using tris-tetra-n-butylammonium hydrogen pyrophosphate in anhydrous acetonitrile to obtain a compound represented by (ix) below (initiating substrate 3) as the substance of interest (yield: 42%). The intermediate in each synthesis step and the final product were confirmed by TLC and instrumental analysis (IR, NMR).
Synthesis was carried out with farnesol as a starting material. The hydroxy group of farnesol was chlorinated using N-chlorosuccinimide (NCS) and dimethyl sulfide (DMS) in anhydrous dichloromethane in a nitrogen atmosphere to obtain a chloride (compound represented by (i) below) (yield: 91%). Next, the chloride was reacted with ethyl cyanoacetate in the presence of lithium hydroxide in anhydrous N,N-dimethylformamide to obtain an ester form (compound represented by (ii) below) (yield: 34%). Next, the ester was hydrolyzed with potassium hydroxide and methanol to obtain a carboxylic acid (compound represented by (iii) below) (yield: 88%). Next, the carboxylic acid was decarboxylated with dimethyl sulfoxide and common salt to obtain a nitrile form (compound represented by (iv) below) (yield: 40%). The nitrile was reduced with lithium diisobutyl hydride and saturated ammonium chloride in anhydrous dichloromethane to obtain an aldehyde form (compound represented by (v) below) (yield: 81%). The aldehyde was treated with sodium hydride and ethyl diethylphosphonoacetate in anhydrous tetrahydrofuran to obtain a trans ester form (compound represented by (vi) below) (yield: 84%). Next, the ester was reduced using lithium diisobutyl hydride and methanol in anhydrous dichloromethane and anhydrous hexane to obtain an alcohol form (compound represented by (vii) below) (yield: 30%). Next, the primary hydroxy group was replaced by chlorine using N-chlorosuccinimide and dimethyl sulfide in an anhydrous dichloromethane solvent to obtain a chloride (compound represented by (viii) below) (yield: 86%). Next, the chloride was diphosphorylated using tris-tetra-n-butylammonium hydrogen pyrophosphate in anhydrous acetonitrile to obtain a compound represented by (ix) below (initiating substrate 4) as the substance of interest (yield: 41%). The intermediate in each synthesis step and the final product were confirmed by TLC and instrumental analysis (IR, NMR).
Next, the compound represented by the formula (G), the compound represented by the formula (I), and the compound represented by the formula (Q) were synthesized in the same way as in Production Examples 1 to 11.
Next, reaction was performed under conditions shown below using Micrococcus luteus B-P 26-derived undecaprenyl diphosphate synthase as an enzyme and each of the initiating substrates 1 to 4, the compound represented by the formula (B), the compound represented by the formula (C), the compound represented by the formula (G), the compound represented by the formula (K), and farnesyl diphosphate (FPP). The results were indicated in Table 10 by the relative activity of the enzyme on the initiating substrates 1 to 4, the compound represented by the formula (B), the compound represented by the formula (C), the compound represented by the formula (G), and the compound represented by the formula (K) with the activity of the enzyme on farnesyl diphosphate as 100.
A reaction solution containing 500 ng of the enzyme, 50 mM Tris-HCl buffer (pH 7.5), 40 mM magnesium chloride, 40 mM Triton X-100, 25 mM 2-mercaptoethanol, 12.5 μM of an initiating substrate, and 50 μM [1-14C] isopentenyl diphosphate was prepared and reacted for 1 hour in a water bath at 37° C. After the reaction, liquid scintillation counting and TLC quantification were performed to measure the activity of the enzyme on each initiating substrate.
TABLE 10 | |||
Initiating substrate | Relative activity (%) | ||
Farnesyl diphosphate | 100 | ||
Initiating substrate 1 | 0.3 | ||
Initiating substrate 2 | 0.6 | ||
Initiating substrate 3 | 1.2 | ||
Initiating substrate 4 | 5.9 | ||
Compound of formula (B) | 68.4 | ||
Compound of formula (C) | 74.8 | ||
Compound of formula (G) | 72.9 | ||
Compound of formula (K) | 40.6 | ||
As is evident from the results of Table 10, the enzymatic reaction hardly proceeded in the case of using the initiating substrates 1 to 4 not maintaining the structure of moiety I in the formula (I). In contrast, the enzymatic reaction proceeded in the case of using the initiating substrates maintaining the structure of moiety I in the formula (I).
Next, the following experiment was conducted using Bacillus stearothermophilus-derived farnesyl diphosphate synthase and Sulfolobus acidocaldarius-derived geranylgeranyl diphosphate synthase in order to demonstrate the fact that even enzymes having prenyltransferase activity, derived from organisms other than Micrococcus luteus B-P 26 exhibit the same tendencies as described for Micrococcus luteus B-P 26-derived undecaprenyl diphosphate synthase, depending on whether or not the initiating substrate used has maintained the structure of moiety I in the formula (I).
First, Bacillus stearothermophilus-derived farnesyl diphosphate synthase was prepared.
E. coli BL21 (DE3) was transformed in the same way as above, with a plasmid pET22b containing the base sequence of Bacillus stearothermophilus-derived farnesyl diphosphate synthase (this plasmid is referred to as pET22b/BsFPS). This pET22b/BsFPS was kindly provided by Professor Koyama (Institute of Multidisciplinary Research for Advanced Materials Tohoku University).
The E. coli BL21(DE3)/pET22b/BsFPS was inoculated into a test tube containing 3 mL of an LB medium containing 50 μg/mL ampicillin and shake-cultured at 37° C. for 5 hours. A 1 mL aliquot of the obtained culture solution was inoculated into a 500-mL Erlenmeyer flask containing 100 mL of an LB medium containing 50 μg/mL ampicillin and shake-cultured at 37° C. for 3 hours. Then, IPTG was added thereto at a concentration of 0.1 mmol/L, and the bacterial cells were shake-cultured at 30° C. for 18 hours. The culture solution was centrifuged to obtain wet bacterial cells. The wet bacterial cells thus obtained were disrupted by sonication and then centrifuged. A protein having prenyltransferase activity (Bacillus stearothermophilus-derived farnesyl diphosphate synthase) was purified from the obtained supernatant using HisTrap (manufactured by Amersham Biosciences Corp.). The purification of the purified protein was confirmed by SDS-PAGE.
Next, Sulfolobus acidocaldarius-derived geranylgeranyl diphosphate synthase was prepared.
E. coli BL21 (DE3) was transformed in the same way as above, with a plasmid pET22b containing the base sequence of Sulfolobus acidocaldarius-derived geranylgeranyl diphosphate synthase (this plasmid is referred to as pET22b/SaGGPS). This pET22b/SaGGPS was kindly provided by Professor Tokuzo Nishino (School of Engineering, Tohoku University).
The E. coli BL21(DE3)/pET22b/SaGGPS was inoculated into a test tube containing 3 mL of an LB medium containing 50 μg/mL ampicillin and shake-cultured at 37° C. for 5 hours. A 1 mL aliquot of the obtained culture solution was inoculated into a 500-mL Erlenmeyer flask containing 100 mL of an LB medium containing 50 μg/mL ampicillin and shake-cultured at 37° C. for 3 hours. Then, IPTG was added thereto at a concentration of 0.1 mmol/L, and the bacterial cells were shake-cultured at 30° C. for 18 hours. The culture solution was centrifuged to obtain wet bacterial cells. The wet bacterial cells thus obtained were disrupted by sonication and then centrifuged. A protein having prenyltransferase activity (Sulfolobus acidocaldarius-derived geranylgeranyl diphosphate synthase) was purified from the obtained supernatant using HisTrap (manufactured by Amersham Biosciences Corp.). The purification of the purified protein was confirmed by SDS-PAGE.
Reaction was performed under conditions shown below using the obtained Bacillus stearothermophilus-derived farnesyl diphosphate synthase and each of the initiating substrates 1 to 4, the compound represented by the formula (F), the compound represented by the formula (I), the compound represented by the formula (Q), and geranyl diphosphate (GPP) whose structure is shown below. The results were indicated in Table 11 by the relative activity of the enzyme on the initiating substrates 1 to 4, the compound represented by the formula (F), the compound represented by the formula (I), and the compound represented by the formula (Q) with the activity of the enzyme on geranyl diphosphate as 100.
A reaction solution containing 500 ng of the purified enzyme, 50 mM Tris-HCl buffer (pH 8.5), 40 mM magnesium chloride, 50 mM ammonium chloride, 40 mM Triton X-100, 25 mM 2-mercaptoethanol, 12.5 μM of an initiating substrate, and 50 μM [1-14C] isopentenyl diphosphate was prepared and reacted for 1 hour in a water bath at 55° C. After the reaction, liquid scintillation counting and TLC quantification were performed to measure the activity of the enzyme on each initiating substrate.
TABLE 11 | |||
Initiating substrate | Relative activity (%) | ||
Geranyl diphosphate | 100 | ||
Initiating substrate 1 | 1.4 | ||
Initiating substrate 2 | 3.2 | ||
Initiating substrate 3 | 2.1 | ||
Initiating substrate 4 | 0.7 | ||
Compound of formula (F) | 52.3 | ||
Compound of formula (I) | 44.1 | ||
Compound of formula (Q) | 54.3 | ||
Likewise, reaction was performed under conditions shown below using Sulfolobus acidocaldarius-derived geranylgeranyl diphosphate synthase and each of the initiating substrates 1 to 4, the compound represented by the formula (B), the compound represented by the formula (C), the compound represented by the formula (G), the compound represented by the formula (K), the compound represented by the formula (F), the compound represented by the formula (I), the compound represented by the formula (Q), farnesyl diphosphate (FPP), and geranyl diphosphate (GPP). The results were indicated in Tables 12 and 13 by the relative activity of the enzyme on the initiating substrates 1 to 4, the compound represented by the formula (B), the compound represented by the formula (C), the compound represented by the formula (G), the compound represented by the formula (K), the compound represented by the formula (F), the compound represented by the formula (I), and the compound represented by the formula (Q) with the activity of the enzyme on farnesyl diphosphate or geranyl diphosphate as 100.
A reaction solution containing 500 ng of the purified enzyme, 50 mM Tris-HCl buffer (pH 5.8), 40 mM magnesium chloride, 50 mM ammonium chloride, 40 mM Triton X-100, 25 mM 2-mercaptoethanol, 12.5 μM of an initiating substrate, and 50 μM [1-14C] isopentenyl diphosphate was prepared and reacted for 1 hour in a water bath at 55° C. After the reaction, liquid scintillation counting and TLC quantification were performed to measure the activity of the enzyme on each initiating substrate.
TABLE 12 | |||
Initiating substrate | Relative activity (%) | ||
Geranyl diphosphate | 100 | ||
Initiating substrate 1 | 0.4 | ||
Initiating substrate 2 | 0.4 | ||
Initiating substrate 3 | 0.6 | ||
Initiating substrate 4 | 0.8 | ||
Compound of formula (F) | 52.3 | ||
Compound of formula (I) | 44.1 | ||
Compound of formula (Q) | 54.3 | ||
TABLE 13 | |||
Initiating substrate | Relative activity (%) | ||
Farnesyl diphosphate | 100 | ||
Initiating substrate 1 | 2.3 | ||
Initiating substrate 2 | 2.5 | ||
Initiating substrate 3 | 3.9 | ||
Initiating substrate 4 | 1.4 | ||
Compound of formula (B) | 70.6 | ||
Compound of formula (C) | 37.3 | ||
Compound of formula (G) | 70.4 | ||
Compound of formula (K) | 38.6 | ||
As is evident from the results of Tables 11 to 13, the enzymatic reactions of Bacillus stearothermophilus-derived farnesyl diphosphate synthase and Sulfolobus acidocaldarius-derived geranylgeranyl diphosphate synthase hardly proceeded in the case of using the initiating substrates 1 to 4 not maintaining the structure of moiety I in the formula (I), as in use of Micrococcus luteus B-P 26-derived undecaprenyl diphosphate synthase. In contrast, the enzymatic reactions proceeded in the case of using the initiating substrates maintaining the structure of moiety I in the formula (I).
The results of Tables 1 to 3 and 10 to 13 have demonstrated that by maintaining the structure of moiety I in the formula (I) in the naturally occurring initiating substrate farnesyl diphosphate, geranyl diphosphate, or the like, even when a desired structure is introduced in a moiety other than moiety I, it is possible to produce isoprene oligomers in the presence of an enzyme having prenyltransferase activity, which is a naturally occurring oligomer-producing enzyme, or any enzyme obtained by partial mutation thereof.
SEQ ID NO: 1: Base sequence of Micrococcus luteus B-P 26-derived undecaprenyl diphosphate synthase (wild-type enzyme)
SEQ ID NO: 2: Amino acid sequence of Micrococcus luteus B-P 26-derived undecaprenyl diphosphate synthase (wild-type enzyme)
SEQ ID NO: 3: Base sequence of variant enzyme N31A
SEQ ID NO: 4: Amino acid sequence of variant enzyme N31A
SEQ ID NO: 5: Base sequence of variant enzyme N77A
SEQ ID NO: 6: Amino acid sequence of variant enzyme N77A
SEQ ID NO: 7: Base sequence of variant enzyme L91N
SEQ ID NO: 8: Amino acid sequence of variant enzyme L91N
SEQ ID NO: 9: Base sequence of variant enzyme L91D
SEQ ID NO: 10: Amino acid sequence of variant enzyme L91D
SEQ ID NO: 11: Base sequence of variant enzyme N31Q
SEQ ID NO: 12: Amino acid sequence of variant enzyme N31Q
SEQ ID NO: 13: Base sequence of variant enzyme N77Q
SEQ ID NO: 14: Amino acid sequence of variant enzyme N77Q
SEQ ID NO: 15: Base sequence of variant enzyme L91G
SEQ ID NO: 16: Amino acid sequence of variant enzyme L91G
SEQ ID NO: 17: Base sequence of variant enzyme L91K
SEQ ID NO: 18: Amino acid sequence of variant enzyme L91K
SEQ ID NO: 19: Base sequence of variant enzyme F95A
SEQ ID NO: 20: Amino acid sequence of variant enzyme F95A
SEQ ID NO: 21: Base sequence of variant enzyme F95W
SEQ ID NO: 22: Amino acid sequence of variant enzyme F95W
SEQ ID NO: 23: Sense primer for preparation of variant enzyme N31A
SEQ ID NO: 24: Antisense primer for preparation of variant enzyme N31A
SEQ ID NO: 25: Sense primer for preparation of variant enzyme N77A
SEQ ID NO: 26: Antisense primer for preparation of variant enzyme N77A
SEQ ID NO: 27: Sense primer for preparation of variant enzyme L91N
SEQ ID NO: 28: Antisense primer for preparation of variant enzyme L91N
SEQ ID NO: 29: Sense primer for preparation of variant enzyme L91D
SEQ ID NO: 30: Antisense primer for preparation of variant enzyme L91D
SEQ ID NO: 31: Sense primer for preparation of variant enzyme N31Q
SEQ ID NO: 32: Antisense primer for preparation of variant enzyme N31Q
SEQ ID NO: 33: Sense primer for preparation of variant enzyme N77Q
SEQ ID NO: 34: Antisense primer for preparation of variant enzyme N77Q
SEQ ID NO: 35: Sense primer for preparation of variant enzyme L91G
SEQ ID NO: 36: Antisense primer for preparation of variant enzyme L91G
SEQ ID NO: 37: Sense primer for preparation of variant enzyme L91K
SEQ ID NO: 38: Antisense primer for preparation of variant enzyme L91K
SEQ ID NO: 39: Sense primer for preparation of variant enzyme F95A
SEQ ID NO: 40: Antisense primer for preparation of variant enzyme F95A
SEQ ID NO: 41: Sense primer for preparation of variant enzyme F95W
SEQ ID NO: 42: Antisense primer for preparation of variant enzyme F95W
Claims (8)
1. An isoprene oligomer comprising a substituted trans structural moiety and a cis structural moiety, wherein at least one atom or group of an unsubstituted trans structural moiety A of a preliminary isoprene oligomer having the following formula (1) selected from a hydrogen atom, a methyl group, a methylene group, a carbon atom, or a methine group is replaced by a different atom or group to provide the substituted trans structural moiety, and the different atom or group is selected from the group consisting of a nitrogen atom, an oxygen atom, a sulfur atom, a silicon atom, a carbon atom, an acetoxy group, an alkoxy group, a hydroxy group, an aryl group, an alkyl group, an acetyl group, an N-alkyl-acetamino group, and an azide group:
wherein n represents an integer from 1 to 10; m represents an integer from 1 to 30; the preliminary isoprene oligomer has a cis structural moiety B; and Y represents a hydroxy group, a formyl group, a carboxy group, an ester group, a carbonyl group, or a group having the following formula (2):
2. The isoprene oligomer according to claim 1 , further comprising a substituted trans group-containing moiety II, an unsubstituted trans moiety III, and the remainder of the isoprene oligomer being a cis group-containing moiety,
wherein at least one atom or group of an unsubstituted trans group-containing moiety II in the following formula (1-1) selected from a hydrogen atom, a methyl group, a methylene group, a carbon atom, or a methine group is replaced by a different atom or group to provide the substituted trans group-containing moiety II; the different atom or group is selected from the group consisting of a nitrogen atom, an oxygen atom, a sulfur atom, a silicon atom, a carbon atom, an acetoxy group, an alkoxy group, a hydroxy group, an aryl group, an alkyl group, an acetyl group, an N-alkyl-acetamino group, and an azide group,
4. The isoprene oligomer according to claim 1 , wherein the isoprene oligomer is biosynthesized using an allylic diphosphate and isopentenyl diphosphate; the allylic diphosphate has the following formula (3), wherein at least 1 atom or group in the isoprene units in formula (3) selected from a hydrogen atom, a methyl group, a methylene group, a carbon atom, or a methine group is replaced by a different atom or group, and the different atom or group is selected from the group consisting of a nitrogen atom, an oxygen atom, a sulfur atom, a silicon atom, a carbon atom, an acetoxy group, an alkoxy group, a hydroxy group, an aryl group, an alkyl group, an acetyl group, an N-alkyl-acetamino group, and an azide group:
5. The isoprene oligomer according to claim 4 , wherein the biosynthesis is carried out using an enzyme that shows prenyltransferase activity.
6. The isoprene oligomer according to claim 5 , wherein the enzyme that shows prenyltransferase activity is any of the following proteins:
[1] a protein comprising an amino acid sequence having any of the following SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22;
[2] a protein comprising an amino acid sequence that is derived from the amino acid sequence having any of the following SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22 by substitution, deletion, insertion, or addition of 1 or more amino acids, and possessing the ability to catalyze a reaction between an allylic diphosphate and isopentenyl diphosphate, wherein the allylic diphosphate has the following formula (3), wherein at least 1 atom or group in the isoprene units in formula (3) is replaced by another atom or group; or
[3] a protein comprising an amino acid sequence that shows 45% or higher sequence identity to the amino acid sequence having any of the following SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22 and possessing the ability to catalyze a reaction between an allylic diphosphate and isopentenyl diphosphate, wherein the allylic diphosphate has the following formula (3), wherein at least 1 atom or group in the isoprene units in formula (3) is replaced by another atom or group:
7. A process for producing the isoprene oligomer according to claim 1 , comprising biosynthesis of the isoprene oligomer in presence of allylic diphosphate and isopentenyl diphosphate, wherein the allylic diphosphate has the following formula (3), wherein at least 1 atom or group in the isoprene units in formula (3) is replaced by another atom or group:
8. The process for producing the isoprene oligomer according to claim 7 , wherein the biosynthesis is carried out in presence of an enzyme showing prenyltransferase activity.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/133,084 US9657313B2 (en) | 2010-07-14 | 2016-04-19 | Isoprene oligomer, polyisoprene, processes for producing these materials, rubber composition, and pneumatic tire |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010-160120 | 2010-07-14 | ||
JP2010160120 | 2010-07-14 | ||
JP2010-277384 | 2010-12-13 | ||
JP2010277384A JP5058332B2 (en) | 2010-07-14 | 2010-12-13 | Isoprene oligomer, polyisoprene, and production methods thereof, rubber composition, and pneumatic tire |
PCT/JP2011/064774 WO2012008298A1 (en) | 2010-07-14 | 2011-06-28 | Isoprene oligomer, polyisoprene, processes for producing these materials, rubber composition, and pneumatic tire |
US13/809,616 US9371342B2 (en) | 2010-07-14 | 2011-06-28 | Isoprene oligomer, polyisoprene, processes for producing these materials, rubber composition, and pneumatic tire |
US15/133,084 US9657313B2 (en) | 2010-07-14 | 2016-04-19 | Isoprene oligomer, polyisoprene, processes for producing these materials, rubber composition, and pneumatic tire |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/064774 Division WO2012008298A1 (en) | 2010-07-14 | 2011-06-28 | Isoprene oligomer, polyisoprene, processes for producing these materials, rubber composition, and pneumatic tire |
US13/809,616 Division US9371342B2 (en) | 2010-07-14 | 2011-06-28 | Isoprene oligomer, polyisoprene, processes for producing these materials, rubber composition, and pneumatic tire |
Publications (2)
Publication Number | Publication Date |
---|---|
US20160222418A1 US20160222418A1 (en) | 2016-08-04 |
US9657313B2 true US9657313B2 (en) | 2017-05-23 |
Family
ID=45469306
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/809,616 Active 2032-01-31 US9371342B2 (en) | 2010-07-14 | 2011-06-28 | Isoprene oligomer, polyisoprene, processes for producing these materials, rubber composition, and pneumatic tire |
US15/133,084 Active US9657313B2 (en) | 2010-07-14 | 2016-04-19 | Isoprene oligomer, polyisoprene, processes for producing these materials, rubber composition, and pneumatic tire |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/809,616 Active 2032-01-31 US9371342B2 (en) | 2010-07-14 | 2011-06-28 | Isoprene oligomer, polyisoprene, processes for producing these materials, rubber composition, and pneumatic tire |
Country Status (7)
Country | Link |
---|---|
US (2) | US9371342B2 (en) |
EP (1) | EP2594597A1 (en) |
JP (1) | JP5058332B2 (en) |
KR (1) | KR20130043172A (en) |
CN (1) | CN103025785A (en) |
BR (1) | BR112013000786A2 (en) |
WO (1) | WO2012008298A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6468512B2 (en) * | 2012-09-12 | 2019-02-13 | 住友ゴム工業株式会社 | Isoprene oligomer, polyisoprene, and production methods thereof, rubber composition, and pneumatic tire |
EP2848693A1 (en) * | 2013-09-12 | 2015-03-18 | LANXESS Deutschland GmbH | Concatenation of halogenated alkenyl diphosphate derivatives |
CN103833691A (en) * | 2014-03-17 | 2014-06-04 | 上海应用技术学院 | Preparation method of 5-(3,3-dimethylethylene oxide-2-yl)-3-methyl-2-pentenyl acetate |
JP6531304B2 (en) * | 2014-05-28 | 2019-06-19 | 住友ゴム工業株式会社 | Isoprene oligomer, polyisoprene, method for producing the same, rubber composition, and pneumatic tire |
JP6241403B2 (en) | 2014-10-24 | 2017-12-06 | 横浜ゴム株式会社 | Phosphoric acid modified polymer |
JP6608213B2 (en) * | 2015-08-05 | 2019-11-20 | 横浜ゴム株式会社 | Method for producing modified polymer |
CN106085910B (en) * | 2016-06-22 | 2021-07-23 | 中国人民解放军总医院 | Space methylobacterium LCT-S10-2 |
JP7209718B2 (en) * | 2018-06-20 | 2023-01-20 | エルジー・ケム・リミテッド | Modified polymerization initiator and method for producing the same |
CN110708635B (en) * | 2019-10-31 | 2020-11-24 | 歌尔股份有限公司 | Sound generating device's vibrating diaphragm and sound generating device |
KR102612230B1 (en) * | 2021-05-12 | 2023-12-11 | 금호타이어 주식회사 | Method of manufacturing tire tread rubber and tire tread manufactured by using it |
CN113603814B (en) * | 2021-08-23 | 2022-05-13 | 无锡安睿驰科技有限公司 | Method for repairing tire inner liner |
CN115028527A (en) * | 2022-05-28 | 2022-09-09 | 汉瑞药业(荆门)有限公司 | Preparation method of 3-hydroxymethyl-2, 2-dimethylcyclopropanecarboxylic acid |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4886904A (en) * | 1980-11-28 | 1989-12-12 | Kuraray Co., Ltd. | Polyprenyl composition or compounds and process for the production thereof |
JPH0225415A (en) | 1988-07-13 | 1990-01-26 | Nisshin Flour Milling Co Ltd | Agent for suppressing metastasis of cancer |
JPH04283548A (en) | 1991-03-12 | 1992-10-08 | Eisai Co Ltd | New terpene derivative and its production |
JPH09268162A (en) | 1996-01-31 | 1997-10-14 | Nisshin Flour Milling Co Ltd | Isoprene derivative |
US5756475A (en) | 1996-01-31 | 1998-05-26 | Nisshin Flour Milling Co., Ltd. | Isoprene derivatives |
JPH10316715A (en) | 1997-05-20 | 1998-12-02 | Jsr Corp | Aqueous dispersion of epoxy-modified polymer |
JP2000001575A (en) | 1998-06-15 | 2000-01-07 | Sumitomo Rubber Ind Ltd | Rubber composition containing modified diene rubber |
JP2000001573A (en) | 1998-06-15 | 2000-01-07 | Sumitomo Rubber Ind Ltd | Rubber composition |
EP1050582A2 (en) | 1999-05-03 | 2000-11-08 | Korea Kumho Petrochemical Co. Ltd. | Recombinant microorganisms expressing small rubber particle-associated protein |
EP1083201A2 (en) | 1999-09-10 | 2001-03-14 | The Goodyear Tire & Rubber Company | Rubber comnposition containing hydroxl terminated polyalkylene polymer and tire with tread thereof |
JP2003238603A (en) | 2002-02-20 | 2003-08-27 | Hiroshi Okamoto | Modified rubber |
CN101160328A (en) | 2005-04-15 | 2008-04-09 | 株式会社普利司通 | Modified conjugated diene copolymer, rubber compositions and tires |
EP2093222A1 (en) | 2008-02-22 | 2009-08-26 | Newbiotechnic, S.A. | Polyisoprenoid epoxides useful for decreasing cholesterol and/or increasing coenzyme Q biosynthesis |
CN101688191A (en) | 2007-04-03 | 2010-03-31 | 菲力普莫里斯产品股份公司 | Genes encoding z,z-farnesyl diphosphate synthase and a sesquiterpene synthase with multiple products and uses thereof |
US20100218272A1 (en) | 2009-02-25 | 2010-08-26 | Hitachi Zosen Corporation | Long-Chain Trans-Prenyl Diphosphate Synthase Gene |
US20110201771A1 (en) * | 2008-11-06 | 2011-08-18 | University Of Akron | Biosynthesis of polyisoprenoids |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58110600A (en) | 1981-12-25 | 1983-07-01 | Kyowa Hakko Kogyo Co Ltd | Recombinant plasmid containing human beta-interferon gene |
ATE255162T1 (en) | 1983-01-13 | 2003-12-15 | Max Planck Gesellschaft | TRANSGENIC DICOTYLEDONE PLANT CELLS AND PLANTS |
NL8300698A (en) | 1983-02-24 | 1984-09-17 | Univ Leiden | METHOD FOR BUILDING FOREIGN DNA INTO THE NAME OF DIABIC LOBAL PLANTS; AGROBACTERIUM TUMEFACIENS BACTERIA AND METHOD FOR PRODUCTION THEREOF; PLANTS AND PLANT CELLS WITH CHANGED GENETIC PROPERTIES; PROCESS FOR PREPARING CHEMICAL AND / OR PHARMACEUTICAL PRODUCTS. |
DE3588230D1 (en) | 1984-05-11 | 2001-09-13 | Syngenta Participations Ag | Plant heritage transformation |
ZA872705B (en) | 1986-04-22 | 1987-10-05 | Immunex Corporation | Human g-csf protein expression |
JPS63233798A (en) | 1986-10-09 | 1988-09-29 | Kyowa Hakko Kogyo Co Ltd | Production of 5'-guanylic acid |
IL84459A (en) | 1986-12-05 | 1993-07-08 | Agracetus | Apparatus and method for the injection of carrier particles carrying genetic material into living cells |
JP2545078B2 (en) | 1987-04-06 | 1996-10-16 | 協和醗酵工業株式会社 | Method for producing nucleic acid-related substance |
JP2928287B2 (en) | 1988-09-29 | 1999-08-03 | 協和醗酵工業株式会社 | Novel polypeptide |
JPH0322979A (en) | 1989-06-19 | 1991-01-31 | Kyowa Hakko Kogyo Co Ltd | Novel plasminogen-activation factor |
US5204253A (en) | 1990-05-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Method and apparatus for introducing biological substances into living cells |
WO1994000977A1 (en) | 1992-07-07 | 1994-01-20 | Japan Tobacco Inc. | Method of transforming monocotyledon |
KR100555161B1 (en) | 1996-09-17 | 2006-11-30 | 교와 핫꼬 고교 가부시끼가이샤 | Preparation method of sugar nucleotides and complex sugars |
-
2010
- 2010-12-13 JP JP2010277384A patent/JP5058332B2/en active Active
-
2011
- 2011-06-28 WO PCT/JP2011/064774 patent/WO2012008298A1/en active Application Filing
- 2011-06-28 KR KR1020137002529A patent/KR20130043172A/en not_active Application Discontinuation
- 2011-06-28 BR BR112013000786A patent/BR112013000786A2/en not_active IP Right Cessation
- 2011-06-28 CN CN2011800355183A patent/CN103025785A/en active Pending
- 2011-06-28 US US13/809,616 patent/US9371342B2/en active Active
- 2011-06-28 EP EP11806628.1A patent/EP2594597A1/en not_active Withdrawn
-
2016
- 2016-04-19 US US15/133,084 patent/US9657313B2/en active Active
Patent Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4886904A (en) * | 1980-11-28 | 1989-12-12 | Kuraray Co., Ltd. | Polyprenyl composition or compounds and process for the production thereof |
JPH0225415A (en) | 1988-07-13 | 1990-01-26 | Nisshin Flour Milling Co Ltd | Agent for suppressing metastasis of cancer |
US5004735A (en) | 1988-07-13 | 1991-04-02 | Nisshin Flour Milling Co., Ltd. | Pharmaceutical compositions for the inhibition of tumor metastasis |
JPH04283548A (en) | 1991-03-12 | 1992-10-08 | Eisai Co Ltd | New terpene derivative and its production |
US5245060A (en) | 1991-03-12 | 1993-09-14 | Eisai Co. Ltd. | Terpene derivatives and process for preparing the same |
JPH09268162A (en) | 1996-01-31 | 1997-10-14 | Nisshin Flour Milling Co Ltd | Isoprene derivative |
US5756475A (en) | 1996-01-31 | 1998-05-26 | Nisshin Flour Milling Co., Ltd. | Isoprene derivatives |
JPH10316715A (en) | 1997-05-20 | 1998-12-02 | Jsr Corp | Aqueous dispersion of epoxy-modified polymer |
JP2000001575A (en) | 1998-06-15 | 2000-01-07 | Sumitomo Rubber Ind Ltd | Rubber composition containing modified diene rubber |
JP2000001573A (en) | 1998-06-15 | 2000-01-07 | Sumitomo Rubber Ind Ltd | Rubber composition |
EP1050582A2 (en) | 1999-05-03 | 2000-11-08 | Korea Kumho Petrochemical Co. Ltd. | Recombinant microorganisms expressing small rubber particle-associated protein |
JP2000316586A (en) | 1999-05-03 | 2000-11-21 | Kumho Petrochemical Co Ltd | Recombinant microorganism expressing small rubber particle-associated protein(srpp) |
EP1083201A2 (en) | 1999-09-10 | 2001-03-14 | The Goodyear Tire & Rubber Company | Rubber comnposition containing hydroxl terminated polyalkylene polymer and tire with tread thereof |
JP2003238603A (en) | 2002-02-20 | 2003-08-27 | Hiroshi Okamoto | Modified rubber |
CN101160328A (en) | 2005-04-15 | 2008-04-09 | 株式会社普利司通 | Modified conjugated diene copolymer, rubber compositions and tires |
US20090292043A1 (en) | 2005-04-15 | 2009-11-26 | Bridgestone Corporation | Modified conjugated diene copolymer, rubber compositions and tires |
CN101688191A (en) | 2007-04-03 | 2010-03-31 | 菲力普莫里斯产品股份公司 | Genes encoding z,z-farnesyl diphosphate synthase and a sesquiterpene synthase with multiple products and uses thereof |
US20100138954A1 (en) | 2007-04-03 | 2010-06-03 | Philip Morris Products S.A. | Genes Encoding Z,Z-Farnesyl Diphosphate Synthase and A Sesquiterpene Synthase with Multiple Products and Uses Thereof |
EP2093222A1 (en) | 2008-02-22 | 2009-08-26 | Newbiotechnic, S.A. | Polyisoprenoid epoxides useful for decreasing cholesterol and/or increasing coenzyme Q biosynthesis |
US20110201771A1 (en) * | 2008-11-06 | 2011-08-18 | University Of Akron | Biosynthesis of polyisoprenoids |
US20100218272A1 (en) | 2009-02-25 | 2010-08-26 | Hitachi Zosen Corporation | Long-Chain Trans-Prenyl Diphosphate Synthase Gene |
JP2010193770A (en) | 2009-02-25 | 2010-09-09 | Hitachi Zosen Corp | Long-chain trans-prenyl diphosphate synthase gene |
Non-Patent Citations (3)
Title |
---|
English Machine Translation of JP-10-316715-A published Dec. 2, 1998. |
English Machine Translation of JP-2003-238603-A published Aug. 27, 2003. |
International Search Report for PCT/JP2011/064774 dated Oct. 11, 2011. |
Also Published As
Publication number | Publication date |
---|---|
WO2012008298A1 (en) | 2012-01-19 |
KR20130043172A (en) | 2013-04-29 |
JP2012036360A (en) | 2012-02-23 |
CN103025785A (en) | 2013-04-03 |
US20160222418A1 (en) | 2016-08-04 |
US20140171675A1 (en) | 2014-06-19 |
US9371342B2 (en) | 2016-06-21 |
BR112013000786A2 (en) | 2016-07-05 |
EP2594597A1 (en) | 2013-05-22 |
JP5058332B2 (en) | 2012-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9657313B2 (en) | Isoprene oligomer, polyisoprene, processes for producing these materials, rubber composition, and pneumatic tire | |
CN1304433C (en) | Process for producing modified polymer, modified polymer obtained by the process, and rubber composition | |
EP2783880B2 (en) | Studless winter tire | |
KR100204129B1 (en) | Elastomeric composition useful for tyre treads | |
EP2883909B1 (en) | Rubber composition for tires, tire member, and pneumatic tire | |
CN105175801B (en) | Truck tyre or bus tire | |
US20120245270A1 (en) | Rubber composition containing glycerol and a functionalized elastomer and tread for a tire | |
WO2019044889A1 (en) | Rubber composition for tire | |
CN110382609A (en) | Studless tire | |
WO2019044892A1 (en) | Rubber composition for heavy-duty tire, and tire | |
WO2019044891A1 (en) | Rubber composition for high grip tire | |
WO2011083050A2 (en) | Modified diene elastomers | |
JP6757938B2 (en) | Isoprene oligomers, polyisoprene, and methods of making them, rubber compositions, and pneumatic tires. | |
JP6532192B2 (en) | Rubber composition for tire, tire member, and pneumatic tire | |
JP6531304B2 (en) | Isoprene oligomer, polyisoprene, method for producing the same, rubber composition, and pneumatic tire | |
US10457752B2 (en) | Silane functionalized poly (farnesene) and rubber compound comprising the same | |
US6699937B1 (en) | Rubber compositions containing hydroxyl groups | |
EP3981610A1 (en) | Silane coupling agent composition containing silane compound and protein denaturing agent, and rubber composition containing said composition | |
EP1172440A1 (en) | Novel mannose isomerase and dna encoding the enzyme | |
JP2022179158A (en) | Rubber composition for passenger car tire and passenger car tire | |
KR20230012580A (en) | Silane coupling agent composition and rubber composition containing the same | |
US20210130287A1 (en) | Functional disulfide vegetable oils, method of making and use in rubber compositions and tires | |
JP2020094191A (en) | Rubber composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |